Molecular pharmacology of AMPA receptor trafficking proteins - TARPs - evidence for an association with 5HT(_2c) receptors by Donoghue , Peter
Durham E-Theses
Molecular pharmacology of AMPA receptor
trafficking proteins - TARPs - evidence for an
association with 5HT( 2c) receptors
Donoghue , Peter
How to cite:
Donoghue , Peter (2009) Molecular pharmacology of AMPA receptor trafficking proteins - TARPs -
evidence for an association with 5HT( 2c) receptors, Durham theses, Durham University. Available at
Durham E-Theses Online: http://etheses.dur.ac.uk/2162/
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or
charge, for personal research or study, educational, or not-for-profit purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in Durham E-Theses
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full Durham E-Theses policy for further details.
Academic Support Office, Durham University, University Office, Old Elvet, Durham DH1 3HP
e-mail: e-theses.admin@dur.ac.uk Tel: +44 0191 334 6107
http://etheses.dur.ac.uk
The copyright of this thesis rests with the 
author or the university to which it was 
submitted. No quotation £rom it, or 
information derived from it may be 
published without the prior written 
consent of the author or university, and 
any information derived from it should be 
acknowledged. 
Molecular Pharmacology of AMPA Receptor 
Trafficking Proteins - TARPs - Evidence for 
an Association with SHTic Receptors. 
Peter Donoghue 
A thesis submitted to the University of Durham in 
accordance with the requirements for the degree of Doctor 
of Philosophy 
School of Biological and Biomedical Sciences 
2009 
Supervisors: Dr Christopher L Thompson and Dr Paul L Chazot 
" 5 mr 
Abstract 
There has been an increasing awareness of the involvement of neurotransmitters other 
than serotonin in depression, with new antidepressants possessing effects on other 
receptor types, such as Agomelatine®, an antagonist of 5HT2c receptors that functions as 
an agonist at melatonin receptors. 
AMPA receptors are one of the families of ionotropic glutamate receptors and another 
neurotransmitter receptor type that have been demonstrated to be important in the 
function of new antidepressants. AMPA receptors possess effects upon brain-derived 
neurotrophic factor (BDNF) expression, a protein involved in neurogenesis in the 
hippocampus, which is believed to be pivotal to antidepressant efficacy, with BDNF 
expression diminishing in critical brain areas in response to chronic stress, but increasing 
in the hippocampus in response to treatment with both antidepressants and/or AMPA 
receptor modulators. 
AMPA receptors interact with a family of accessory proteins, the transmembrane AMPA 
receptor regulatory proteins (TARPs), which not only possess important roles in the 
trafficking and targeting of AMPA receptors, but also function as auxiliary subunits to 
AMPA receptors. Present in several isoforms, each individual TARP also directly 
modifies AMPA receptor kinetics. As such TARPs and their effects must be taken into 
account for any pathophysiological or drug-induced change involving AMPA receptors. 
Despite the vast literature on AMPA receptors, there is comparatively little information 
regarding how TARPs modify AMPA receptor function, largely due to the absence of the 
necessary tools. 
We developed polyclonal antibodies specific to each of the known TARP isoforms (y2, 
y4, y8) mapping the distribution of the TARPs in the mouse CNS, displaying a different 
distribution profile for each of the TARP isoforms. TARP y8 is of particular interest, 
being shown to have a wide expression in the CNS fi-om the frontal cortex to the spinal 
cord, but also a regional distribution in the forebrain that shares similarities to a positive 
allosteric modulator of AMPA receptors. There is also some evidence of a strain 
dependent distribution of TARP 78, possibly contributing to some of the behavioural 
differences between strains. 
With the extensive distribution of TARP y8 in the forebrain, particularly in those 
structures shown to experience severe neuronal atrophy in depression, such as the 
hippocampus, we focused on the antibodies generated to this isofomi to generate 
immunoaffinity columns and immunopurify TARP yS and its interacting proteins from 
Triton X-100™ solubilised, so effectively non-synaptic, cerebral cortex. 
Examination of the purified TARP y8 and its interacting partners by both immunological 
and proteomic techniques revealed a range of proteins previously not implicated as TARP 
interacting proteins important in several pathophysiological situations, including several 
isoforms of actin. Furthermore, the immimopurified TARP y8 material also contained a 
protein identified with multiple 5HT2c receptor antibodies at ~60 kDa, the molecular 
weight correlating to fully glycosylated SHTac receptor. 
Further study of TARP and AMPA receptor levels in the forebrain of mice with either 
forebrain-specific over-expression, or forebrain-specific knockdown of 5HT2c receptors, 
identified several differences in total protein levels of the TARPs and AMPA receptor 
subunits. TARP y8 was shown to possess higher levels of expression in both of the mice 
strains with altered 5HT2c receptor expression, suggesting a complex functional 
interaction between TARPs/AMPA receptors and 5HT2c receptors. 
These results, in addition to providing evidence of strain variations with regard to TARP 
distributions, have also identified several previously unknown TARP y8 interacting 
proteins, including, but not limited to cytoskeletal proteins. The results also show 
evidence of both a physical and functional interaction of TARP y8 and AMPA receptors 
with 5HT2C receptors in the forebrain, particularly the cerebral cortex - findings of 
potential importance regarding the role of AMPA receptors in mood disorders. 
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1.1 The glutamatergic nervous system 
The central nervous system (CNS) is a collection of cells with a variety of functions, of 
which the most obvious cell type are the neurones. Signalling in the CNS is mediated by 
a variety of chemicals termed neurotransmitters, which have specific effects and, as with 
all chemical signalling in biological systems, specific receptors to mediate these effects. 
One critical system of neurotransmitters and receptors is the glutamatergic system, a 
variety of cells that use the neurotransmitter glutamate to mediate their effects. In the 
CNS, activation of glutamate receptors is predominantly excitatory to the cell concerned, 
but some glutamate receptors are inhibitory in their effects on neuronal activity. 
Whilst essential for survival, there is a darker side to the glutamatergic nervous system, 
with the abnormal and excessive release of glutamate being a major contributory factor in 
the spread of damage during a stroke. 
Voltage-gated Ion channel 
Q Pre-synaptic vesicle 
containing glutamate 
| | - AMPA receptor 
NMDA receptor 
,Metabotropic glutamate receptor 
Post synaptic structural proteins, 
^ including PSD-95 
Glutamate transporter 
Figure 1.1: A simplified diagram of a glutamatergic synapse showing the typical 
distribution of the glutamatergic receptors. Based on information from Boeckers Cell 
and Tissue Research 2006. 
There are two currently known families of glutamate receptor, the metabotropic and the 
ionotropic, both of which possess different methods of function and roles in the CNS. 
1.2 Metabotropic glutamate receptors (mGluRs) 
A family of receptors consisting of eight distinct subtypes (mGluRl-8), mGluRs are 
wholly distinct from ionotropic glutamate receptors both in compostion and function, the 
only similarity being their sensitivity to glutamate (Bockaert et al. 1993, Schoepp 1994 -
Reviews). 
The first and perhaps most noticeable distinction is the fact that mGluRs are actually a 
family of G-protein coupled receptors, mediating their effects via intracellular 
messengers that are secondary to the receptor itself (Nakanishi et al. 1998). 
Depending upon the G-protein system to which the mGluR is coupled, in addition to 
responses to specific compounds, it is possible to sub-divide the mGluR receptor family 
into 3 groups: 
• Group I : This group consists of the mGluRs 1 and 5, which are posifively coupled 
to phosphoinosifide hydrolysis. They can be selectively activated by 3, 5 
dihydroxy-phenylglycine (3,5 DHPG). They are fi-equently coupled to 
phospholipase C and when activated stimulate increased release of intracellular 
Ca^ ,^ whilst inhibiting voltage-gated Ca^ ^ channels. 
• Group I I : This group consists of the mGluRs 2 and 3, which are negatively 
coupled to adenylyl cyclase. They can be selectively activated by the agonist 
LY379268. This group is coupled to an inhibition of cyclic AMP cascade in 
addition to regulatory roles in both G-protein coupled, inwardly rectifying K"^  
channels, and intracellular Ca^ .^ 
• Group I I I : This group consists of the mGluRs 4, 6, 7 and 8, which are again 
negatively coupled to adenylyl cyclase, but imlike group II mGluRs, are activated 
by 2-amino-4-phosphobutyrate. The function primarily associated with this group 
of mGluRs is the inhibition of synaptic transmission via the suppression of 
presynaptic voltage-gated Ca^* channels. As such, despite being a glutamate 
receptor, these mGluRs are located in a wide variety of different synapses, 
including GABAergic synapses. 
All mGluRs possess a 7-transmembrane domain topology commonly associated with G-
protein coupled receptors, with an extracellular N-terminal domain, and a large 
intracellular C-terminal domain, which in the cases of mOluRs 1, 3, 5 and 8, can undergo 
extensive editing resulting in numerous splice variants. 
Besides the differences in membrane topology from the ionotropic glutamate receptors, 
the mOluRs also have a contradictory function in the CNS. Whereas the ionotropic 
glutamate receptors are associated with excitatory neurotransmission, the principle role of 
mGluRs is to regulate pre and post-synaptic events, frequently by utilising inhibition. 
Little is known on the functional roles of each of the mGluR subtypes, but they each have 
a distinct distribution within the CNS (Ferraguti et al. 2006). 
1.3 lonotropic glutamate receptors 
There are three known forms of ionotropic receptors present in the CNS that are 
responsive to L-glutamate: NMDA receptors, Kainate receptors and AMPA receptors, all 
of which are so named due to their relative sensitivity to compounds that function as 
agonist at ionotropic glutamate receptors. Al l the ionotropic glutamate receptors are 
similar in general receptor properties and function, but with pronounced differences in 
their specific roles, localisation, and composition. 
Al l ionotropic glutamate receptors are comprised of several constituent subunits, unique 
to each receptor type, that possess unique attributes which in turn influence the resultant 
receptors pharmacology and functional role. 
The topology of the individual subunits for these ionotropic glutamate receptors is the 
same, with an extracellular N-terminal domain, four transmembrane domains (MDl-4) 
and a cytoplasmic C-terminal domain. Without exception the second transmembrane 
domain enters the plasma membrane via the cytoplasmic side, and does not fully transect 
the membrane, instead re-entering the cytoplasm, and as such forms the pore created by 
co-assembly of these subunits in their constituent receptor. 
The ligand binding domain is formed by the extracellular N-terminal region and the first 
extra-cellular loop, located between MD2 and MD4. 
1.3.1 A -^methyl D-aspartate (NMDA) receptors 
NMDA receptors are an extensively studied class of ionotropic glutamate receptors 
integral for excitatory neurotransmission throughout the CNS. They are potentially either 
tetrameric or pentameric structures consisting of two NRl subunits and usually two NR2 
subunits although some receptors contain NR3 subunits. The NR2 and NR3 subunits can 
be further divided into NR2A-D and NR3A-B. The exact composition of the receptor 
subunits has been shown to confer different functional properties to the receptor, with 
specific subunit subtypes being associated with specific neurological processes. The NR2 
subtypes also possess differential expression throughout the both the CNS, but also 
within a cell, in addition to possessing a developmentally regulated expression with some 
NR2B and NR2D containing receptors being replaced with NR2A and NR2C containing 
receptors during development. 
Figure 1.2 Table of NMDAR subunits 
Subunit Variants Location in CNS Associated Physiological Role 
Li et al. (2007) 
NRl 
Anantharam et al. 
(1992), Nakanishi et 
al.. (1992). Sugihara 
etal. (1992), Kusiak 
and Norton (1993) 
8 Splice 
Variants 
( N R l a -
NRlh) 
Throughout the CNS. 
Nakanishi (1992), 
Standaert etal. (1993) 
All NMDA receptor-related 
processes. 
Durand et al. (1993), Hollmann et 
al. (1993), Micu et al. (2006) 
NR2 
Monyer et 
al. (1992) 
Nakanishi (1992) 
Ishiiet al. (1993), 
Buller et al. (1994), 
Wenzel et al. (1995), 
NR2A A distribution similar to 
the NRl subunit. Uniform 
distribution between 
cortex, hippocampus and 
cerebellum. Low levels in 
the striatum. Petralia et al. 
(1994), Vallano et al. 
Integral for induction of synaptic 
Long Term Potentiation (LTP) 
Karadottir et al. (1995) 
(2005) NR2B Primarily the forebrain. 
Present in the cerebellum 
during early development. 
Petralia et al. (1994), 
Vallano et al. (1995) 
Integral for induction of synaptic 
Long Term Depression (LTD) 
NR2C Enriched in the 
cerebellum. Also present 
in myelinated cells, 
thalamus and olfactory 
structures. Absent in 
hippocampus. Vallano et 
al. (1995) 
Some neuroprotective effects. 
Also influences NMD A receptor 
channel permeability. Pizzi et al. 
(1999), Micu et al. (2006) 
NR2D Distribution follows a 
developmental pattern. 
Regions of expression in 
adults include the striatum, 
hippocampus and superior 
colliculus. Concentrated in 
thalamus and spinal cord 
in addition to mid-brain 
and brainstem. 
Important in retinal Rod bipolar 
cells. 
Also important, but not essential for 
the developing hippocampal 
formation. Potential role in 
excitatory pathways in mature 
hippocampus. 
Thompson et al. (2002) 
NR3 
Chatterton et al. 
(2002) 
NR3A 
Nishi et al. 
(2001) 
Associated with 
myelinated cells. 
Karadottir et al. (2005) 
Poorly defined, may have roles 
mediating ischaemic insult in 
oligodendrocytes. Salter et al. 
(2005), Micu et al. (2006) 
NR3B Highest levels in motor 
neurones within the pons, 
medulla and spinal cord. 
Developmentally 
dependent expression 
pattern. Fukaya et al. 
(2005) 
Important in cell surface trafficking 
of NMDARs and influences 
Calcium permeability. Forms 
excitatory glycine receptor with 
NRI subunit, although this result is 
still controversial. (Micu et al. 2006) 
The NRl subunit of NMDA receptors are essential components of a functional receptor, 
and the majority are believed to combine with the NR2A subunit, with this being the 
prevalent NR2 subunit in the CNS. The NRl subunit itself contains a glycine binding 
domain, a property unique to NMDA receptors when compared with other ionotropic 
glutamate receptors, and equates to the NMDA receptor requiring co-activation by both 
glutamate (or a suitable equivalent agonist) and glycine. Once active, the NMDA receptor 
is permeable to both Na^ but primarily Ca^ ^ and is responsible for the much of the Ca^ ^ 
influx that occurs as a consequence of excitatory neurotransmission. 
Another property unique to NMDA receptors compared to other ionotropic glutamate 
receptors is that at resting membrane potential, the Ca^ ^ ion channel is blocked by Mg"^, 
with the NMDA receptor requiring a depolarising event to occur in the membrane 
potential to remove the Mg"^ ^ and allow the receptor to function. 
N R l NR2 
N Terminal domains: The NRl subunit may contain an 
allosteric binding domain. The NR2 subunit contains a 
known binding site for allosteric modulators, such as 
Zn^^ on the NR2A subunit. Extracellular. 
Agonist binding domains: The NRl subunit contains the 
glycine binding site. The NR2 subunit contains the 
glutamate binding site, which is also the suitable binding 
site for competitive agonists/antagonists. May possess a 
binding site within the ion channel opening. 
Extracellular. 
Transmembrane domains: These comprise of three 
membrane spanning regions (1,3,4) and a re-entrant loop 
(2) that in the completed NMDA receptor, aligns with 
the analogous domain on other NMDA receptor subunits 
and forms the pore. This region can be manipulated by 
pore-blockers but also may possess another binding site 
external to the ion channel. 
C Terminal domains: No known binding sites for 
pharmacological agents. Intracellular. 
Figure 1,3: Diagram showing the potential binding sites present on the NMDA 
receptor Extensively adapted from Paoletti and Neyton 2007 
The NMDA receptor also has several important interactions with AMPA receptors in 
several key neurological processes including synaptic LTP and LTD, both of which are 
discussed in more detail in section 1.4. 
1.3.2 Kainate receptors (KA receptors) 
Kainate receptors, are one of the two non-NMDA ionotropic glutamate receptors 
identified in the CNS that are a component of the glutamatergic nervous system. They 
were originally identified by their preferential response to kainate, namely a rapid 
desensitization in its presence that distinguished them from the other class of non-NMDA 
ionotropic glutamate receptor; AMPA receptors (Davies et al. 1979, Bettler and Mulle, 
1995). 
Kainate receptors are comprised of five receptor subunits GluR5, GluR6, GluR7, Kal 
and Kal (Hollmann and Heinemann 1994), which have been shown to co-assemble into 
both homomeric and heteromeric receptors depending upon the subunits investigated and 
conditions in which they were expressed. 
Compared to other ionotropic glutamate receptors, the kainite receptors are poorly 
understood, with very few neurological processes where the roles of the kainate receptors 
are fully understood. As such they are perhaps unique in the sense that they are the only 
ionotropic glutamate receptors with no known ftmdamental role in synaptic LTP and 
LTD. 
1.3.3 a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) 
receptors 
AMPA receptors are part of the family of ionotropic glutamate receptors present in the 
central nervous system and are responsible for rapid excitatory glutamatergic 
8 
neurotransmission. Frequently found in the post synaptic density, they also occur pre-
synaptically, most frequently mediating the release of neurotransmitters - although the 
former location is the most extensively studied. 
They possess a tetrameric structure existing as either heteromers or homomers of four 
possible subunits - GluRl, GluR2, GluR3 and GluR4 all of which can undergo some 
RNA editing, and exist as either flip or flop splice isoforms (Sommer et al. 1990, Derkach 
et al. 2007), with these RNA edits affecting their inherent trafficking properties (Coleman 
et al. 2006). 
2 
Figure 1.4: Generic structure of an AMPA receptor GluR subunit (Amended from 
Sun et al. 2002). 
Each GluR subunit of an AMPA receptor possesses an extra-cellular 
N terminus, an intracellular C terminus and four membrane transecting domains, of 
which the second (P in Figure) only partially transects the plasma membrane before 
returning to the cytoplasm. In the fully assembled AMPA receptor, this region (P) forms 
the ion channel pore. Region F shows the flip-flop domain. 
The majority of AMPA receptors expressed endogenously in vivo are either GluRl/2 or 
GluR2/3 heteromers. Their cycling both to and from the cell surface and the synapse is 
widely regarded as of essential importance with regard to their function, and they seem to 
possess at least several forms of cycling, some of which are activity-dependant (Luscher 
et al. 1999). They are also believed to undergo constitutive cycling from extra-synaptic 
regions in the plasma membrane either translocating into the synapse, or entering 
intracellular pools of AMPA receptors, of which some are degraded, but others can be 
recycled back to the cytoplasmic membrane (Liang F et al. 2001). 
AMPA receptors are believed to be involved in a couple of neurological phenomena that 
are regarded as being fundamental to not only learning and memory, but also to synaptic 
plasticity in excitatory synapses - namely synaptic Long term potentiation (LTP), and 
synaptic Long term depression (LTD) (Eamshaw et al. 2006). Both of these processes 
involve the activity-dependant trafficking of AMPA receptors that serves to either 
strengthen a synapse, as is the case of the former, or weaken it, as is the case of the latter. 
During constitutive AMPA receptor synaptic cycling GluR2 containing AMPA receptors 
are shuttled between extra-synaptic locations and the synapse in an activity-independent 
manner. The cycling is rapid (Adesnik et al. 2005), and appears to be regulated by 
synaptic anchoring interactions of the GluR2 PDZ domain with various proteins, 
although it is uncertain as to what extent these interactions affect the constitutive state 
cycling compared with an activity-induced cycling process. In the post-synaptic density 
GluR2 PDZ binding appears to show a preference for Glutamate Receptor Interacting 
Protein 1 (GRIPl) (Dong et al. 1997 Wyszynski et al. 1999, Osten et al. 2000). However, 
phosphorylation of ser880 of the GluR2, occurring as a consequence of PKC activation 
(Matsuda et al. 1999, Chung et al. 2000, Daw et al. 2000), disrupts GRIPl binding, with 
the phosphorylated GluR2 diffiising from synaptic locations, seemingly via interactions 
with Protein Interacting with C Kinase 1 (PICKl) (Perez et al. 2001, Iwakura et al. 2001, 
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Kim et al. 2001). There is also evidence that the constitutive cycling of GluR2 containing 
AMPA receptors to the cell surface and their subsequent synaptic trafficking requires 
interactions with various other cytosolic proteins. These include NSF (Nishimune et al. 
1998, Song et al. 1998, Luscher et al. 1999, Huang et al. 2005), HSP90 (Gerges et al. 
2004), NEEP21 (Steiner et al. 2002) and Rab8 (Gerges et al. 2004), in addition to 
unknown palmitoylating enzymes, such as GODZ, whereby palmitoylation of the GluR2 
subunit limits exiting from the Golgi apparatus (Hayashi et al. 2005). 
Interestingly GluR3 contains the same PDZ binding motif as GluR2, but does not appear 
to be the important AMPA receptor subunit regulating constitutive AMPA receptor 
cycling (Sans et al. 2001, Sheng and Lee 2001), with GluR2-regulated constitutive 
cycling being important even for those AMPA receptors located at pre-synaptic sites 
(Pittaluga et al. 2005). 
Several forms of LTP, a process that requires the activity-dependant synaptic targeting of 
AMPA receptors does not appear to be mediated via the GluR2 subunit rather it is the 
GluRl subunit that appears to be crucial for the activity of LTP (Oh et al.. 2005). 
GluRl containing AMPA receptors, particularly those which do not contain the GluR2 
subunit, are predominantly located in non-synaptic neuronal regions during baseline 
levels of activity (Chen et al. 1998). Their trafficking to the cell surface and synaptic 
targeting possesses notable differences in interacting proteins to GluR2, not least in the 
demonstrated interaction of GluRl with Synapse Associating Protein 97 (Sap-97) - a 
protein that is related to PSD-95, but is located predominantly in the cytoplasm (Sans et 
al. 2001), but also their interaction with the 4.IN protein located in the PSD 
cytoarchitecture. This interaction is disrupted following palmitoylation of the GluRl 
subunit, promoting removal of the GluRl containing AMPA receptor from the synapse 
(Hayashi et al. 2005). 
However, following the induction of LTP, which stimulates the activation of NMDA 
receptors and an increase in intracellular Ca^ ^ levels, there is an increase of GluR2-
lacking AMPA receptors frequently homomeric GluRl receptors being detectable in the 
PSD, in the first 30 minutes following the induction of LTP, suggesting that it is the 
increase in Ca^^ permeable AMPA receptors that enables the synaptic strengthening 
involved in LTP (Kauer and Malenka 2006). The precise mechanism for this induction of 
GluRl containing AMPA receptors in LTP is unknown, but phosphorylation of the 
ser845 of GluRl via multiple candidate kinases, not the least significant of which being 
CAMKIl - activated as a consequence of NMDA receptor activation - has been shown to 
be important for the synaptic targeting of GluRl (Sheng and Lee 2001). 
The interactions of PSD-95 have also been shown to be important in the recruitment of 
GluR2-lacking AMPA receptors to the PSD following LTP. This interaction appears to 
be indirect, but dependant upon the palmitoylation state of PSD-95, with N-terminal 
palmitoylation being required for cell-surface targeting - indeed expression of dominant 
negative forms of PSD-95 abolish LTP induction. PSD-95 has no discemable effect on 
the constitutive induction of GluR2 into the PSD (Ehriich and Malinow 2004). 
It has been shown however, that following LTP and the increase in GluR2 lacking 
AMPA receptors, there is a long-term increase in the number of GluR2 containing 
AMPA receptors detectable at the synapse several days after the induction of LTP (Kauer 
and Malenka 2006, McCormack et al. 2006). - most likely because the LTP and 
subsequent increase in synaptic strength, not to mention an increase in synaptic size - a 
consequence of recruitment of additional PSD proteins - has led to an increase in the 
number of active AMPA receptors likely to be present under 'normal' physiological 
conditions. 
Induction of LTD also promotes an activity-dependant increase in the removal of GluR2 
containing AMPA receptors from a synapse, suggesting that it is their removal that is 
important in the subsequent loss of synaptic strength. 
Several possible mechanisms for this have been suggested for both LTD induced and 
constitutive AMPA receptor endocytosis, with PSD-95 being cited as important in 
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regulating the rate of AMPA receptor removal from a synapse via ubiquitination of PSD-
95 and its subsequent proteolytic degradation (Colledge et al. 2003). 
Each of the mechanisms, despite having different inducers, appear to possess a similar 
mechanism of action, with the AMPA receptor dissociating from the synapse and 
undergoing dynamin-dependent endocytosis in clathrin-coated vesicles (Man et al. 2000, 
Lin et al. 2000). One of the mechanisms has been shown to be dependant upon Ca"^  
influx, ironically via NMDA receptor activation, with evidence suggesting it is the 
subunit composition of the NMDA receptor that determines whether LTP or LTD is 
induced following activation, activating PPl, PP2A and calcineurin, which serve to 
dephosphorylate the AMPA receptor subunit in the C-terminal domain, promoting its 
removal from the synapse and subsequent endocytosis in a ligand-independent manner 
(Lin et al. 2000, Beattie et al. 2000). 
With particular reference to the subunit composition of NMDA receptors involved in 
AMPA receptor internalization it has been shown that NR2B containing NMDA 
receptors promote LTD by activation of Rap 1, a small GTPase that promotes activity in 
the p38-MAPK signalling pathway, which appears to facilitate intemalisation of 
heteromeric AMPA receptors containing the GluRl and GluR2 subunits. Rap2 on the 
other hand, promotes depotentiation of AMPA receptors containing the GluR2 and 
GluR3 subunits via NR2A NMDA receptor activation of the JNK signalling pathway 
(Zhu et al. 2005). 
AMPA receptor subunits also appear to undergo ligand-promoted endocytosis, which is 
distinguishable from that promoted by NMDA receptor activation, with AMPA-induced 
endocytosis resulting in AMPA receptors being targeted to late endosomes for proteolytic 
degradation, and a subsequently slow recovery of AMPA receptor activity compared with 
those internalised following NMDA receptor activation (Ehlers 2000). 
1.4 Transmembrane AMPA receptor interacting proteins (TARPs) 
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TARPs are a unique family of AMPA receptor interacting proteins consisting of five 
identified members; TARP y2 (also known as stargazin), y3, y4, y? and y8 (Tomita et al. 
2003; Kato et al. 2007) that have some sequence homology, and are believed to be related 
to the y subunit of Voltage-gated Calcium channels (Chu et al. 2001). 
Transmembrane 
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Figure 1.5: Tree diagram showing the relationship between the TARPs and other 
members of the CACN protein family, including the voltage-gated Ca^* channel 
subunit y l . Amended (Now showing that y5 and y7 are considered TARP proteins) from 
Tomita et al., 2003 The Journal of Cell Biology. 
They consist of four transmembrane spanning regions and intracellular N and C terminals 
- the C-terminus of the y2, y3, y4 and y8 isoforms containing a PDZ binding motif. 
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Figure 1.6: SimpHfied generic structure of a TARP. N and C terminals are located 
within the cytoplasm, transmembrane domains are highlighted (1-4). Extreme C-
terminal contains PDZ binding motif. 
Of the five isoforms, TARP y2 is the most extensively studied and was the initial TARP 
isoform identified, primarily due to the defining of the stargazer mutant mouse - a model 
of cerebella ataxia that also experiences absence epilepsy - which was shown to possess a 
truncated version of the CACNyll gene that resulted in a failure to express the TARP y2 
protein. A direct consequence of this failure in TARP y2 expression was the absence of 
spontaneous AMPA receptor activity detectable in cultured cerebellar granule neurones 
(CGNs), leading to the realisation, that rather than, as originally thought, being a 
neuronal homologue of the y l VGCC, TARP y2 was actually involved in the expression 
of AMPA receptors at the cell surface. This discovery, in turn led to the identification of 
the other TARP isoforms of which TARP y7 is the most recent (identified in 2008). 
Whilst still being considered to be related to VGCC's, with TARP y2, y3 and y4 being 
known to co-immunoprecipitate with both AMPA receptor subunits and the a IB subunit 
of VGCCs (Black 2003), TARPs demonstrate little to no effect when expressed with 
15 
VGCCs in heterologous cells (Osten and Stem-Bach 2006), with any VGCC role being 
considered at best, a secondary function. 
The primary role of TARPs, as their name suggests, is to be found in the nature of their 
interactions with AMPA receptors and the numerous fiinctions that these interactions 
serve. The earliest investigation into TARPs demonstrated their ability to rescue AMPA 
receptor current when TARP Y2 was transfected into cultured CGNs derived from the 
stargazer mutant mouse (Chen et al. 2000) - a property also shared, and indeed used to 
identify the other TARP isoforms (Tomita et al. 2003). These studies implied two major 
properties of TARPs, namely to both traffick AMPA receptors to the cell membrane, and 
to be involved in the subsequent synaptic targeting of AMPA receptors. 
The N-terminal extracellular loop of stargazin has been identified as being a domain 
critical for conferring the ability to traffic AMPA receptors to the cytoplasmic membrane. 
This was demonstrated using the Y5 subunit of the related protein family, that possesses 
no inherent TARP fiancfion developing these properties following domain swapping of 
the N-terminal extracellular loop with TARP y2 (Tomita et al. 2004). 
Whilst the precise mechanism by how TARPs are responsible for the surface trafficking 
of AMPA receptors is unknown, facets of their interacfion have been glimpsed and 
important insights gained. It is known that TARP Y2 interacts with AMPA receptor 
subunits in the endoplasmic reticulum (ER) where the two proteins have been shown to 
be detectable in close proximity and whilst it is unknown at what stage of AMPA 
receptor assembly TARP y2 interacts with AMPA receptors, it appears that TARP y2 
plays a role in the correct folding of AMPA receptor subunits prior to their exiting the ER 
(Vandenberghe et al. 2005, Z i f f 2007). At the current time however, the exact ratio of 
TARP molecules to AMPA receptor subunits is unknown, indeed speculatively it is 
possible that it might even be more than one TARP isoform involved in interaction with 
some AMPA receptor subunit combinations. What is known however is that the 
interactions are sufficiently durable to warrant TARP Y2 the title of an AMPA receptor 
auxiliary subunit - effectively present together with AMPA receptors from their exiting 
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the ER, their passage through the Golgi until their subsequent from the cell surface 
(Vandenburghe et al. 2004, Tomita et al. 2004). 
It has also been demonstrated that upon exiting the ER the TARP-AMPA receptor 
complex interacts both with the cytosolic Golgi-preferring protein nPIST, which may be 
at least in part responsible for synaptic clustering (Cuadra et al. 2004), but also 
microtubule associating protein light chain 2 (MAP1A-LC2), which again may be 
important in transporting the TARP-AMPA receptor complex via the cytoskeleton both 
to the cytoplasmic membrane and subsequently the synapse (Ives et al. 2004). 
The synaptic targeting of AMPA receptors appears to be dependant upon the C-terminal 
tail of the TARP isoform (Chen et al. 2000), most likely because of the PDZ motif 
present there, which has been shown to interact with a variety of proteins typically 
associated with the post synaptic density including PSD-95, PSD-93, SAP-97, SAP-102 
and the afore-mentioned MAGI-2 and nPIST (Dakoji et al. 2003). 
Certainly with regard to PSD-95 there is increasing evidence supporting this hypothesis. 
Over-expression of PSD-95 in cultured neurones shows an increased expression of 
AMPA receptors detectable in the synapse, with a corresponding decrease in AMPA 
receptor expression non-synaptically. Conversely, over-expression of TARP y2 whilst 
causing an increase in the overall surface expression of AMPA receptors does not alter 
the ratio of synaptic AMPA receptors to non-synaptic AMPA receptors, suggesting that 
in this instance, the amount of PSD-95 - an effective correlate of the size of post-synaptic 
density, is the limiting factor in determining the number of synaptic AMPA receptors in 
addition to their ratio to diffuse AMPA receptors (Bats et al. 2007). 
MAGI-2 on the other hand is another post synaptic density protein possessing similar 
PDZ domains to PSD-95, with its interaction with TARP y2 being suggested by yeast two 
hybrid analysis. Unusually, this protein possesses several PDZ binding motifs, 3 of which 
(1,3, and 5) possess the theoretical capacity to bind to TARPs, but one of these regions 
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(namely 5) also interacts with NMDA receptors - suggesting a direct physical link 
between AMPA receptors and NMDA receptors within a synapse (Deng et al. 2006). 
Studies have also shown that, as is the case with AMPA receptor subunits themselves, the 
phosphorylation states of TARP isoforms are important in the initiation and maintenance 
of synaptic localisation of AMPA receptors. Phosphorylation of the TARP Y2 isoform by 
CAM KI I and PKC - which as stated earlier are activated as a consequence of Ca^ * influx 
during NMDA receptor activation, promotes trafficking of TARP-AMPA receptor 
complexes to a synaptic localisation due to the phosphorylation of serines in the C-
terminal tail, enhancing the complexes binding capability with PSD-95. Conversely, 
NMDA receptor mediated activation of phosphatases PPl and PP2 promotes 
dephosphorylation of TARPs, which in turn promotes their dissociafion from PSD-95 and 
subsequent loss from a synapse. These two processes, effectively suggest a mechanism of 
action for LTP and LTD respectively (Tomita et al. 2005). 
The most recent studies have also demonstrated, at least for some TARP isoforms, that 
they have the capacity to influence AMPA receptor kinetics by at least two distinct 
mechanisms. 
Firstly, via an interaction between the N-terminal extracellular domain and AMPA 
receptor subunits, TARP isoforms are able to increase the efficacy of kainate, a partial 
agonist of AMPA receptors expressed in heterologous cells, increasing its functional role 
to that of a fijU agonist and vastly enhancing its effects on AMPA receptor activation. 
These effects are dependent upon the TARP isoform present - the Y2 and Y3 isoforms 
having greater effects than Y4, Y7 and yS (Turetsky et al. 2005, Tomita et al. 2005). 
Secondly, via the C-terminal domain, TARPs are capable of decreasing the rate of 
AMPA receptor desensitization in response to glutamate, in addition to increasing the 
rate of recovery from a desensitized state (Turetsky et al. 2005), again this being variable 
dependent upon the TARP isoform involved (Kott et al. 2007). TARPs also enhance the 
evoked response of AMPA receptors following application of glutamate, via what is 
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believed to be an allosteric mechanism that may affect the functional properties of the 
glutamate binding domain of the AMPA receptor (Priel et al. 2005, Tomita et al. 2006). 
Perhaps more importantly considering the aim of this research project is the evidence that 
in addition to their effects on AMPA receptor trafficking, targeting and kinetics, TARPs 
can also influence the pharmacology of AMPA receptor potentiators, in the case of 
cyclothiazide (CTZ), an inhibitor of AMPA receptor deactivation. TARP yl 
demonstrated the capacity to not only enhance the effect of CTZ, but also lessened CTZs 
preference for the flip isoform of AMPA receptor subunits by increasing its affinity for 
flop isoforms via a currently unknown mechanism (Tomita et al. 2006). 
These data demonstrating the importance of TARP-AMPA receptor interactions, 
highlights the potential of utilising TARP isoforms as a possible target for future 
pharmacological treatments, permitting modulatory effects on AMPA receptors 
minimising the risk usually present with compounds that interact directly upon AMPA 
receptors or of any non-specific interaction with KA receptors. It also, by demonstrating 
a known interacting protein of AMPA receptors, opens up possible avenues of 
investigation for other proteins that may interact with AMPA receptors indirectly. 
1.5 AMPA receptors in neurological disorders 
As the principle excitatory amino acid in the CNS, the importance of glutamate and its 
receptors is obvious. However, despite, or perhaps because of this importance the number 
of neurological conditions where dysftinction in the glutamatergic system was considered 
to be a contributory factor in disease pathology was limited. 
One such condition believed to have a critical glutamatergic component is Schizophrenia, 
for which a glutamate hypothesis was developed in the early 1990's based upon the 
observation that non-competitive antagonists to the NMDA receptor were capable of 
eliciting schizophrenia-like symptoms in healthy individuals and could worsen 
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schizophrenic symptoms in those who already suffered f rom the condition (Hertzmann et 
al., 1990). 
This hypothesis was expanded to include non-NMDA ionotropic glutamate receptors, 
most significantly A M P A receptors, which have become the current focus o f study into 
the glutamatergic basis o f schizophrenia. 
Studies o f human tissue have shown minimal differences between schizophrenics and 
non-sufferers in A M P A receptor protein and mRNA levels in a variety o f brain regions, 
with the notable exception o f the hippocampus; with the current hypothesis regarding 
A M P A receptor involvement in schizophrenia believed to be an abnormal function o f the 
interacting proteins associated with the receptor (Gao et al. 2000, Woodruff et al. 2001, 
Beneyto et al. 2006). Obviously there are complications with approaches to treating a 
neurological disorder by targeting the glutamatergic system, not the least o f which being 
excitotoxicity. As a consequence individual aspects o f that system, such as the 
composition o f the A M P A receptors in Schizophrenic patients, including the flip/flop 
variants, identified as being altered in Schizophrenics (Eastwood et al. 1997), are being 
examined to determine their functional significance. Using the flip/flop variants o f the 
A M P A receptor subunits as an example, it is known that the expression o f these variants 
appears to be affected by the chronic administration o f anti-psychotics (O'Connor et al. 
2007). 
Schizophrenia is not the only neurological disorder where a glutamatergic component has 
been investigated, recent studies have also began to investigate the possibility o f a 
glutamatergic component in disorders traditionally associated with different 
neurotransmitters and receptors, such as depression - a condition traditionally believed to 
be predominantly involving the serotonergic system, which was in some form or other, 
the most common pharmaceutical target for traditional therapeutics. 
For example, there is evidence that acute stress and chronic affective disorders, including 
depression, can elicit several neurological responses that affect the glutamatergic aspect 
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o f neurotransmission, wi th acute stress and chronic stress having different effects and 
requiring different treatments. Acute stress can cause the impairment o f LTP (Watanabe 
et al. 1992) and the disruption o f signalling pathways in the CNS in favour o f others. A 
prevalent example o f this is the disruption o f the hippocampal-frontal cortical and 
hippocampal-amgdala pathways that are disrupted fol lowing severe acute stress, whilst 
the amygdala-frontal cortical pathway is unaffected. This can have effects on memory 
formation, particularly the emotional context, although it can be prevented by the 
administration o f tianeptine, an antidepressant wi th effects on A M P A receptors. 
Figure 1.7: Diagram showing the effect of acute stress on neuronal signalling 
pathways and its reversal by tianeptine. Kindly provided by Michael Spedding. 
Chronic stress can lead to several morphological changes within the CNS, particularly 
within the hippocampal formation, wi th dendritic atrophy and decreased neurogenesis 
being predominant features, this in turn decreases total hippocampal volume. 
Antidepressants can also reverse this loss o f arborisation following chronic 
administration o f treatment, which also alters the pharmacological properties o f the 
regions o f the CNS that had been aberrant as a consequence of the chronic depression. 
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primarily the hippocampal formation. There is also evidence that the administration of 
antidepressants alters the expression o f A M P A receptor subunits within the regions o f 
effect (Martinez-Turrillas et al. 2002, Marti'nez-Turrillas et al. 2005). 
Tianeptine is not the only antidepressant compound possessing effects on A M P A 
receptors, in fact there is an increasing number o f antidepressant drugs that either possess 
effects on A M P A or display enhanced potency fol lowing administration o f A M P A 
receptor modulators (Lia X et al. 2002). These discoveries have led to an increase in the 
investigation o f chronic and acute application o f antidepressants on the proteins 
downstream o f glutamatergic signalling pathways. 
A n early observation made fol lowing the chronic application o f antidepressants was the 
upregulation o f Brain derived neurotrophic factor (BDNF) (Coppell et al. 2003), a trophic 
agent present in the CNS that has since been shown to have important effects both in 
neuroprotection, but also in neurogenesis. Such is the importance o f BDNF, that it has 
been attributed to being a protein lynchpin in the treatment o f depression, wi th the 
upregulation o f BDNF seemingly being essential to l imit neuronal atrophy and loss o f 
dendritic arborisation typically associated with chronic exposure to stress, such as that in 
seen in depression. This upregulation o f BDNF in response to chronic antidepressant 
administration occurs predominantly in the hippocampus, one o f the areas most affected 
by depression and chronic stress, which when coupled with the restoration o f 
neurogenesis and neuronal architecture, is compelling evidence supporting the 
importance o f BDNF in both the treatment o f depression, but also alluding to the 
importance o f BDNF in the healthy brain. 
This importance o f BDNF in the treatment o f depression appears to underlie the 
importance o f A M P A receptors within the condition, with increased phosphorylation of 
A M P A receptors, as a consequence o f restored/enhanced LTP, seemingly being linked to 
an increase in BDNF expression within the hippocampus in particular. Indeed, some 
A M P A receptor modulatory compounds, the AMPAkines, possess compounds that 
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promote the upregulation o f BDNF when used as an antidepressant treatment, suggesting 
that modulation o f A M P A receptors influences BDNF expression (Mathew et al. 2005). 
mm 
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Figure 1.8: Changes in B D N F mRNA expression in the hippocampus following 
administration of AMPAkines. 
Slide A is the control fol lowing no administration o f AMPAkines. As can be seen the 
AMPAkines enhance BDNF mRNA levels significantly fol lowing application, 
suggesting A M P A receptors influence BDNF expression. 
Provided c/o M. Spedding, personal communication. 
It has also been observed that application o f antidepressants has several secondary 
effects, notably on glutamatergic neurotransmission, such as the restoration o f LTP and 
reversal o f dendritic atrophy (Shakesby et al. 2002). 
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This o f course has implications in other disorders, such as dementia, with both synaptic 
LTP and the hippocampus being believed as being integral to cognition, learning and 
memory, and modulators o f A M P A receptors (AMPAkines) have been shown to have 
effects enhancing cognition, making them a potential pharmaceutical agent to treat the 
symptoms of dementias (Francis 2008). However, with dementia being predominantly a 
neurodegenerative condition as opposed to a 'mood disorder', which, as w i l l become 
apparent in section 1.6 is the primary area o f clinical relevance promoting the work 
undertaken in this PhD, outlining the glutamatergic component o f dementia would disrupt 
the narrative o f the thesis, so it must be excluded from any elaborate consideration. 
Interestingly, the mechanism of action for AMPAkines reveals that they bind to the S1S2 
domain o f the GluR2 subunit (Jin et al. 2005), which is the same site o f action for 
tricyclic antidepressants (Stoll et al. 2007). 
1.6 AMPA receptors and the Serotonergic nervous system 
With the primary focus o f historical antidepressant treatments being on the serotonergic 
nervous system, predominantly in the form o f selective serotonin reuptake inhibitors such 
as Fluoxetine, the increasingly apparent influences o f A M P A receptor modulators on 
antidepressant function and emerging significance o f A M P A receptor interacting proteins 
in the treatment o f depression logically opens a vein o f investigation regarding potential 
interactions between serotonergic neurones and glutamatergic neurones. 
The serotonergic nervous system utilises the neurotransmitter serotonin (5-hydroxy-
tryptamine - 5HT) as its primary neurotransmitter and possesses a diverse variety o f 
receptors sensitive to serotonin. 
There are seven subdivisions o f 5HT receptors, with at least 13 known subtypes o f 5HT 
receptor divided across the seven subdivisions with 5 H T I A - F (minus 5HTic which was 
renamed 5HT2c), SUTJA-C, S H T S A - C , 5HT4, ShtjA, ShtsB SHTe, 5HT7. The Sht.E and 5ht5 
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receptors use lower case naming due to an absence o f any identified functional role. 
(Marsden et al. 1989, Hoyer et al. 1994, Hannon and Hoyer 2008). 
Figure 1.9: Table of 5HT receptors (Roth et al. 1998, Hoyer et al. 2002, Hannon and 
Hoyer 2008). 
Receptor Name Receptor Class 
and Effector 
Distribution and Function 
5HT,A GPCR - Gi/o 
Located in the CNS, peripheral 
nervous system and gastrointestinal 
tract. Concentrated in limbic regions 
o f CNS. Several ftinctions, 
prominently as inhibitory 
autoreceptors. 
5HT ,B GPCR - Gi/o 
Negatively coupled to cAMP. Present 
in the CNS, particularly the basal 
ganglia, where it displays inhibitory 
effects. Also present in vascular tissue 
throughout the body, with exact 
functional role unknown but 
suspected to be fianctionally 'silent' 
until vascular dysfunction, such as 
atherosclerosis. 
5HT ,D GPCR - Gi/o 
Very similar to 5 H T I B in function. 
Expressed at very low levels in the 
CNS, also detectable in other tissues, 
including the heart. 
5ht,E GPCR - Gi/o 
Detected in human frontal cortex, 
speculated to be negatively coupled to 
adenylate cyclase. 
5HT,F GPCR - G^o 
Detected in the CNS, very similar to 
5HTIB/ID receptors. Believed to have a 
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role in migraine. 
5HT2A 
GPCR-Gq/n 
May couple to 
G|2/13 
Expressed in the CNS. Highest levels 
in brain stem nuclei, moderate levels 
in the striatum and basal ganglia. Also 
located in smooth muscle and on 
blood platelets. 
5HT2B 
GPCR-Gq/n 
May couple to 
G|2/13 
Located in the predominantly in the 
stomach fundus, also located in the 
gastrointestinal tract, heart, kidneys, 
lungs. Possibly present in the brain. 
Also found in vascular tissues. 
5HT2C 
GPCR-Gq/H 
May couple to 
G12/13 
Located exclusively in the CNS, 
predominantly in the choroid plexi, 
but also expressed in limbic 
structures. Large potential for 
extensive RNA editing, wi th different 
edits linked to various neurological 
disorders. 
5HT3A 
Ligand-gated ion 
channel 
Expressed in the CNS, but displays 
low levels o f expression in the 
forebrain. Linked to the dorsal motor 
nucleus o f the vagus nerve, with 
5HT3A antagonists displaying 
antiemetic effects. Also present in the 
gastrointestinal tract and peripheral 
nervous system. 
5HT3B 
Ligand-gated ion 
channel 
Similar expression to 5HT3A 
receptors, unkown fimction. 
5HT3C 
Ligand-gated ion 
charmel 
Not currently known. 
5HT4 GPCR- Gs Promotes cAMP production. Located 
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in the CNS, gastrointestinal tract, 
heart and peripheral nervous system. 
Precise function is unknown, but 
some influence on hippocampal LTP 
and L T D in the CNS. 
5ht5A GPCR - Gi/o 
Not currently defined, some evidence 
o f expression within the CNS. 
5ht5B 
GPCR-
Unknown 
Not currently defined. 
5HT6 GPCR - Gs 
Only currently identified in the CNS, 
seemingly linked to cholinergic 
neurotransmission. 
5HT7 G P C R - G s 
Seemingly expressed in the CNS and 
vascular smooth muscle. 
As can be seen, the 5HT2 receptors are predominantly neuronal, with 5HT2A receptors 
and 5HT2C receptors being expressed in the CNS, the latter exclusively (Abramowski et 
al. 1995, Backstrom et al. 1997). 
The interactions between 5HT2 receptors and A M P A receptors in the CNS as a whole 
however, are poorly documented, but there is emerging accumulation o f evidence o f 
fiinctional interactions in at least some brain regions, regulating specific neurological and 
physiological processes. The bulk o f this work has so far focused upon the A M P A 
receptor mediation o f 5HT2A receptors (Zhang and Marek 2008) and 5 H T release in the 
forebrain (Pittaluga et al. 2007). 
There is also evidence o f the reverse - mediation o f A M P A receptor activity by 5 H T 
receptors (Pinilla et al. 2001, Bouryi and Lewis 2003), wi th this modulation o f A M P A 
receptor activity seemingly occuring throughout a diverse range of CNS regions, but 
predominantly involves particularly 5HT2A receptors, which have been shown to co-
localise with the GluR2 A M P A receptor subunit (Peddie et al. 2008). 
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One such system where evidence o f interplay between serotonergic and glutamatergic 
neurotransmission has been suggested but is increasingly becoming evident is in 
locomotor pathways, including the sensory transmission to reticulospinal neurones within 
the brainstem, where 5HT activity depresses the transmission at glutamatergic synapses 
(Antri et al. 2008). 
Other evidence identifies a direct link between decreased A M P A receptor density and 
depleted 5HT expression during development, with a potential implication upon autism 
(Boylan et al. 2007). 
Both o f the CNS-based 5HT2 receptors - the 5HT2A and the 5HT2c receptors are 
predominantly involved in the stimulation o f phospholipase C and subsequent increase in 
inositol 1, 2, 3 triphosphate (IP3), which ultimately leads to an increase in intracellular 
Ca^ "^  (Lucaites et al. 1996). Whereas 5HT2A receptors frequently have excitatory effects 
on neurotransmission, the predominant influence o f 5HT2c receptors appears to be 
inhibitory, via the excitation o f GABAergic intemeurones (L iu et al. 2007, Boothman et 
al. 2008), with some excitatory effects in specific brain regions (Gajendiran 2008). 
This study focuses on the 5HT2c receptor, a subtype o f 5HT receptor that is exclusively 
expressed within the CNS and is important in the serotinergic-based treatments o f 
depression, with 5HT2c receptor agonists alleviating depressive effects in animal models 
(Moreau et al. 1996). Conversely, fluoxetine, a well established SSRJ, displays 
antagonism o f the 5HT2c receptor (Giorgetti and Tecott 2004). Regardless o f the precise 
mechanism though, this receptor subclass appears to possess significance in depression in 
humans as signified by the behavioural differences induced by polymorphisms (Lerer et 
al 2001). It is this clinical relevance that supports the investigation o f the 5HT2c receptor 
subtype with the overall aim o f invesfigating the possibility o f a link with A M P A 
receptors that could identify suitable targets for future antidepressants. 
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Unusually, 5HT2c receptor knockout mice have not been investigated for any effects o f 
their phenotype on depression, but have been shown to demonstrate enhanced 
exacerbation o f diet induced obesity (Wang and Chehab 2006), indeed, there seems to be 
an association between 5HT2c receptors and weight regulation especially fol lowing anti-
psychotic treatment, with polymorphisms in the 5HT2c receptor gene, and indeed, 
knockouts, displaying obesity (Buckland et al. 2005, De Luca et al. 2007). 
There is also evidence o f 5HT2c receptor regulation o f sleep, with 5HT2c receptor 
knockouts exhibiting enhanced responses to sleep deprivation and other sleep defects, 
including increased wakefiilness (Frank et al. 2002). 
Gavarini et al. (2004) speculated upon the possibility o f SHTJA/IC receptors interacting 
with A M P A receptors to promote A M P A receptor recruitment to silent synapses within 
nociceptive pathways within the spinal cord; the recruitment process most likely 
incorporating interactions between SUTIA/IC receptors and a PDZ protein - such as PSD-
95 - facilitating functional interactions with A M P A receptors via TARPs. 
This information enabled the generation o f three primary hypotheses to be investigated 
by this project: 
• 5HT2C receptors possess a physical interaction with A M P A receptors via TARPs 
and an intermediate PDZ protein such as PSD-95. 
• 5HT2C receptors possess a functional interaction with A M P A receptors that 
incorporates TARPs 
• TARPs have a number o f potential interacting protein partners within the CNS 
and a more multifaceted role than previously supposed. 
To test these hypotheses, a series o f experimental techniques, including but not limited to 
generation o f novel immunological probes to investigate and immunopurify TARPs and 
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their interacting proteins from native CNS tissues with an intention to classify the 
distribution o f TARPs and identify previously unknown interacting protein partners. 
In parallel w i l l be studies using experimental animals possessing altered 5HT2c 
expression within the forebrain, where the novel immunological probes w i l l enable the 
physiological consequences o f these experimental conditions upon A M P A receptor and 
TARP expression can be identified. 
Ultimately these studies w i l l provide some evidence regarding the nature o f the 
interaction between 5HT2c receptors and TARPs, but w i l l also provide evidence o f the 
role o f TARPs in the context o f other interacting proteins other than A M P A receptors. 
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Chapter 2: Materials and methods 
Please note that unless otherwise stated all solutions mentioned in this chapter are 
detailed in Appendix A 
2.1 Animals 
Wild-type (C3B6Fe+, +/+) and heterozygous (C3B6Fe+ , +/stg) were derived from 
heterozygous breeding pairs originally obtained f rom The Jackson Laboratory (Bar 
Harbor, Maine, USA) but were the culmination o f a breeding/maintenance programme at 
the Durham University that has continued in excess o f 5 years. Both the homozygous 
wild-type and heterozygous derived brain tissue was combined and subsequently referred 
to as control material. 
Stargazer mutant mouse material (C3B6Fe+, stg/stg) was obtained from the same animal 
populations as the control material. 
These mice were maintained in the L i fe Sciences Support Unit (LSSU), University o f 
Durham. A l l animals had unlimited access to food and water and were maintained on a 
12 hour light/dark cycle. 
For the 5HT2c receptor over-expression and knock-down data, C57/B16 background 
strain mice were used. The mice were maintained at the University o f Edinburgh Animal 
House. The 5HT2c receptor over-expressing mice were transgenic, with the 5HT2c 
receptor cDNA being co-inserted with a C A M K I I promoter, causing confirmed increased 
expression o f 5HT2c mRNA in the fi-ontal cortex as well as some locomotor and other 
phenotypic effects associated with abnormal 5HT2c receptor expression. 
The 5HT2C receptor knockdown mice were derived from several generations subsequent 
to an original C57/B6 cross with mice containing a forebrain-specific TetA binding site 
containing 5HT2c receptor gene. This enabled inactivation o f 5HT2c receptor expression 
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within the forebrain via the addition o f doxycycline in the drinking water, causing 
decreased 5HT2c receptor mRNA expression in the forebrain and phenotypic effects. 
Figure 2.1 In situ hybridisation data showing 5HT2c mRNA levels within the 
forebrain of mice with altered 5HT2c receptor expression and their relevant 
controls. Provided by Megan Holmes 
Images A and B show the 5HT2c receptor mRNA levels in the control mice, wi th A being 
the relevant control for the 5HT2c receptor knockdown mice and B being the relevant 
control for the 5HT2c receptor over-expressing mice. 
Images C and D show the 5HT2c receptor m R N A levels in the mice with altered 5HT2c 
receptor expression. C shows the 5HT2c receptor mRNA levels in the knockdown mice, 
whilst D shows 5HT2c receptor m R N A levels in the 5HT2c receptor over-expressing 
mouse. 
Male New Zealand white rabbits were obtained f rom Charles Rivers (UK) 
The rabbits were maintained in the Animal Unit at the University o f Sunderland 
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A l l animal husbandry, breeding and experimental procedures, at all sites, was performed 
in accordance with the Animals (Scientific Procedures) Act 1986. 
2.2 Generation of TARP isoform-speciflc antibodies 
It was initially decided that at least one antibody should be generated for each o f the 
TARP isoforms currently known, namely; y2, Y3, Y 4 , and 78. 
Antibody generation utilised the generation o f an antigenic peptide sequence taken f rom 
each o f the individual TARP isoforms, wi th the exception o f the TARP ^2 sequence (as 
used in Ives et al 2 0 0 4 ) , all o f the TARP peptide sequences selected were novel in the 
generation o f antibodies. The antigenicity o f the whole peptide sequence was analysed by 
the ANTHEPROT package designed to predict protein antigenic properties (Parker et al. 
1986), with these data being contrasted to the peptide sequence to find regions that were 
not within a transmembrane domain and not conserved between TARP isoforms, yet 
displayed antigenic properties. 
TARP y3: Peptide Sequence C - H S E L L K K S T F A R L 
TARP Y4: Peptide sequence MHDFFQQLKEGFHVS-C 
TARP y8: Two antibodies were generated - one directed to the N-terminus, the other to a 
region o f the proximal C-terminal domain (hereafter referred to as TARP 78N and TARP 
Y8C respectively). N-Terminal sequence M E S L K R W N E E R G L W - C 
Proximal C-terminal sequence RGSSAGFLTLHNAFP-C 
A l l o f the peptide sequences were subjected to the addition o f a terminal cysteine residue 
for utilisation o f sulphide bonding in the subsequent coupling o f the peptide to the carrier 
protein. Keyhole Limpet Haemocyanin ( K L H ) . 
2.3 Rabbit immunisation protocol. 
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2.3.1 Peptide conjugation 
Imject® Malemide activated m c K L H kit. For each o f the peptides five mg o f appropriate 
peptide was dissolved in 300|j,l o f the conjugation buffer supplied in the kit. This 
dissolved peptide solution was immediately mixed with the lOmg/ml m c K L H provided in 
the kit (i.e one vial o f m c K L H dissolved in 200pl o f dH20), and left to incubate for two 
hours at room temperature. 
After the two hour incubation, EDTA was premoved from the peptide/mcKLH solution 
using the desalting columns provided in the kit using the following protocol: 
• Initially one bottle o f purification buffer salts was dissolved in 60 ml dH20, with 
each desalting colunm being washed with 15 ml (three column volumes) o f the 
reconstituted purification buffer. 
• Following the washes, the conjugated peptide solution was added to the desalting 
column. 
• The conjugated peptide solution was then pushed through the column by 10 
aliquots o f purification buffer, added in 0.5ml volumes, with each 0.5ml fraction 
passing through the column being kept individually. 
• The absorbance at 280nm o f each collected fraction was measured, with the 
conjugated peptide being located in fraction with the first absorbance peak, plus 
any subsequent fractions tied in to that peak. 
• The peak fractions containing the conjugated peptide were kept at -20°C for long-
term storage. 
2.3.2 Immunisation protocol 
The conjugated peptides were used for the inoculation procedure. For the initial 
inoculation 300)xl o f conjugated peptide was mixed with 300pl o f Freund's complete 
adjuvant, giving a 1:1 ratio. The mixture was then forcibly expelled and repeatedly taken 
up into a glass syringe until an emulsion was formed. The emulsions were stored at 4*^ C 
ovemight to determine whether the peptide and adjuvant remained in emulsion, and i f 
suitable, were used that morning for inoculation. 
Two male New Zealand rabbits were selected and inoculated intra muscularly with 100^1 
of their specific peptide/adjuvant, and then monitored by the animal unit staff in case o f 
an adverse reaction. 
Subsequent inoculations occurred four weeks after the previous inoculation, but with the 
exception o f the initial inoculation, utilised Freund's incomplete adjuvant. This was 
prepared in the same manner as the complete adjuvant - namely 300|j,l of conjugated 
peptide being emulsified with 300|il o f incomplete adjuvant, left over night, and then 
100\il o f the emulsion being administered. 
The only notable difference in the procedure was the subsequent inoculations being 
administered to alternate hind legs, ensuring the animal never received an injection into 
the same limb as the injection both previous and subsequent to it. 
2.3.3 Collection of blood from rabbits 
Immediately prior to the initial inoculation 10 ml o f blood was collected from each rabbit 
using an ear-bleed procedure. This blood was used as a pre-immune control sample in 
future ELISAs. 
Subsequent collection o f blood was conducted 10 days post inoculation, again via an ear 
bleed procedure, allowing collection o f up to 10ml o f blood. 
One from each pair o f rabbits was subjected to terminal exsanguination instead o f the 
usual ear bleed after the fourth inoculation, with the blood being collected using a cardiac 
puncture protocol conducted by the animal unit staff at the University o f Sunderiand. 
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The remaining rabbits were subjected to terminal exsanguination following the fifth 
inoculation. 
Blood samples collected were stored at 4°C for transport. 
2.3.4 Isolation of sera 
Blood samples were incubated at 37°C for 30 minutes, before having the inside of their 
falcon tubes scraped with a glass Pasteur pipette to promote detachment of any formed 
clot, and also to ensure that any further clotting would not adhere to the tubing. The 
samples were then stored over night at 4"C. 
The following day the blood clots were removed from their respective tubes and 
discarded. The sera was aliquoted into 1.5ml eppendorf tubes and centrifuged at 14,000 G 
for 5 minutes using a micro-centrifuge, to ensure any remaining red blood corpuscles, 
and other detritus could be separated from the serum. 
Following centrifugation, the supernatant sera was carefully collected and aliquoted to 
fresh 1.5ml eppendorf tubes, a 500nl aliquot of each was prepared for use in ELISA's, 
but like all the samples, was flash-frozen in liquid nitrogen and stored at -20°C. 
2.4 Purification of antibodies from inoculated rabbits. 
2,4.1 Generation of peptide columns for purification of antibodies from serum. 
The equipment used to generate the peptide columns was the PIERCE sulfolink kit 
(product number 44895 - now discontinued) purchased from PIERCE Biotechnology. 
The kit is a self-contained source of all the materials required to perform five 
immobilization reactions using terminal sulfhydryl groups on the proteins/peptides of 
choice. 
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The protocol used, was exactly as described in the instruction booklet provided. Outlined 
below in relation to how the kit was used for this project (unless stated otherwise, all 
buffers/items were taken from the kit). Peptides were coupled individually with the 
protocol being completed for a single peptide before commencing the next peptide; 
• 5mg of each of the TARP isoform peptides were dissolved in separate 1.5ml 
eppendorf tubes containing 1 ml of the sample buffer provided by the kit. 
• This peptide solution was then added to the vial containing the reducing agent to 
produce a final concentration of 50mM MEA in the mixture and incubated for 
1.5 hours at 3 7 T 
• Towards the end of the incubation the top and bottom caps were removed from 
the desalting columns provided, and the column was equilibrated with 20ml of 
coupling buffer equivalent to 4 column volumes. 
• The peptide/reducing agent mixture was allowed to cool to room temperature 
then applied to the equilibrated desalting column to remove excess reducing 
agent. 
• After the mixture had been added to the desalting column, 3ml of coupling buffer 
was applied, with the 3ml of solution that flowed through the column being 
collected in 1 ml fractions, with the fraction with the peak absorbance at 280rmi 
being used for production of the peptide column. 
• Equilibrate the sulfolink column with four column volumes of coupling buffer. 
• Replacing the caps, add the reduced peptide, and incubate at RT for 45 minutes, 
mixing gently for the first 15 minutes. 
• Drain solution (absorbance of which can be read to determine coupling 
efficiency) and wash column with three column volumes of coupling buffer. 
• Block by incubation for 45 minutes with 2ml of coupling buffer containing 
0.05M L-Cysteine, again with agitafion for the first 15 minutes of the incubation. 
• Column was then washed with 6 column volumes of wash solution, and 
subsequently equilibrated using the lab stock of phosphate buffered saline (PBS), 
with the storage solution being PBS 0.05% (w/v) sodium azide. 
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2.4.2 Serum purification 
The purification of sera from each rabbit was conducted in a manner based upon the 
protocol outlined by Ives et al (2002). 
Using the peptide columns generated, 3ml of isolated serum was thawed and added to the 
peptide column generated using the same peptide. The column itself was connected to a 
peristaltic pump to ensure continual circulation of the serum, and also to prevent the 
column from drying. This was conducted overnight at 4°C. 
The following day, the pump was disconnected and the flow-through collected and flash-
frozen before being stored at -20°C. The peptide column itself was washed with 6 column 
volumes of PBS and after the wash had passed through the column, the purified antibody 
was eluted by the addition of 8ml of Glycine buffer pH 2.5, and collected in 1ml fractions 
that were neutralised by I M Tris. The absorbance of each fraction was measured at 
280nm, and the fractions with the highest absorbance were pooled for dialysis. 
2.4.3 Preparation of dialysis membrane. 
The dialysis membrane used for the dialysis of the generated antibodies possessed a 
12,000 - 14,000 dalton molecular weight cut off point. It was prepared for use by placing 
into a solution of 1 mM EDTA, 2% (w/v) NaHCOs and brought to boil for 10 minutes. 
After these initial 10 minutes, the tubing was removed from the first solution, rinsed 
briefly in de-ionised water, and transferred to a second beaker containing I mM EDTA, 
2% (w/v) NaHCOs and brought to boil for another 10 minutes. 
Once these 10 minutes had elapsed, the tubing was rinsed thoroughly in de-ionised water 
and placed into a beaker of dH20 0.05% NaN03 for storage at 4°C. 
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When used to dialyse the antibody samples, the dialysis tubing was removed from its 
storage solution, rinsed in de-ioinsed water, and then, once sample had been added, tied 
and clamped at both ends. The solution used for dialysis, which is what ultimately the 
antibodies were stored in, consisted of PBS 0.05% NaNOs. 
2.4.4 E L I S A protocol 
ELISA's were used to determine the antibody titre of each bleed from each rabbit, to 
provide some form of indication as to the quality of the antibody production, but also to 
aid with determining at which time point the rabbits should be terminated. The 
generalised protocol was the same for each of the bleeds/rabbits. 
Half of a 96 well plate was incubated overnight at 4°C containing 100|il of sodium 
bicarbonate buffer pH 9.5 containing peptide at 1 iig/\i\. The other lanes were incubated 
overnight at 4°C with just the bicarbonate buffer without the peptide to serve as the blank 
for each bleed concentration. 
On the second day, each well was washed three times with 200^1 of PBS/0.25% (w/v) 
gelatin, with each wash being removed immediately after it had been added to every well 
on the plate. A fourth wash was then added and left to block the wells whilst the plate 
wash incubated at 37°C for 45 minutes. 
Following the 45 minutes blocking step, the wells were aspirated and the appropriate 
sera/purified antibody was added, in semi-log dilutions down each column, with row A 
being the most concentrated, right down to row H with the most dilute samples. The plate 
was then incubated overnight at 4°C to facilitate antibody binding. 
Following overnight incubation with the primary antibody each well was washed three 
times with 200nl of PBS/0.25% (w/v) gelatin (as per the previous day), with a fourth 
wash being left incubating in the wells for 10 minutes. 
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Once the 10 minutes were over, the wellplate was aspirated and 100^1 of HRP-
conjugated secondary antibody (in the case of every experiment described in this thesis 
anti-rabbit IgG) diluted in the PBS/0.25% (w/v) gelatine was incubated in each well for 
90 minutes at 37°C. 
Following the 90 minute incubation with the secondary antibody the well plate was 
aspirated and then washed four times with 200|al of PBS/0.25% (w/v) gelatine, before a 
fifth wash of200til of PBS. 
After the PBS wash, each well was incubated with 100|il of substrate (4mM O-
phenylanine diamine, 0.02M citric acid, 25mM di-sodium hydrogen orthophosphate, at 
pH 5, with 10|il of hydrogen peroxide being added to the substrate solution immediately 
prior to its addition to the wellplate. 
The wellplate was then stored in the dark for five minutes, or until any wells in the blank 
half started to turn yellow. 
Reaction was stopped by adding 50[il of dH2O/20% (v/v) sulphuric acid, with the 
absorbance of each well being measured at 490nm. 
2.4.5 Cardiac perfusion 
Mice were terminally anaesthatised with pentobarbitone and tested for hindleg reactions, 
blinking reflexes. Once unresponsive the animals were placed on a dissectiong tray and 
the fur of the abdomen and thorax removed. A small incision was made in the abdominal 
wall, enabling access to the chest cavity, which was opened by incision across the rib 
cage exposing the heart £ind lungs. The fi-ont of the chest was clamped open and away 
from the main body, whilst a hyperdermic needle attached to a peristalfic pump inserted 
into the left ventricle. A small incision was made to cut the right atrium, then the 
peristaltic pump activated, initially pumping ice-cold PBS 0.01% (w/v) Sodium nitrite 
into the circulatory system for at least 10 minutes, during which time the liver, lungs and 
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internal vasculature was observed to determine clearance of the blood. This technique 
was used both for preparing tissue for dissection with a vibromicrotome, but also for 
perfusion-fixation for immunohistochemistry. 
2.5 TARP distribution mapping 
2.5.1 Tissue dissection for subsequent solubilisation 
Age and gender-matched C3B6Fe'^  wild-type (both +/+ and +/stg) and stargazer (stg/stg) 
mice were selected in batches of three and individually injected with a terminal dose of 
anaesthetic before being subjected to cardiac perfusion with ice cold PBS/0.1% sodium 
nitrite (w/v) containing the following protease inhibitors; Aprotinin (2 j^g/ml), Leupeptin 
(1 |j.g/ml), and Pepstatin A (1 (a,g/ml). 
The brain was then extracted from the skull and stored in ice, whilst the cerebellum from 
each mouse was dissected out and flash frozen. Also the spinal column was extracted 
from each mouse and stored in ice until the spinal cord could be readily extracted. 
The brains themselves were cut into 200 |im coronal sections using a vibrotome 
containing a bath ice-cold of PBS/0.1% (w/v) sodium nitrite and were subsequently 
dissected using a light microscope at 4°C. 
From each of the sections the cerebral cortex, hippocampus proper, dentate gyrus, 
striatum, and thalamus were dissected individually. Samples from each of the three mice 
were pooled together because the dissections occurred simultaneously, with the pooled 
tissues, in addition to the cerebella and spinal cords, flash frozen and stored at -80"C until 
solubilisation. 
2.5.2 Tissue solubilisation for TARP distribution mapping. 
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Tissues collected were homogenised and solubilised for 30 minutes at room temperature 
in 500 ^il of solubilising buffer (2% (w/v) SDS, 50 mM Tris, 2 mM EDTA). All solutions 
contained protease inhibitors; Aprotinin (2|ig/ml), Leupeptin (1 ng/ml) and Pepstatin A 
(1 |a.g/ml). After solubilisation the tissues were centrifiaged at 14,000 G for 10 minutes, 
following which the supernatant was collected, aliquoted, and flash frozen for storage at -
80°C. 
2.6 Generic techniques common for all immunoblotting preparations 
2.6.1 Chloroform-methanol precipitation 
The chloroform-methanol precipitation used for the preparation of samples for SDS-
PAGE in this thesis was the standard protocol established in the literature (Wessel D, 
Flugge UI 1984, Duggan et a/., 1991). 
To summarise: Up to lOOjil (one volume) of sample was placed into a 1.5ml eppendorf 
tube, to which four volumes of methanol was added and the mixture vortexed briefly. 
Following vortexing, one volume of chloroform was added to the sample/methanol 
mixture, and again, this mixture was vortexed briefly. Immediately after, three volumes 
of dH20 were added to the mixture, the sample was vortexed briefly then subjected to 
centrifugation on a table-top centrifiige at 14,000 G for two minutes. 
Following centrifugation, three layers were detectable. Using a pipette, the uppermost 
layer was largely aspirated, and discarded. To the remainder of the mix, three volumes of 
methanol was added, and the sample gently tapped to mix the layers, before being 
subjected to centrifiigation, again at 14,000 G for two minutes. 
After this second period of centrifugation, all of the supernatant was aspirated and 
discarded, and the pellet was dried in a vacuum desiccator. 
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Once dry, the pellet was re-suspended in 2X SDS-PAGE sample buffer and heated to 
95°C for five minutes, before being centrifuged at 14,000 G and either loaded onto an 
SDS-PAGE gel, or frozen for storage at -20°C. 
2.6.2 Immunoblotting 
Samples for immunoblotting were subjected to SDS-PAGE (Summers et al. 1965, revised 
as outlined Thompson et al. 1998) using 10% (v/v) acrylamide resolving gels prepared 
between alumina and glass plates suitable for use in a Hoefer Mighty Small II vertical 
slab gel electrophoresis unit. The plates and the spacers used were pre-rinsed with 100% 
ethanol and subsequently acetone prior to use, with the resolving gels prepared in batches 
of 11 and stored at 4°C in running gel buffer diluted 1:3 with dH20. 
For sample loading a 3.5% acrylamide stacking gel was prepared and set above the 
resolving gel with a 0.75mm 10 well comb being placed into the mixture prior to it 
setting. Once the stacking gel had set, the gels were immersed in IX electrode buffer and 
the samples loaded into the wells using a Icm^ Hamilton syringe. Pre-stained protein 
standards of known molecular weights (range 10-250 kDa) were also loaded. 
For CNS tissues lOng of protein was loaded in a volume of 10^1 of 2X SDS-PAGE 
sample buffer effectively at Ip-g/iJl final concentration. The protein concentration was 
calculated using the Lowry Protein Assay (Lowry et al 1951). 
For all controls and antibody characterisation where TARP transfected HEK293 cells 
were used HEK293 samples were of an unknown final protein concentradon, with 100^1 
of cells taken from stock and resuspended in 100|xl of 2X SDS-PAGE sample buffer 
making their final concentration much higher than l|xg/iJ.l 
For the immunoblots where 5HT2c receptor expressing cells or their respective controls 
CHO cells transfected with either empty vector (M) were provided by Servier and were 
prepared by initially diluting 1 in 4 with PBS. 100^1 of these diluted cells were then 
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subjected to Chloroform-methanol precipitation and subsequent re-suspension in 100^1 
of 2X SDS-PAGE sample buffer, of which 10^1 was loaded per lane. 
Once all samples were loaded, electrophoresis was conducted at 80V until the samples 
entered the resolving gel, and at 1OOV subsequent. 
The completed SDS-PAGE gel was subjected to protein transfer onto nitrocellulose using 
a Hoefer TE series transphor unit set at 50V for two hours, whilst suspended in IX 
transfer buffer. Cassette set-up was as recommended for the equipment, with care taken 
to eliminate any air bubbles. 
2.6.3 Antibody labelling of immunoblots 
Nitrocellulose containing the protein samples was blocked for 1 hour at room temperature 
in ~50ml of blocking buffer prior to overnight incubation in a 50ml Falcon tube 
containing primary antibody in 3ml of incubation buffer. 
Antibody concentrations used for immunoblots: 
• TARP Y2 = 0.5 ^ig/ml 
• TARP y4 = 2 ^ig/ml 
• TARP Y8C = 0.5 iig/ml 
• GluRl = 1 |ig/ml commercial antibody from Cambridge Research Biochemicals 
• GluR2 = 1 in 500 dilution of commercial antibody purchased from Santa Cruz 
Laboratories 
• 5HT2C = Mouse and goat raised antibodies were used at a 1 in 250 dilution of the 
stock solution, again both were commercial antibodies purchased from Santa Cruz 
Laboratories 
• PSD-95 = 1 in 1000 dilution of stock solution, commercial antibody purchased 
from Abeam 
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P-Actin = 1 in 5000 dilution of commercial mouse monoclonal antibody, 
purchased from Sigma 
Subsequent to overnight incubation the nitrocellulose was washed three times with 15-
20ml of wash buffer in five minute wash steps, before being incubated with the 
appropriate horse radish peroxidase-linked secondary antibody for 1 hour at room 
temperature on rollers. 
Secondary antibody concentrations 
• Rabbit = 1 in 1000 dilution of commercial antibody, purchased from Amersham 
Life Sciences 
• Mouse = 1 in 1000 dilufion of commercial antibody, purchased from Amersham 
Life Sciences 
• Goat = 1 in 5000 dilution of commercial antibody, purchased from Amersham 
Life Sciences 
After incubation with the secondary antibody, nitrocellulose was washed five more times; 
the initial three times with wash buffer and the final two with PBS. 
After washes the nitrocellulose was dried and labelled with diluted HRP-linked antibody 
to identify the protein standards and consequently the molecular weights. 
The nitrocellulose itself was subjected to enhanced chemiluminescence utilising 
incubation in 1.25M luminol, 68mM p-coumaric acid (dissolved in DMSO) and hydrogen 
peroxidase for one minute, with subsequent exposure to ECL hyperfilm (Amersham) 
being of variable timings determined by the primary antibody. Film was developed 
manually using Kodak GBX fixer and developer solutions. 
The subsequent bands on the film were analysed using Image J to quantify the intensity 
of labelling compared to the background. 
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2.7 Immunohistochemistry 
2.7.1 Perfusion of tissue for immunohistochemistry 
Protocol followed the cardiac perfusion as outlined earlier, however, after clearance with 
the PBS 0.01% (w/v) sodium nitrite, the tissue was perfiised with ice-cold fixative 
solution. The needle was held in place for 10 minutes until the heart was sufficiently 
fixed to clamp the needle in place and left for 20 minutes post-clamping, for a total fix 
time of 30 minutes. 
2.7.2 Fixing of tissue and preparation for immunohistochemistry 
Samples were subjected to perfusion fixation and left in fixative containing 4% (w/v) 
paraformaldehyde overnight at 4°C. Where this was not possible, as in the case with the 
Edinburgh material, samples were post-fixed for 48 hours in fixative solution, which was 
changed at the 24 hour interval. Samples were dehydrated using sucrose infiltration, 
before being sliced into 30|j,m sections using a crystoat at -30°C. Brains were sectioned 
coronally, horizontally, or sagitally, whereas spinal cord was only sectioned sagitally. To 
prepare the spinal cord, the entire spinal column was extracted from the animal and left 
for overnight in fixative solution, after which the vertebrae were removed by careful 
dissection prior to sucrose infiltration - dehydrating the tissue so that ice crystals will not 
form during freezing. 
Following sucrose infiltration, the samples were frozen in iso-pentane at -70°C for 1 
minute and sectioned in a Cryostat at -26°C into 30^m thick sections. 
Sections were transferred into a 24 well dish, with each well containing PBS 0.05% (w/v) 
sodium azide and stored at 4°C until use. 
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With the 5HT2C receptor over-expressing and knockdown mice and their respective 
controls perfusion-fixation was not possible; Brains were dissected quickly and placed in 
4% paraformaldehyde-based fixative and stored at 4°C, with daily changes of fixative. 
2.7.3 Immunohistochemistry/lmmunocytocheinistry 
Samples were transferred from their storage solution and placed into 300fil of Tris-
buffered saline (TBS)/10% (v/v) methanol/3% (v/v) Hydrogen Peroxide, and incubated 
with mild agitation at room temperature for 30 minutes. This step was to inhibit any 
endogenous peroxidase activity present in the sample, for example, any residual red 
blood corpuscles. 
Following this incubation the samples were washed three times with TBS 0.2% (v/v) 
Triton X-100™ (Hereafter referred to as TBS-T), with each wash lasting five minutes. 
After the wash stages, samples were incubated in TBS 0.2% (w/v) glycine for 30 minutes 
at room temperature to quench excess paraformaldehyde. 
After incubation with TBS-glycine, the samples were incubated for one hour at room 
temperature with TBS-T/10% blocking serum (either horse i f goat primary antibodies 
were to be used; goat i f rabbit primary antibodies were to be used; or rabbit i f mouse 
primary antibodies were to be used). After which the samples were incubated in primary 
antibody diluted in TBS/1% blocking serum over night at 4''C. 
The following day the samples were allowed to equilibrate to room temperature for one 
hour before being washed with the TBS-T as per the previous day, prior to being 
incubated in the appropriate biotinylated secondary antibody (From the Vectastain ABC 
kit) diluted in TBS/1% blocking serum (one drop in 10ml of TBS/serum). 
Incubation with the secondary antibody was for two hours at room temperature, before 
another wash stage, and incubation with ABC reagent diluted in TBS for one hour at 
room temperature. 
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After incubation with the ABC reagent, the samples were subjected to one wash stage 
(3X5 minute washes with TBS-T) and two further washes of TBS before being incubated 
in TBS 0.5mg/ml 3'3'-Diaminobenzidine (DAB) to which 0.00067% (v/v) hydrogen 
peroxide was added. 
Samples were allowed to develop until an optimal signal had been achieved, without 
compromising the control sections. 
After staining, the DAB mixture was aspirated and the samples washed twice with dH20 
before being dehydration mounted onto glass slides and set with DPX mountant. 
In the case of immunocytochemisty, the HEK293 cells that had been transfected with 
individual TARP isoforms using the Lipofectamine 2000 (Invitrogen) protocol 
(transfections performed by Dr V Harm) were cultured on glass cover-slips and stored 
individually in wells in a 24 well-dish. 
2.7.4 Concentrations of primary antibodies used in 
immunohistochemistry/immunocytochemistry 
• TARP 74 = 0.5\ig/m\ 
• TARP Y8C = 0.0626ng/ml 
• GluRl = 0.5|ig/ml dilution of source antibody (commercially obtained as 
mentioned in section 2.6.3). 
• GluR2 = 1 in 1000 dilution of source antibody (commercially obtained as 
mentioned in section 2.6.3). 
2.7.5 Peptide block (Only conducted using the generated TARP isoform-specific 
antibodies) 
2.7.5.1 Immunohistochemisty 
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To screen the antibodies and determine the specificity of antibody binding to its antigenic 
peptide, the primary antibody was pre-incubated overnight at 4°C with a 5-fold excess of 
its respective peptide before being used as standard in the immunohistochemical protocol. 
2.7.5.2 Immunoblotting 
Again, for the purposes of determining antibody specificity to the antigenic peptide, the 
primary antibody used to probe the immunoblots was incubated for 30 minutes at room 
temperature with its respective pepfide, before the antibody-peptide mixture was used in 
the afore-mentioned immunoblotting protocol. 
2.7.5.3 Immunocytochemistry 
Cells were prepared as standard for immunocytochemistry. Peptide block was conducted 
using an antibody-peptide pre-incubation identical to that used for the 
immunohistochemistry. 
2.8 Immuopurifications 
2.8.1 Tissue solubilisation for immunoaffinity purification 
The preparation of tissue for immunopurification was based upon the protocol outlined 
by Kannenberg et al. (1997): 
Eight cortices of fissue were initially homogenised in 50ml ice cold Sigel's buffer (NaCl-
based) plus containing protease inhibitors; aproprotein (2 |ig/ml), leupeptin (1 )ag/ml), 
pepstatin A (1 |ag/ml), and PMSF (ImM). Homogenate was centrifuged at 18,500 G for 
30 minutes at 4"C. Supernatant was discarded and the pellet resuspended in Sigel's buffer 
(as above) with 1% Triton X-100^'^, and incubated at 4''C for 30 minutes on rollers. The 
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mixture was then subjected to centrifugation at 23,000 G for 30 minutes at 4°C, with the 
supernatant being collected and subjected to ultra-centrifugation at 40,000 G at 4"C for 
75 minutes. The supernatant from this centrifiigation was then passed onto a pre-
equilibrated immunoaffinity column (equilibration with 60ml ice cold sigels buffer/1% 
Triton X-lOO'^'^), and left to incubate overnight at 4"C. The following morning the 
column was washed (with 60ml ice cold sigels buffer/1% Triton X-lOO™) and subjected 
to acid elution with lOOmM glycine pH 2.5 - neutralised in I M Tris. The immunoaffinity 
purification process was repeated for a second night in an attempt to ensure all TARP y8 
protein complexes were purified. Eluted fractions were flash-frozen immediately after 
collection, as were the Triton X-lOO^*^ insoluble pellets from centrifugation. 
2.8.2 Immunopurification of Triton X-100^^ Soluble Material 
The protocol for immunopurification of the Triton X-lOO"^ material was based upon the 
protocol used by Ives et al (2004), and essentially the same as that outlined by section 
2.4.2, with the material circulated through the immunoafifinity column derived from the 
TARP isoform-specific antibody of choice, overnight at 4°C. The following morning, the 
bound proteins were eluted using glycine buffer pH 2.5. 
2.9 Proteomics 
2.9.1 Clean-up of purified samples 
The purified fractions containing the highest amount of eluted material (peak fractions), 
as determined from immunoblotting (data not shown), were initially pooled into 2ml 
samples and concentrated into -lOO^il samples using microcon centrifuge tubes at 14,000 
G at 4°C for four hours. Samples were then subjected to clean up using a 2D clean up kit 
(GE Healthcare). This was because of previous problems in proteomic identification 
caused by the buffers used in immunopurification and subsequent elution.neutralisation 
(personal communication, Dr H Payne). The protocol was exactly as outlined in the kit, 
to outline; 
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• Samples were incubated on ice for 15 minutes with 300|il of the precipitant 
(provided by kit recipe not given). Before addition of 300^1 of co-precipitant 
(again as supplied), and subsequent centrifugation at 12000 G for five minutes at 
4°C. 
• Supernatant was then aspirated, with samples pulse centrifuged to ensure all 
supernatant could be accessed. Once aspiration was complete 40p.l of co-
precipitant was added and samples were incubated on ice for five minutes. 
• Samples were then centrifuged for five minutes identical to that mentioned in the 
first step, with the supernatant being removed and replaced by 25^1 of ultrapure 
water. The sample/water mixture was then gently vortexed for 10 seconds before 
addition of 1ml of wash buffer (at -20°C, again from kit) and 5^1 of wash additive 
(supplied in kit), with the resultant sample mixture then incubated at -20°C for 30 
minutes with occasional mixing. 
• After the incubation step, samples were centrifuged as in the previous step, with 
the bulk of the supernatant aspirated, the pellet being allowed to dry and 
subsequently re-suspended in 100|il lysis buffer (Appendix A). 
The cleaned samples were then subjected to chloroform-methanol precipitation and 
resuspended in 15^1 of I X Proteomic sample buffer for loading onto pre-cast NuPAGE^'^ 
gels for electrophoresis at 200V for one hour. For all proteomic gels concentrated peak 
samples from the Non-specific IgG, TARP ySN IgG and TARP ySC IgG immunoaffinity 
were used, with 12 nl of the sample/lX proteomic sample buffer being loaded per well. 
During electrophoresis, gels were immersed in IX NuPAGE running buffer diluted from 
the 20X concentrated stock. 
2.9.2 Silver stained gels: Protocol for use with MALDI-TOF 
Following electrophoresis, the NuPAGE gels were subjected to silver-staining using the 
following protocol: Standard pre-cast NuPAGE gels (10% acrylamide) were inifially 
subjected to 30 minutes fixation using a 10% (v/v) acefic acid, 40% (v/v) methanol, 50% 
(v/v) dH20 mixture, with fresh fix being substituted after 15 minutes. 
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After fixation the gels were sensitized using a solution containing 30% methanol (v/v) 
and 4% (w/v) sodiumthiosulphate plus 6.8% (w/v) sodium acetate for 30 minutes. 
Following sensitization, the gel was washed three times with dHiO for five minutes per 
wash before staining in 0.25% (w/v) silver nitrite for 20 minutes. 
Subsequent to staining, the gels were briefly washed twice with dHjO before being 
developed using 2.5% (w/v) sodium carbonate plus 0.04% (v/v) formaldehyde until the 
bands were detectable at a suitable intensity. Developing was stopped using 1.46% (w/v) 
EDTA for 10 minutes. 
After stopping development, the gel was washed several times with dH20 and any bands 
specific to either of the TARP yS IgG samples were cut out and subjected to MALDl-
TOF or MALDI-TOF/TOF analysis. 
2.9.3 MALDI-TOF/MALDI-TOF/TOF analysis 
The protein bands were transferred to a 96-well microtitre plate and then subjected to the 
ProGest long trypsin digestion protocol at a ProGest workstation (Genomic Solutions 
Ltd): 
• Initially the bands were equilibrated in 50)il of 50mM ammonium bicarbonate 
before subsequent reductive alkylation with lOmM DTT and lOOmM 
iodoacetamide. 
• The reductively alkylated bands were then destained and desiccated using 
acetonitrile. 
• Bands were subsequently re-hydrated with 50mM ammonium bicarbonate 
containing 6.6% (w/v) trypsin (Promega) and digested overnight. 
• The following morning, peptides were extracted using 50% (v/v) acetonitrile, 
0.1% (v/v) TFA into a final volume of 50\i\ (2 x 25|xl extractions) 
• The resulting extracts were then freeze-dried and re-suspended in 10 nl of 0.1 % 
formic acid. 
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For MALDI-TOFAnalysis 
• Using the 'thin-film' method: Approx. 0.2 ,^1 of matrix (a-cyano-4-hydroxy-
cinnamic acid in nitrocellulose/acetone) was spotted to the target plate, with 1 | i l 
of digested sample was applied to the thin film & allowed to dry. 
• The samples were then washed in-situ with 0.1 % TFA and left to dry before 
performing MALDI-TOF using a Voyager-DE^M STR BioSpectrometryT"^ 
Workstation (Applied Biosystems). 
• De-isotoped & calibrated spectra were then used to generate peak lists which were 
searched using MASCOT (www.matrixscience.com) mass spectrometry database 
search software. 
For MALDI-TOF/TOFAnalysis 
• Matrix is a-cyano-4-hydroxy-cinnamic acid / in 50% acetonitrile. 1 |al of matrix 
was spotted and 1 | i l of digested sample on top and allowed to dry. 
• MALDI-TOF/TOF was performed using a 4800 Plus MALDl TOF/TOF Analyzer 
(Applied Biosystems) - From the initial MS spectra, the top 10 precursor pepfides 
are selected for subsequent MS/MS sequencing. 
• De-isotoped & calibrated spectra were then used to generate peak lists. Peak lists 
and accompanying MS/MS spectra were used to search against MASCOT 
(www.matrixscience.com) database search software. 
All MALDI-TOF and MALDI-TOF/TOF analysis was completed by Joanne Robson. 
2.10 Receptor autoradiography 
2.10.1 Collection and preparation of tissue 
Whole brains were collected fi-om terminally anaesthatised 5HT2c receptor over-
expressing and knockdown mice, and their respective controls, and stored in PBS/20% 
sucrose at 4°C imtil use. 
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For sectioning, the brains were subjected to hemisectemy and one hemisphere, selected 
for autoradiography and flash-frozen in isopentane at -40°C for 3 minutes prior to being 
sectioned on a cryostat into sections 16^m thick. 
The sections were thaw-mounted onto polysine coated glass slides and stored at -20°C 
until their use in autoradiography. 
2.10.2 Autoradiography of mice possessing altered SHTic receptor expression 
• Sections were pre-incubated for 20 minutes in pre-incubation buffer containing 
30mM Tris at pH 7.4 on ice. 
• Following preincubation, sections were transferred to buffer that was identical to 
the pre-incubation buffer with the addition of the radio-Iigand, in this instance 
[^H] AMPA at a 20nM and lOOmM KSCN; on ice for 1 hour. 
• After incubation with the ligand containing buffer, sections were subjected to a 
series of staggered immersion washes of 15 seconds each, with the first three 
washes being wash buffer (30mM Tris, pH 7.4, lOOmM KSCN, and the final 
being dH20; all conducted on ice. 
• After washes, sections were left overnight to dry before being placed in an 
autoradiography cassette exposed to ["'H] Hyperfilm (Amersham), prepared in a 
darkroom and left for 5 weeks before manual developing using the Kodak GBX 
fixer solutions as per immunoblots. 
• For non-specific binding samples were incubated in radio-ligand buffer to which 
ImM glutamate had been added and left for one hour on ice. 
The film was analysed using Image J and the relative intensities of the cortical labelling 
calculated between the experimental samples and their controls. 
2.11 Statistical analysis of immunoblots and autoradiography. 
This was conducted using Microsoft Excel and GraphPad software in an un-paired / test, 
with p<0.05 considered statistically significant. 
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Chapter 3: Generation of novel TARP isoform-specific 
antibodies and their use in determining TARP isoform 
distribution in the CNS. 
Introduction 
The initial aim of this project was to develop and validate a panel of antibodies specific to 
the known TARP isoforms. There are several TARPs expressed in the mammalian brain, 
with the information regarding their distribution based largely upon in situ hybridisation. 
However, a lack of suitable probes has resulted in limited information regarding the 
distribution of the TARP isoforms at the protein level. The panel of new probes wil l be 
used to not only define the distribution of the TARP isoforms throughout the CNS, but 
will also help both identify the most relevant TARP to investigate for an interaction with 
5HT2C within the forebrain and enable investigations regarding the nature of this 
interaction. As such, these antibodies will be vital to define the anatomical framework for 
this project, not only in the determination of the relevant TARP for study, but also for use 
in generating immunoaffinity columns for identifying specific TARP interacting partners 
by immunopurification. 
To that end, the peptide sequences of each of the known TARP isoforms were studied, 
with peptide sequences from each TARP isoform selected to try to maximize 
antigenicity, but primarily to maximize TARP isoform specificity by minimizing the 
similarities between the sequence chosen and its analogous coimterparts in the other 
TARP isoforms. The resultant sequences were then used to generate novel peptides used 
as antigens to generate polyclonal antibodies specific to each of the TARP isoforms. 
There was alsot he consideration of potential binding sites to consider, so where possible, 
sequences in domains similar to successful TARP y2 antibodies already in use in the lab 
were selected. 
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Once the probes were generated and validated using recombinant TARPs expressed in 
HEK293 cells, they were used to map the distribution of each of the TARP isoforms 
throughout the CNS to both compare with, and expand upon the TARP distribution data 
already in the literature, with the specific goal of identifying which TARP isoforms were 
prevalent in the regions of interest. 
Results 
Initially, for generation of the TARP isoform-specific antibodies for use in this project, 
the peptide sequence for each of the TARPs had to be examined for suitable regions to 
use in the generation of isoform-specific antibodies. Regions had to be highly specific to 
the TARP isoform of choice, but also within regions unlikely to undergo epitope masking 
by other proteins. Ideally, the regions also displayed high antigenicity. 
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Figure 3.1.1 Amino acid sequences for each of the TARP isoforms 
Aligned amino acid sequences for each of the TARP isoforms. Transmembrane domains are 
underlined, the peptide sequences used to generate each antibody are green. The black dots 
correspond to empty stretches of sequence. 
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I A n l i g e n i c i t y 
1 13 25 37 49 61 73 85 97 109 121 133 145 157 159 181 193 205 217 229 241 253 265 277 289 301 313 325 
Figure 3.1.2 Graph showing peak regions of antigenicity in the TARP Y2 isoform 
peptide sequence 
The antigenicity of the TARP y2 isoform as shovm using the ANTHEPROT package, 
with the region corresponding to the site of peptide sequence selected for antibody 
generation highlighted in red. 
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I Antigenici ty 
1 15 29 43 57 71 85 99 113 127 141 155 169 183 197 211 225 239 253 267 281 295 309 
Figure 3.1.3 Graph showing peak regions of antigenicity in the TARP yS isoform 
peptide sequence 
The antigenicity of the TARP Y3 isoform as shown using the ANTHEPROT package, 
with the region corresponding to the site of peptide sequence selected for antibody 
generation highlighted in red. 
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Figure 3.1.3 Graph showing peak regions of antigenicity in the TARP y4 isoform 
peptide sequence 
The antigenicity of the TARP y4 isoform as shown using the ANTHEPROT package, 
with the region corresponding to the site of peptide sequence selected for antibody 
generation highlighted in red. The regions chosen for this antibody weren't the most 
antigenic because of the possibility of epitope masking and lack of isoform-specific 
peptide sequence within the most antigenic sites. 
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I Anitgenici ty 
1 19 37 55 73 91 109 127 145 163 181 199 217 235 253 271 289 307 325 343 361 379 397 415 
Figure 3.1.4 Graph showing peak regions of antigenicity in the TARP y8 isoform 
peptide sequence 
The antigenicity of the TARP y8 isoform as shown using the ANTHEPROT package, 
with the region corresponding to the site of peptide sequence selected for generation of 
the TARP y8 N-terminal directed antibody is highlighted in red, whilst the site of peptide 
sequence selected for the generation of the C-terminal directed antibody is in green. 
The peptide sequences selected for each of the TARP isoform-speciflc antibodies 
generated are specific to their TARP isoform. 
From examining Figure 1.1 it is obvious that there is a low sequence homology between 
each of the peptide sequences chosen for antibody generation when compared with the 
comparable peptide sequences of the other TARP isoforms. The sequences themselves 
also possessed reasonable antigenic properties as shown in Figure 1.2. 
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Rabbit I Bleed 3 
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Log Dilution 
Figure 3.2.1.1 Graphical representation of ELISA data obtained for Rabbit 1 bleed 
3. 
Graph shows the absorbance @450nm of each dilution of serum from rabbit 1 bleed 3. 
Serum was incubated in semi-log dilution factors up to a maximal dilution factor of 
1/31600 overnight at 4°C in wells containing bound peptide. 
Titre of the antibody was determined as the dilution factor where the peak absorbance 
recorded had diminished 50%. 
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Figure 3.2.1.2 Graphical representation of ELISA data obtained for Rabbit 3 bleed 
3. 
Graph shows the absorbance @450rmi of each dilution of serum from rabbit 3 bleed 3. 
Serum was incubated in semi-log dilution factors up to a maximal dilution factor of 
1/31600 overnight at 4°C in wells containing bound peptide. 
Titre of the antibody was determined as the dilution factor where the peak absorbance 
recorded had diminished 50%. 
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Figure 3.2.1.3 Graphical representation of ELISA data obtained for Rabbit 6 bleed 
3. 
Graph shows the absorbance @450nm of each dilution of serum from rabbit 6 bleed 3. 
Serum was incubated in semi-log dilution factors up to a maximal dilution factor of 
1/31600 overnight at 4°C in wells containing bound peptide. 
Titre of the antibody was determined as the dilution factor where the peak absorbance 
recorded had diminished 50%. 
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Figure 3.2.1.4 Graphical representation of ELISA data obtained for Rabbit 8 bleed 
3. 
Graph shows the absorbance @450imi of each dilution of serum from rabbit 8 bleed 3. 
Serum was incubated in semi-log dilution factors up to a maximal dilution factor of 
1/31600 overnight at 4°C in wells containing bound peptide. 
Titre of the antibody was determined as the dilution factor where the peak absorbance 
recorded had diminished 50%. 
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Rabbit 10 Bleed 3 
Log Dilution 
Figure 3.2.1.5 Graphical representation of ELISA data obtained for Rabbit 10 bleed 
3. 
Graph shows the absorbance @450nm of each dilution of serum from rabbit 10 bleed 3. 
Serum was incubated in semi-log dilution factors up to a maximal dilution factor of 
1/31600 overnight at 4°C in wells containing bound peptide. 
Titre of the antibody was determined as the dilution factor where the peak absorbance 
recorded had diminished 50%. 
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Figure 3,2.2 Graphical representation of E L I S A data obtained for Rabbit 9 over thie 
entire innocuiation protocol. 
Graph shows the absorbance @450nm of each dilution of serum from each bleed for a 
single antibody, in this case the TARP y8 C-terminal directed antibody being generated 
by rabbit 9. Serum was incubated in semi-log dilution factors up to a maximal dilution 
factor of 1/31600 overnight at 4°C in wells containing bound peptide. 
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l i t re of the antibody was determined as the dilution factor where the peak absorbance 
recorded had diminished 50%. 
Figure 3.2.2 Summary table of approximate E L I S A titres for each of the bleeds 
obtained from each rabbit. 
Rabbit T A R P 
isoform 
Bleed Number 
1 2 3 4 
Titre (Approx) 
1 T A R P Y2 1/200 1/200 1/200 1/500 
2 T A R P 72 1/500 1/10000 1/5000 -
3 T A R P Y 3 1/10 1/10 1/200 1/1000 
4 T A R P Y 3 1/20 1/200 1/100 -
5 TARPy4 1/150 1/175 1/1500 -
6 TARP Y4 0 1/100 1/10 1/30 
7 TARP Y8N 1/100 1/1000 1/1500 -
8 TARP Y8N 1/200 1/200 1/200 1/100 
9 TARPySC 1/10 1/200 1/200 -
10 TARP Y 8 C 1/20 1/100 1/200 1/10 
Table shows the approximate Titre obtained for each bleed taken from each rabbit. Titre 
was calculated using the graphical presentation of absorbance Vs dilution factor, as 
mentioned in Figure 3.2.1.1-10. 
The E L I S A data was used to indicate immune response in the rabbits and determine 
duration of the inoculation protocol. 
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The purpose of the ELISAs was to identify the level of immune response in each of the 
rabbits following inoculation with the peptide-adjuvant combination. 
When the ELISA titre recorded remained static, or began to diminish, it was decided to 
administer the terminal bleed subsequent to the next inoculation, with one rabbit for each 
of the TARP isoform-specific antibodies being subjected to one ftirther inoculation prior 
to terminal exsanguination. 
As can be seen in Figures 3.2.1.1-10. 3.2.2, the litres recorded for each antibody were 
quite variable, with little comparison between the different TARP isoforms. 
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Figure 3.3.1 Screening the anti TARP j2 antibody by Immunoblotting 
Figure shows an immunoblot of a 10% SDS-PAGE gel loaded with 10 ^g SDS-
solubilised mouse cerebellum (CBM) and HEK293 cells transfected with either empty 
vector (M), or one of the four TARP isoforms; y2, yS, y4 or y8, then screened using the 
anti TARP y2 antibody at 0.5)xg/ml. The immunoreactive species of interest is indicated 
by the black arrows either in the native tissue sample (CBM) or the transfected HEK293 
cells. The slightly higher molecular weight immunoreactive species in the y2 transfected 
HEK293 cells is TARP y2 subsequent to some form of post translational modification, 
which is has not been investigated in the context of this thesis. 
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Figure 3.3.2 Screening the anti TARP y4 antibody by Immunoblotting 
Figure shows an immunoblot of a 10% SDS-PAGE gel loaded with 10 ^ig SDS-
solubilised mouse cerebellum (CBM), forebrain (FB) and HEK293 cells transfected with 
either empty vector (M), or one of the four TARP isoforms; y2, y3, y4 or y8, then 
screened using the anti TARP y4 antibody at 2ja,g/ml. Immunoreactive species of interest, 
corresponding to TARP y4 can be seen, as indicated by the red arrows, in the FB and 
TARP y4 transfected HEK293 cells. 
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Figure 3.3.3 Screening the anti TARP Y8 N-terminal directed antibody by 
Immunoblotting 
Figure shows an immunoblot of a 10% SDS-PAGE gel loaded with 10 ^ig SDS-
solubilised mouse cerebellum (CBM), forebrain (FB) and HEK293 cells transfected with 
either empty vector (M), or one of the four TARP isoforms; y2, y3, y4 or y8, then 
screened using the anti TARP y8 N-terminal directed antibody at 4)j,g/ml. Three diffuse 
bands, most likely corresponding to various post-translational states of TARP y8, can be 
detected, as indicated by the bracket, in the TARP yS transfected HEK293 cells and very 
weakly within the FB sample. 
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Figure 3.3.4 Screening the anti TARP yS C-terminal directed antibody by 
Immunoblotting 
Figure shows an immvinoblot of a 10% SDS-PAGE gel loaded with 10 pg mouse SDS-
solubilised cerebellum (CBM), forebrain (FB) and HEK293 cells transfected with either 
empty vector (M), or one of the four TARP isoforms; y2, yS, y4 or y8, then screened 
using the anti TARP y8 C-terminal directed antibody at Ipg/ml. Immunoreactive species 
corresponding to TARP y8, within the region indicated by the bracket, but possessing 
different molecular weights - most likely as a consequence of post translational 
modification - can be detected within the CBM, FB and TARP y8 transfected HEK293 
cells. 
The TARP isoform-specific antibodies were specific to the TARP isoform to which 
they were raised (Figure 3). 
Figure 3.3.1 shows the TARP y2 isoform-specific antibody generated when screened 
against recombinant cells expressing one of the TARP isoforms in addition to native CNS 
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tissue taken from the cerebellum of C3B6Fe+ mice. As this was the peptide used 
previously to generate a TARP y2 specific antibody, it is little surprise that it appears to 
be highly specific, with detectable bands appearing at approximately 36-38 kDa in the 
CBM and 34-39 kDa in the recombinant TARP y2 expressing cells. Most important is the 
absence of any detectable bands in the cells transfected with other TARP isoforms. 
Figure 3.3.2 shows the TARP y4 isoform-specific antibody generated when screened 
against recombinant cells expressing one of the TARP isoforms in addition to material 
taken from both the forebrain and cerebellum of C3B6 mice. Forebrain was included as a 
native CNS tissue in this screen due to the published evidence suggesting TARP y4 is 
diffuse throughout the mouse brain, at least at the mRNA level (Tomita et al. 2004). 
As can be seen, three major, specific immunoreactive species can be seen (20, 37 and 50 
kDa) in the TARP y4 transfected recombinant cells, with the 50kDa band also being 
detectable in the forebrain sample. 
The abnormal nature of expression within HEK293 cells, a cell type where mouse TARP 
y4 shouldn't typically be expressed, might also explain the multiple immunoreactive 
species detected, with the high levels of TARP y4 being expressed, potentially activating 
cellular defences against protein aggregation. The non-specific binding displayed in the 
HEK293 cells appears to correspond to proteins not typically found within the mouse 
CNS, but further investigation would be required to determine their identity. In mouse 
CNS the TARP y4 immunoreactive species do not fully align with those detected in the 
TARP y4 transfected HEK293 cells, speculatively due to post-translational modification 
of the protein, the precise nature of which is currently unknown but would likely include 
different phosporylation states (H Payne, unpublished). 
Figure 3.3.3 shows the antibody generated using TARP y8 N-terminal peptide. As with 
the TARP y4, it displays some low-level non-specific labelling detectable in the 
recombinant cell samples. Three major, specific immunoreactive species are detected 
(molecular weights ranging from 40-60 kDa) in the TARP y8 expressing cells. The single 
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immunoreactive band detected in the CNS tissues corresponds in molecular weight (-55 
kDa) to the strongest labelled band in the TARP y8 expressing cells. Again reference can 
be made to the multiple immunoreactive species present being due to possible 
phosphorylation states, a common feature with the various TARP isoforms studied in the 
lab (H Payne, unpublished). 
Figure 3.3.4 Shows the antibody generated using the TARP y8 C-terminal peptide. As 
can be clearly seen, of the recombinant cells, only the TARP yS expressing cells show 
any labelling, a band of approximately 55 kDa being prevalent, which corresponds to the 
bands detected in the CNS tissues. As with the other TARP antibodies, this immunoblot 
demonstrates that the antibody generated is highly specific to the TARP isoform it was 
generated towards. 
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Figure 3.4.1 Screening the anti-TARP Y4 antibody using heterologous cells 
transfected with an empty vector. 
HEK293 cells transfected with an empty vector - effectively a mock transfection. Cells 
were cultured on a glass coverslip for two weeks before being fixed with 4% 
paraformaldehyde and subjected to immunocytochemistry. Cells were probed with the 
anti-TARP y4 antibody at a dilution of 0.5fj,g/ml, shown at 200X magnification. Scale bar 
= 100 \im. 
77 
Figure 3.4.2 Screening the anti-TARP y4 antibody using heterologous cells 
transfected with the TARP y2 isoform. 
HEK293 cells transfected with the TARP y2 isoform. Cells were cultured on a glass 
coverslip for two weeks before being fixed with 4% paraformaldehyde and subjected to 
immunocytochemistry. Cells were probed with the anti-TARP y4 antibody at a dilution of 
0.5|ig/ml, shown at 200X magnification. Scale bar = 100 |am. 
Figure 3.4.3 Screening the anti-TARP y4 antibody using heterologous cells 
transfected with the TARP y3 isoform. 
HEK293 cells transfected with the TARP y3 isoform. Cells were cultured on a glass 
coverslip for two weeks before being fixed with 4% paraformaldehyde and subjected to 
immunocytochemistry. Cells were probed with the anti-TARP y4 antibody at a dilution of 
0.5pg/ml, shown at 200X magnification. Scale bar = 100 pm. 
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Figure 3.4.4 Screening the anti-TARP y4 antibody using heterologous cells 
transfected with the TARP yS isoform. 
HEK293 cells transfected with the TARP y8 isoform. Cells were cultured on a glass 
coverslip for two weeks before being fixed with 4% paraformaldehyde and subjected to 
immunocytochemistry. Cells were probed with the anti-TARP y4 antibody at a dilution of 
0.5|j.g/ml, shown at 200X magnification. Scale bar = 100 \im. 
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Figure 3.4.5 Screening the anti-TARP y4 antibody using heterologous cells 
transfected with the TARP y4 isoform. 
HEK293 cells transfected with the TARP y4 isoform. Cells were cultured on a glass 
coverslip for two weeks before being fixed with 4% paraformaldehyde and subjected to 
immunocytochemistry. Cells were probed with the anti-TARP y4 antibody at a dilution of 
0.5|ag/ml, shown at 200X magnification. Scale bar = 100 |am. 
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Figure 3.4.6 Screening the anti-TARP Y4 antibody using TARP Y4 expressing 
heterologous cells, following peptide block. 
HEK293 cells transfected with the TARP y4 isoform. Cells were cultured on a glass 
coverslip for two weeks before being fixed with 4% paraformaldehyde and subjected to 
immunocytochemistry. Cells were probed with the anti-TARP y4 antibody at a dilution of 
0.5|ig/ml that had been incubated overnight with l.25\ig/ml of the TARP y4 pepfide, 
shown at 200X magnification. Scale bar = 100 |j.m. 
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The antibody generated using the TARP y4 shows suitability for use in 
immunocytochemistry, with demonstrable specificity for recombinant cells 
expressing the TARP y4 isoform but not recombinant cells expressing other TARP 
isoforms or empty vector (Figure 4). 
Figure 3.4.1 shows recombinant cells expressing empty vector probed using the antibody 
generated using the TARP y4 peptide. The absence of any detectable labelling, indicates 
that the weak non-specific labelling detected by immunoblotting is not detectable in 
immunocytochemisty. 
Figures 3.4.2-4.4 show recombinant cells expressing TARP isoforms y2, y3 and y8 
respectively, display very low background labelling. This is easily distinguished with 
Figure 3.4.5 showmg the TARP y4 expressing recombinant cells labelled with the anti 
TARP y4 antibody, these cells displaying noticeably intense labelling, which is abolished 
when pre-blocked using the TARP y4 peptide as shown in Figure 3.4.6, indicating that 
the antibody is specific not only for the TARP, but also to the peptide used in its 
generation. 
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Figure 3.5.1 Screening the anti-TARP 78 C-terminal directed antibody using 
heterologous cells transfected with an empty vector. 
HEK293 cells transfected with an empty vector - effectively a mock transfection. Cells 
were cultured on a glass coverslip for two weeks before being fixed with 4% 
paraformaldehyde and subjected to irmnunocytochemistry. Cells were probed with the 
anfi-TARP y8 C-terminal directed antibody at a dilution of 0.0625|a.g/ml, shown at 200X 
magnification. Scale bar =100 [xm. 
Figure 3.5.2 Screening the anti-TARP yS C-terminal directed antibody using TARP 
yl expressing heterologous cells. 
HEK293 cells transfected with the TARP y2 isoform. Cells were cultxired on a glass 
coverslip for two weeks before being fixed with 4% paraformaldehyde and subjected to 
immunocytochemistry. Cells were probed with the anti-TARP yS C-terminal directed 
antibody at a dilution of 0.0625|ig/ml, shown at 200X magnificafion. Scale bar = 100 jam. 
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Figure 3.5.3 Screening the anti-TARP y8 C-terminal directed antibody using TARP 
73 expressing heterologous cells. 
HEK293 cells transfected with the TARP yS isoform. Cells were cultured on a glass 
coverslip for two weeks before being fixed with 4% paraformaldehyde and subjected to 
immunocytochemistry. Cells were probed with the anti-TARP y8 C-terminal directed 
antibody at a dilution of 0.0625\ig/m, shown at 200X magnification. Scale bar = 100 (xm. 
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Figure 3.5.4 Screening the anti-TARP y8 C-terminal directed antibody using TARP 
y4 expressing heterologous cells. 
HEK293 cells transfected with the TARP y4 isoform. Cells were cultured on a glass 
coverslip for two weeks before being fixed with 4% paraformaldehyde and subjected to 
immunocytochemistry. Cells were probed with the anti-TARP y8 C-terminal directed 
antibody at a dilution of 0.0625^g/ml, shown at 200X magnification. Scale bar = 100 |j.m. 
Figure 3.5.5 Screening the anti-TARP 78 C-terminal directed antibody using TARP 
78 expressing heterologous cells. 
HEK293 cells transfected with the TARP 78 isoform. Cells were cultured on a glass 
coverslip for two weeks before being fixed with 4% paraformaldehyde and subjected to 
immunocytochemistry. Cells were probed with the anti-TARP 78 C-terminal directed 
antibody at a dilution of 0.0625|ig/ml, shown at 200X magnificafion. Scale bar = 100 |am. 
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Figure 3.5.6 Screening the anti-TARP 78 C-terminal directed antibody using TARP 
78 expressing heterologous cells, following peptide block. 
HEK293 cells transfected with the TARP 78 isoform. Cells were cultured on a glass 
coverslip for two weeks before being fixed with 4% paraformaldehyde and subjected to 
immunocytochemistry. Cells were probed with the anti-TARP 78 C-terminal directed 
antibody at a dilution of 0.0625}j,g/ml that had been incubated overnight with 
0.3125pg/ml of the TARP 78 C-termmal peptide, shown at 200X magnification. Scale bar 
= 100 pm. 
Figures 3.5.1-5.6 
These Figures show the immunocytochemical screening of the TARP yS C-terminal 
directed antibody against HEK293 cells transfected with either empty vector (3.5.1) or 
one of the following four TARP isoforms; y2 (3.5.2), y3 (3.5.3), y4 (3.5.4), y8 (3.5.5). 
As can be seen, the TARP yS C-terminal directed antibody demonstrates a high degree of 
specificity for the HEK293 cells expressing the TARP y8 isoform, with no significant 
labelling of the HEK cell expressing any of the other TARP isoforms or the empty vector, 
fiirther supporting the data provided by immunoblotting to screen the antibody. 
To confirm specificity, the antibody was also subjected to a peptide block protocol, 
whereby the working concentration of the TARP y8 C-terminal directed antibody was 
incubated with a concentration of the TARP y8 C-terminal peptide that was effectively 
five times the working concentration of antibody, overnight at 4°C. This peptide blocked 
antibody was then used in immunocytochemistry alongside the non-peptide blocked 
TARP y8 C-terminal directed antibody. 
As can be seen in the TARP y8 transfected HEK293 cells probed with the peptide 
blocked antibody (3.5.6) there is no discemable labelling compared with the mock 
transfected (3.5.1) HEK293 cells, confirming that this labelling is specific both to the 
peptide the antibody was raised to, but also to the TARP isoform that the peptide was 
derived from. 
The TARP y8 C-terminal directed antibody shows suitability for 
immunocytochemistry with highly specific labelling of recombinant cells expressing 
the TARP y8 isoform compared with recombinant cells expressing other TARP 
isoforms (Figure 3.5). 
As with the TARP y4 specific antibody, the antibody generated using the C-terminal 
peptide of the TARP y8 isoform demonstrates very low background labelling of 
recombinant cells expressing either empty vector, or other TARP isoforms, as shown in 
Figures 3.5.1-5.4. Figure 5.5 shows a clearly apparent specific labelling of the TARP y8 
expressing recombinant cells which when coupled with the Figure 3.5.6 peptide block 
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data indicates that the TARP y8 c-terminal directed antibody is highly specific to the 
TAR? yS C-terminal peptide to which it was generated. 
50 kDa 
37 kDa 
Stg SPG C B M T H STR C T X HP DG M y2 
HEK293 cells 
Figure 3.6.1 Immunoblot showing distribution of the TARP y2 isoform across a 
range of dissected GNS tissue probed with the anti TARP y2 isoform specific 
antibody. 
Al l tissues were solubilised in SDS-solubilising buffer (see methods) before being 
precipitated using chloroform-methanol precipitation into 150^1 2X SDS-PAGE sample 
buffer, with 10|xg of each were loaded onto a 10% SDS-PAGE gel. Stargazer cerebellum 
(stg) was used as a negative control. Wild type tissues loaded; Spinal cord (SPG); 
Cerebellum (CBM); Thalamus (TH); Striatum (STR); Cerebral cortex (CTX); 
Hippocampus (HP); Dentate gyrus (DG). HEK293 cells transfected with either empty 
vector (M) or the TARP y2 isoform were also loaded. Immunoreactive bands 
corresponding to TARP y2 are indicated by the black arrows, or the bracket in the TARP 
y2 transfected HEK293 cells. 
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-H- 1 1 1 1 ++ + 1 1 1 -H- -1 1 1 1 1 1 1 
Figure 3.6.2 Table showing relative TARP 72 amounts across the range of dissected 
tissues. 
Samples were SDS-solubilised, with relative amounts being determined by the intensity 
of bands detected by immunoblotting in relation to one another. 
TARP 72 is detectable in a range of CNS tissues. 
As shown by Figure 3.6.1, TARP 72 is detectable by immunoblotting in all of the CNS 
tissues dissected, except for the dentate gyrus, and is most concentrated in the 
cerebellum, but also detectable at high levels in the cerebral cortex and thalamus. It is 
also detectable at modest levels in the spinal cord and hippocampal formation. 
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Figure 3.7.1 Immunoblot showing distribution of the TARP 74 isoform across a 
range of dissected CNS tissue when probed with the anti TARP 74 isoform specific 
antibody. 
All tissues were solubilised in SDS-solubilising buffer (see methods) before being 
precipitated into 150pl 2X SDS-PAGE sample buffer, with 1 Opg of each were loaded 
onto a 10% SDS-PAGE gel. Wild type tissues loaded; Spinal cord (SPC); Cerebellum 
(CBM); Thalamus (TH); Striatum (STR); Cerebral cortex (CTX); Hippocampus (HP); 
Dentate gyrus (DG). HEK293 cells transfected with either empty vector (M) or the TARP 
74 isoform were also loaded. Anti TARP 74 antibody used was from an earlier bleed to 
that used in Figure 3.3.2 (That bleed was used for generation of a TARP 74 
immunoaffinity column), so there are some differences in affinity and appearance of 
immunoreactive species. Immunoreactive species corresponding to TARP 74 are 
indicated by the brackets. 
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Figure 3.7.2 Table showing relative TARP y4 amounts across the range of dissected 
tissues. 
Samples were SDS-solubilised, with relative amounts being determined by the intensity 
of bands detected by immunoblotting in relation to one another. 
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Figure 3.7.3.1 Immunohistochemical mapping of the TARP y4 isoform in the 
cerebral cortex. 
Brain was fixed with 4% (w/v) paraformaldehyde and subsequently cut into 30|im 
sections. Tissue is labelled with the anti-TARP y4 antibody at 0.5ng/ml working 
concentration. 
Image shows cerebral cortex at 200X magnification, taken fi-om the approximate location 
of fi-ontal cortex area 3. Scale bar =100 |j,m. 
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Figure 3.7.3.2 Immunohistochemical mapping of the TARP 74 isoform in the 
hippocampal formation (1). 
Tissue was fixed in 4% (w/v) paraformaldehyde and probed with the anti-TARP 74 
antibody at a 0.5}j.g/ml working concentration. 
Image shows the hippocampus at the CAl location at 200X magnificafion. Scale bar 
100 pm. 
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Figure 3.7.3.3 Immunohistochemical mapping of the TARP y4 isoform in the 
hippocampal formation (2). 
Tissue was fixed in 4% (w/v) paraformaldehyde and probed with the anti-TARP y4 
antibody at a 0.5pg/ml working concentration. 
Image shows the hippocampus at the CAl - CA2 location at 200X magnification. Scale 
bar = 100 |im. 
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Figure 3.7.3.4 Immunohistochemical mapping of the TARP Y4 isoform in the 
dentate gyrus. 
Tissue was fixed in 4% (w/v) paraformaldehyde and probed with the anti-TARP y4 
antibody at a 0.5|a.g/ml working concentration. 
Image shows the dentate gyrus at 200X magnification. Scale bar = 100 ^ .m. 
98 
Caudate Putamen 
Figure 3.7.3.5 Immunohistochemical mapping of the TARP 74 isoform in the 
Striatum. 
Tissue was fixed in 4% (w/v) paraformaldehyde and probed with the anti-TARP 74 
antibody at a 0.5pg/ml working concentration. 
Image shows the caudate putamen at 200X magnification. Scale bar = 100 pm. 
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Figure 3.7.3.6 Immunohistochemical mapping of the TARP y4 isoform in the 
Thalamic Region. 
Tissue was fixed in 4% (w/v) paraformaldehyde and probed with the anti-TARP y4 
antibody at a 0.5\ig/m] working concentration. 
Image shows the thalamic region at the CAl location at 200X magnification. Scale bar 
100 fim. 
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Figure 3.7,3.7 Immunohistoehemical distribution of the TARP y4 isoform in 
cerebellum. 
Tissue was fixed in 4% (w/v) paraformaldehyde and probed with the anti-TARP y4 
antibody at a 0.5fxg/ml working concentration. 
Image shows the cerebellum at 200X magnificafion. Scale bar = 100 ^m. 
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Figure 3.7.3.8 Immunohistochemical distribution of the TARP y4 isoform in the 
spinal cord. 
Tissue was fixed in 4% (w/v) paraformaldehyde and probed with the anti-TARP y4 
antibody at a 0.5|xg/ml working concentration. 
Image shows the ventral hom of the spinal cord at 200X magnification. Scale bar = 100 
pm. 
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Figure 3.7.3.9 Confirming the TARP y4 immunohistochemical distribution data 
with peptide block. 
Tissue was fixed in 4% (w/v) paraformaldehyde and dissected into SO^m thick sections. 
Tissue was subsequently probed with the anti-TARP y4 antibody at 0.5p,g/ml working 
concentration, that had been pre-incubated with 1.25mg/ml of the TARP y4 peptide. 
Image shows the cerebellum at 200X magnification. Scale bar = 100 pm. 
TARP Y4 is distributed at low levels throughout the CNS, but is concentrated in the 
deep brain structures. 
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Figure 3.7.1 shows the distribution of TARP y4 by immunoblotting, with the most 
concentrated and readily detectable levels of TARP y4 being present in the thalamus. 
This is confirmed by the IHC shown in Figure 3.7.3, where, despite some region-specific 
concentrated levels of TARP y4 being present in the hippocampus, the most intense 
levels of TARP y4 are detectable in both the thalamus, and the cerebellum. 
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Figure 3.8.1 Immunoblot showing distribution of the TARP y8 isoform across a 
range of dissected CNS tissue when probed with the and TARP y8 C terminal 
directed antibody. 
All tissues were solubilised in SDS-solubilising buffer (see methods) before being 
precipitated into 150pl 2X SDS-PAGE sample buffer, with 1 Opg of each were loaded 
onto a 10% SDS-PAGE gel. Wild type fissues loaded; Spinal cord (SPC); Cerebellum 
(CBM); Thalamus (TH); Striatum (STR); Cerebral cortex (CTX); Hippocampus (HP); 
Dentate gyrus (DG). HEK293 cells transfected with either empty vector (M) or the TARP 
y8 isoform were also loaded. A l l immunoreactive species correspond with TARP y8, the 
bands corresponding to mature TARP y8, expressed as a doublet in CTX, HP and DG, aire 
indicated by the black arrow. 
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Figure 3.8.2 Table showing relative TARP yS amounts across the range of dissected 
tissues. 
Samples were SDS-solubilised, with relative amounts being determined by the intensity 
of bands detected by immunoblotting in relation to one another. 
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Figure 3.8.3.1 Immunohistochemical mapping of the TARP yS isoform in the 
cerebral cortex. 
Brain was fixed with 4% (w/v) paraformaldehyde and subsequently cut into SO^m 
sections. Tissue is labelled with the anti-TARP ySC antibody at 0.0625pg/ml working 
concentration. 
Image shows cerebral cortex at 200X magnification, taken from the approximate location 
of frontal cortex area 3. Scale bar = 100 pm. 
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Figure 3.8.3.2 Immunohistochemical mapping of the TARP y8 isoform in the 
hippoeampal formation. 
Brain was fixed with 4% (w/v) paraformaldehyde and subsequently cut into 30pm 
sections. Tissue is labelled with the anti-TARP y8C antibody at 0.0625pg/ml working 
concentration. 
Image shows the hippocampus at the CA2 - CA3 location, taken at 200X magnification. 
Scale bar = 100 pm. 
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Figure 3.8.3.3 Immunohistochemical mapping of the TARP yS isoform in the 
dentate gyrus. 
Brain was fixed with 4% (w/v) paraformaldehyde and subsequently cut into 30nm 
sections. Tissue is labelled with the anti-TARP ySC antibody at 0.0625^g/ml working 
concentration. 
Image shows the dentate gyrus at 200X magnification. Scale bar = 100 |xm. 
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Caudate Putamen 
Figure 3.8.3.4 Immunohistochemical mapping of the TARP y8 isoform in the 
striatum. 
Brain was fixed with 4% (w/v) paraformaldehyde and subsequently cut into 30pm 
sections. Tissue is labelled with the anti-TARP y8C antibody at 0.0625pg/ml working 
concentration. 
Image shows the striatum, more specifically the caudate putamen, at 200X magnification. 
Scale bar = 100 pm. 
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Figure 3.8.3.5 Immunohistochemical mapping of the TARP y8 isoform in the 
cerebellum. 
Brain was fixed with 4% (w/v) paraformaldehyde and subsequently cut into 30^m 
sections. Tissue is labelled with the anti-TARP y8C antibody at 0.0625|xg/ml working 
concentration. 
Image shows the cerebellum at 200X magnification. Scale bar = 100 ^m. 
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Figure 3.8.3.6 Immunohistochemical mapping of the TARP 78 isoform in the spinal 
cord (1). 
Tissue was fixed with 4% (w/v) paraformaldehyde and subsequently cut into 30pm 
sections. Tissue is labelled with the anti-TARP ySC antibody at 0.0625pg/ml working 
concentration. 
Image shows the dorsal horn of the spinal cord at 200X magnification. Scale bar = 100 
pm. 
I l l 
Figure 3.8.3.7 Immunohistochemical mapping of the TARP y8 isoform in the spinal 
cord (2). 
Tissue was fixed with 4% (w/v) paraformaldehyde and subsequently cut into 30jj,m 
sections. Tissue is labelled with the anti-TARP y8C antibody at 0.0625pg/ml working 
concentration. 
Image shows the both the dorsal (DH) and ventral horn (VH) at 200X magnification. 
Scale bar = 100 ^m. 
TARP y8 is distributed throughout the CNS, at highest levels in the forebrain. 
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Figure 3.8.1 shows that TARP y8 is present in all of the regions of the CNS that were 
probed by immunoblotting, including the spinal cord and cerebellum. As was expected 
the highest levels of TARP y8 were detected in the dentate gyrus and hippocampal 
formation. The cerebral cortex also showed high levels of TARP y8 expression. 
Figure 3.8.3 confirms and expands on this information, demonstrating that TARP y8 is 
detectable in each of the tissues by immvinohistochemistry, and displays some cell-
specific labelling, particularly in the hippocampal formation, where it is not expressed in 
the cell bodies of the granule cell layer of the dentate gyrus. 
Figure 3.9.1 Immunohistochemically screened horizontal section of brain probed for 
TARP y8 using the anti-TARP y8C antibody. 
Brain was fixed in 4% (w/v) paraformaldehyde and cut into 30pm thick sections. Probed 
with anti-TARP y8C antibody at 0.0625pg/ml working concentration. Scale bar = 5 nrni. 
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Figure 3.9.2 Immunohistochemically screened horizontal section of brain probed for 
GluRl . 
Brain was fixed in 4% (w/v) paraformaldehyde and cut into 30|im thick sections. Probed 
with anti-GluRl antibody at a l|j,g/ml working concentration. Scale bar = 5 mm. 
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Figure 3.10.1 Sagittal section of brain probed with the anti-TARP yS C antibody. 
Brain was fixed in 4% (w/v) paraformaldehyde and cut into 30pm thick sections, which 
were probed using the anti TARP y8 C-terminal directed antibody at 0.0625pg/ml 
working concentration. Notable regions of labelling include the hippocampal formation 
(HP), Layer IV of the cerebral cortex (CTX). Scale bar = 5 mm. 
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Figure 3.10.2 Sagittal section of brain probed with the anti-GluR2 antibody. 
Brain was fixed in 4% (w/v) paraformaldehyde and cut into 30|a,m thick sections, which 
were probed using a commercial anti-GluR2 antibody at l|a,g/ml working concentration. 
Scale bar 5 mm. Scale bar = 5 mm. 
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Figure 3.10.3 Immunohistochemically screened horizontal section of brain probed 
for T A R P Y8 using the ant i -TARP ySC antibody. 
Brain was f ixed in 4% (w/v) paraformaldehyde and cut into 30^m thick sections. Probed 
with anti-TARP y8C antibody at 0.0625\ig/m\ working concentration. Scale bar = 5 mm. 
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Figure 3.10.4 Immunohistochemically screened horizontal section of brain probed 
for GIuR2. 
Brain was fixed in 4% (w/v) paraformaldehyde and cut into 30|xm thick sections. Probed 
with anti-GluR2 1 ng/ml working concentration. Scale bar = 5 mm. 
The G l u R l and GluR2 A M P A receptor subunits show some similarity in regional 
distribution with the T A R P yS isoform. 
Figures 3.9 and 3.10 show the distribution o f the GluRl and GluR2 A M P A receptor 
subunits, with the distribution o f both, particularly the GluR2 subunit, showing striking 
similarities to the distribution o f TARP yS seen immunohistochemically. This is most 
detectable in the cerebral cortex and hippocampal formation. 
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I 
Figure 3.11. Distribution of a [ H] positive ailosteric A M P A receptor modulator in 
the mouse brain (Provided by Servier, c/o Michael Spedding). 
Main image shows the distribution o f binding o f a ["'H] positive allosteric A M P A 
receptor modulator developed by Servier, specific for GluR flop isoforms. 
Inset shows Figure 10.1 - TARP y8 distribution in the mouse brain probed using the 
TARP y8C antibody. 
Binding of a positive allosteric modulator of A M P A receptors (AMPAIdne) displays 
a very similar regional distribution to the T A R P yS isoform. 
Figure 3.11 shows binding data provided by Servier regarding an AMPAkine compound, 
specific for GluR flop isoforms. Its binding distribution in the mouse CNS is very similar 
to the distribution o f TARP y8 with the AMPAkine displaying slightly less binding in the 
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CA3 region of the hippocampus due to the prevalence of GluR flip isoforms in this 
region. 
Discussion 
Novel antibodies to each of the known TARP isoforms were designed and subsequently 
generated, with the finished antibodies screened against both native tissue and 
recombinant cells transfected with the TARP isoforms using several immunological 
techniques. Of these, antibodies specific to the T A R P Y2, 74 and T A R P 78 isoforms were 
successfully generated, with the finished antibodies demonstrating suitability for a range 
of techniques, with the focal point being on the generation of immunopurification 
columns. 
Regrettably, the lack of suitable available immunological probes for 
immunohistochemical labelling of the 5HT2c receptor distribufion, combined with its low 
expression levels in the CNS, make analysis of 5HT2c receptor at the protein level, 
extremely difficult using these techniques, and insufficient time was available to try an 
altemative approach. 
T A R P Y 2 
As can be seen, the generation of an antibody specific to the T A R P y2 isoform was 
successful, especially with its earlier bleeds, which showed no cross-reactivity with any 
of the other T A R P isoforms, the latter bleeds detecting T A R P y8 as well as TARP y2. 
The antibody is suitable for use in immunoblotting, and the later bleeds were also used to 
generate an immunoaffinity column capable of purifying T A R P y2. 
Unfortunately, the antibody did demonstrate its unsuitability for use in 
immunohistochemistry, with the early bleeds displaying no discemable labelling on 
paraformaldehyde-fixed sections. The later bleeds, which displayed some cross-reactivity 
with T A R P yS, only labelled what appeared to be T A R P y8 and even then only in the 
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regions where T A R P y8 was most concentrated. A similar problem with the cross-
reactivity was also encountered with the T A R P y2 immunoaffmity column, limiting the 
number of uses for this antibody. 
Screening the dissected tissues for TARP y2 (Figure 3.6.1) demonstrated a variable 
distribution of T A R P y2 throughout the tissues investigated, with low levels of TARP y2 
being detected in the striatum, reasonable levels of T A R P y2 being detectable in the 
spinal cord, thalamus, cerebral cortex and the hippocampal formation, and the highest 
level of expression of TARP 72 is detectable in the cerebellum. This is consistent with 
data obtained from the investigation of the stargazer mutant mouse phenotype, which 
suggests that T A R P y2 is the predominant T A R P isoform detectable in the cerebellum. 
Extensive testing of the dentate gyrus however, revealed no detectable T A R P y2, and in 
this respect, is unique with regard to the tissues investigated. 
T A R P y4 
The anti T A R P y4 antibody developed demonstrated suitability for a wide variety of 
techniques, including both immunoblotting and immunohistochemistry, with no cross-
reactivity to any of the other T A R P isoforms, despite some very minor non-specific 
labelling being detected in the immunoblotting. 
The anti T A R P y4 antibody also displayed the most variance in affinity between bleeds, 
with the earlier bleeds, whilst specific, displayed less affinity for T A R P y4 than 
subsequent bleeds. 
When used to screen dissected tissues for T A R P yA expression, the antibody was 
consistent with the mRNA data for TARP y4 distribution in the CNS as described by 
Tomita et al. (2003), with T A R P y4 being expressed at low levels seemingly throughout 
the CNS, with its highest levels of expression being in the thalamus, seen by both 
immunoblotting (Figure 3.7.1) and immunohistochemistry (Figure 3.7.3.6). A key 
difference with the mRNA distribution in the literature, is the absence of detectable 
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TARP y4 in the striatum (Figure 3.7.1; Figure 3.7.3.5), indicating a difference between 
the mRNA distribution of T A R P y4 when compared with the protein distribution. 
This may potentially be explained by the possibility of T A R P y4 protein being expressed 
within a different region of its parent neurone to its mRNA, with the protein being 
detectable in the processes extending from the neurones, whilst the mRNA is localised to 
the neurones origin. Another plausible explanation for the differences observed, and one 
which shall be also discussed with regard to the T A R P y8 isoform both in this chapter 
and in chapter 5, is the possibilities of variation between the mice strains used both in this 
thesis, and those in the literature. 
T A R P Y8 
The development of the two antibodies specific to the TARP yS isoform was highly 
successful, with both antibodies displaying no cross-reactivity with any of the other 
TARP isoforms (Figures 3.3.3 and 3.3.4). Only the antibody generated using the TARP 
yS C-terminal (anti TARP ySC) domain sequence was suitable for use in 
immunohistochemistry, the anti T A R P yS N-terminal antibody (anti TARP yS N) 
demonstrated no ability to label either recombinant cells or native tissue (data not 
shown). In immunocytochemisty and immunohistochemistry the anti TARP y8 C -
terminal antibody displayed a high degree of specificity (Figures 3.5.1-5.5) that could be 
blocked by incubation with the peptide used to generate the antibody (Figure 3.5.6). 
Due to the fact that the anti TARP y8C antibody demonstrated a higher affinity for the 
TARP y8 isoform than the anti T A R P y8N counterpart, combined with the lack of any 
non-specific binding detected with the T A R P ySC antibody, the T A R P y8C antibody was 
selected as the antibody for use in the distribution mapping of TARP y8 (Figures 3.8.1, 
3.8.3). 
The immunoblot of the dissected tissues probed with the anti T A R P y8C antibody 
revealed that the T A R P y8 isoform was present in all of the tissues examined, with the 
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highest levels of expression in the forebrain structures, particularly the hippocampus, 
which correlates to the data in the literature (Rouach et al. 2005), but also expands upon 
it, with evidence of T A R P yS expression in the cerebellum, but also the spinal cord. 
Of potential interest in the cerebral cortex and hippocampal formation, a closely-spaced 
doublet species pattern can be detected with the anti TARP ySC antibody. This has been 
previously observed in our laboratory with T A R P y2 and has correlated to the activity-
dependant phosphorylation state of the T A R P (Payne et al., unpublished), with this being 
the most likely explanation for observation with T A R P y8. This does beg the question as 
to why only a single band is detectable in the cerebellum and spinal cord, and would be a 
potential avenue for further investigation. 
The immunohistochemical data observed with the anti T A R P y8C antibody further 
supports the immunoblotting data, with the most immediately apparent staining being 
detectable in the hippocampal formation. However, when the whole section is examined 
(Figures 3.9.1 and 3.10.1), a much more extensive labelling distribution can be seen, with 
a distribution, particularly in the cerebral cortical laminae being mirrored by the AMPA 
receptor GluR2, subunit, but also to a lesser extent by the GluRl subunit (Figure 3.10.2). 
Again, supporting the information obtained by immunoblotting, T A R P y8 was detectable 
within the spinal cord, a region not previously described as expressing T A R P y8, possibly 
implying a less-specialised role than would have been considered if T A R P y8 was 
expressed exclusively in the hippocampal formation. 
The importance of this TARP distribution data as stand-alone evidence is minimal, the 
ftiU significance only being apparent once the roles of the T A R P isoforms within each of 
these CNS regions have been determined. To allude to these roles and indeed what 
neurological processes these TARPs, and the AMPA receptors they traffic, are 
contributing to, it is important to isolate the T A R P isoforms and their interacting proteins 
using the isoform specific probes generated, characterised, and validated in this chapter to 
develop immunoaffinity columns capable of purifying the individual T A R P isoforms. 
123 
Chapter 4: Immunoaffinity purification of TARPs and their 
interacting proteins analysed by immunoblotting and 
proteomic methodologies. 
Introduction 
In the last chapter, a panel of antibodies specific to each of the T A R P isoforms were 
generated and validated. The T A R P y8 isoform was selected specifically for further study 
in this chapter for two key reasons; Firstly from a scientific and information perspective, 
as the prevalent TARP in the hippocampal formation it possess vast implications in such 
neurological phenomena as L T P ; Secondly, from a methodological perspective, T A R P 
y8s distinction at the time as the prevalent T A R P isoform in the hippocampal formation -
and the only T A R P isoform expressed in the dentate gyrus (Payne et al. 2006) - offered a 
valuable environment for looking at the potential interaction with 5HT2cR of an 
individual T A R P isoform, potentially in a culture environment, but crucially as an 
effectively isolated system that needed no further experimental isolation from the other 
T A R P isoforms, somewhat similar to the possibilities offered by the cerebellum with 
regard to T A R P y2. Based on the distribution partem, it is clear that the T A R P y8 most 
closely matches AMPA receptor topology in the mouse forebrain, with high levels of 
expression in the cortex and hippocampal formation. Clearly as predicted from mRNA 
studies, TARP y8, and not T A R P y2 is the major isoform expressed in the hippocampus 
as shown in Chapter 3. 
The intent of generating two T A R P y8 antibodies, one to the extreme N-terminus and one 
to the C-terminal domain, was to ensure that potential epitope masking by interacting 
proteins would not be a problem. Using the T A R P isoform-specific antibodies generated 
to test the hypothesis that 5HT2c receptors interact with TARP/AMPA receptors via a 
physical interaction, immunoaffinity columns were generated with the intent to purify the 
individual T A R P isoforms. In addition to the T A R P isoforms, any interacting proteins 
associated to the T A R P of interest would be purified, ideally in large, multi-protein 
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complexes. The subsequent screening of these complexes, many of which potentially 
could contain previously unknown interacting partners, would utilise both immunological 
and proteomic methodologies, immunological using antibodies specific to individual 
proteins of interest with regard to the hypothesis, most notably the 5HT2c receptor, and 
proteomic to identify novel interacting partners that had not been considered previously. 
Known interacting proteins for the T A R P isoforms obviously include AMPA receptors, 
of which GluRl and GluR2 are the prevalent subunits expressed in the CNS. Another 
known TARP interacting protein is Microtubule associated protein l A (MAP-IA) , 
originally shown to interact with the T A R P y2 isoform (Ives et al. 2004), but 
subsequently identified in our laboratory as an interacting partner with other T A R P 
isoforms (Hann et al., unpublished). These known T A R P interacting proteins were to be 
investigated immunologically and could be used to as a criterion in determining whether 
the immunoaffinity columns were successfiilly purifying intact TARP-interacting protein 
complexes. 
Potential TARP interacting proteins, to be identified utilising proteomic tools, in this case 
M A L D l - T O F and possibly M A L D I - T O F / T O F could be any protein from a vast and 
diverse range of fiinctional families. The most likely candidates being proteins that are 
related to the functional roles of the TARPs such as those proteins that are located within 
the synapse, those that are involved either in trafficking, or the cytoarchitecture, or the 
ER. 
Results 
ImmuDopurifications of T A R P y8 and its interacting proteins using the 
immunoaffinity columns generated using the N and C terminal directed antibodies. 
Utilising the immunoaffinity columns generated using the Promega kit and the two TARP 
y8 specific antibodies, a series of immunopurifications of Triton X-lOO^"^ soluble frontal 
cortex was conducted, with the resultant purified material being screened by 
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immunoblotting for T A R P y8 and potenfial interacting proteins. In all instances T X Insol 
refers to the Triton X-100^'^ insoluble fraction; Input/TX Sol refers to the Triton X -
100™ soluble fraction that was loaded onto the columns; F1-F5 refers to the eluted 
fraction in the sequential order they were eluted from the column; F T refers to the Flow-
Through, essentially the unbound material that had passed through the column (Input 
minus purified fractions). 
50 kDa 
Whole T X hiputy F l F2 F3 F4 F5 FT 
Prep Insol. T X Sol ^ 
Eluted Fractions 
Figure 4.1: Immunoblot of Triton X-lOO^"^ soluble frontal cortex fractions purified 
using the immunoffinity column generated using the T A R P y8 N-terminal antibody 
probed for T A R P yS using the ant i -TARP ant i -TARP ySC antibody. 
For eluted fractions 150pl of sample was chloroform-methanol precipitated and 
resuspended in 25pl 2X S D S - P A G E sample buffer, of which 10[il of sample was loaded 
per lane. Immunoblot was probed with the anti T A R P y8C antibody at a working 
concentration of 0.5/ig/ml. The immunoreactive species of interest, corresponding to 
T A R P y8 is indicated by the black arrow. 
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CHO Cells T X S o l I ^ I 
Eluted Fractions day 1 Eluted Fractions day 2 
Figure 4.2: Immunoblot of Triton X-100^'^ soluble frontal cortex fractions purified 
using the immunoffinity column generated using the T A R P yS N-terminal antibody 
probed for 5HT2cR using the Santa Cruz mouse monoclonal antibody. 
For eluted fi-actions 150^1 of sample was chloroform-methanol precipitated and 
resuspended in 25nl 2X SDS-PAGE sample buffer, o f which lO^il o f sample was loaded 
per lane. Immunoblot was probed with the Santa Cruz mouse monoclonal anti-5HT2cR 
antibody at a 1 in 250 dilution.The immunoreactive species o f interest, corresponding to 
the 5HT2C receptor is indicated by the black arrow. 
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Eluted Fractions day 1 Eluted Fractions day 2 
Figure 4.3: Immunoblot of Triton soluble frontal cortex fractions purified 
using the immunoffinity column generated using the T A R P y8 N-terminal antibody 
probed for 5HT2cR using the Santa Cruz mouse monoclonal antibody. 
For eluted fractions 150pl o f sample was chloroform-methanol precipitated and 
resuspended in 25)al 2X SDS-PAGE sample buffer, o f which 10|j.l o f sample was loaded 
per lane. Immunoblot was probed with the Santa Cruz mouse monoclonal anti-5HT2cR 
antibody at a 1 in 250 dilution. The immunoreactive species o f interest, corresponding to 
the 5HT2C receptor is indicated by the black arrow and detectable in the F3 and F4 eluted 
fractions f rom day 1. 
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Figure 4.4: Immunoblot of Triton X-100™ soluble frontal cortex fractions purified 
using the immunoffinity column generated using the T A R P y8 N-terminal antibody 
probed for PSD-95. 
For eluted fractions 150|a,l o f sample was chloroform-methanol precipitated and 
resuspended in 25|j,l 2X SDS-PAGE sample buffer, o f which 10p,l o f sample was loaded 
per lane. Immunoblot was probed with the Abeam anti-PSD-95 antibody at a 1 in 500 
dilution. The immunoreactive species o f interest, corresponding to PSD-95 are indicated 
by the black arrow, which has been placed to emphasise the presence o f PSD-95 in the 
purified fractions. 
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Input/ 
T X S o l 
Eluted Fractions day 1 Eluted Fractions day 2 
Figure 4.5: Immunoblot of Triton soluble frontal cortex fractions purified 
using the immunofflnity column generated using the T A R P y8 N-terminal antibody 
probed for the G l u R l A M P A R subunit. 
For eluted fractions 150^1 o f sample was chloroform-methanol precipitated and 
resuspended in 25pl 2X SDS-PAGE sample buffer, o f which 10(xl o f sample was loaded 
per lane. Immunoblot was probed wi th the Cambridge Research Biochemicals anti GluRl 
antibody at a 1 in 500 dilution. The immunoreactive species o f interest, corresponding to 
GluRl are indicated by the black arrow. 
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Figure 4.6: Immunoblot of Triton X-lOO^"^ soluble frontal cortex fractions purified 
using the immunoffinity column generated using the T A R P y8 N-terminal antibody 
probed for the GIuR2 A M P A R subunit. 
For eluted fractions 150^1 of sample was chloroform-methanol precipitated and 
resuspended in 25^1 2X SDS-PAGE sample buffer, o f which 10|il o f sample was loaded 
per lane. Immunoblot was probed with the Santa Cruz anti GluRl antibody at a 1 in 500 
dilution. A weak signal f rom the immunoreactive species o f interest, corresponding to 
GluR2 is detectable in F3. A l l immunoreactive species o f interest are indicated by the 
black arrow, which emphasises the weak signal in F3. 
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Figure 4.7: Immunoblot of T r i t o n X-100 ™ soluble f ron t a l cortex fractions pur i f ied 
using the immunof f in i t y column generated using the T A R P 78 C-terminal antibody 
probed f o r T A R P y8 using the an t i -TARP ant i -TARP 78C antibody. 
For elated fractions 150^1 of sample was chloroform-methanol precipitated and 
resuspended in 25|a,l 2X SDS-PAGE sample buffer, of which 10|j,l of sample was loaded 
per lane. Immunoblot was probed with the anti TARP ySC antibody at a working 
concentration of 0.5ng/ml. The immunoreactive species of interest, corresponding to 
TARP y8 are indicated by the black arrow. 
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Figure 4.8: Immunoblo t o f T r i t o n soluble f ron ta l cortex fractions pur i f i ed 
using the immunof f in i t y column generated using the T A R P yS C-terminal antibody 
probed f o r 5HT2cR using the Santa Cruz mouse monoclonal antibody. 
For eluted fractions I50\i\ of sample was chloroform-methanol precipitated and 
resuspended in 25nl 2X SDS-PAGE sample buffer, of which lO^il of sample was loaded 
per lane. Immunoblot was probed with the Santa Cruz mouse monoclonal anti-5HT2cR 
antibody at a 1 in 250 dilution. The immunoreactive species of interest, corresponding to 
the 5HT2C receptor is in samples F3i and F32, indicated by the black arrow. 
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Figure 4.9: Immunoblo t o f T r i t o n soluble f ron t a l cortex fractions pur i f i ed 
using the immunof f in i t y column generated using the T A R P yS C-terminal antibody 
probed f o r 5HT2cR using the Abeam rabbi t polyclonal antibody. 
For eluted fractions 150(j,l of sample was chloroform-methanol precipitated and 
resuspended in 25pl 2X SDS-PAGE sample buffer, of which 10^1 of sample was loaded 
per lane. Immunoblot was probed with the Abeam rabbit anti-5HT2cR polyclonal 
antibody at a 1 in 500 dilution. Species variations between the 5HT2c Receptor expressed 
by the CHO cells compared with species used to generate the Abeam anti 5HT2c receptor 
antibody resulted in the Abeam antibody not detecting 5HT2c receptor in the CHO cells. 
The immunoreactive species of interest, corresponding to the 5HT2c receptor are most 
easily detectable in samples F3|-2 and F4|.2 and are indicated by the black arrow. 
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Figure 4.10: Immunoblo t of T r i t o n X-lOO'^'^ soluble f ron ta l cortex fractions pur i f i ed 
using the immunof f in i t y column generated using the T A R P 78 C-terminal antibody 
probed f o r the G l u R l A M P A R subunit. 
For eluted fractions 150|al of sample was chloroform-methanol precipitated and 
resuspended in 25^1 2X SDS-PAGE sample buffer, of which \0\il of sample was loaded 
per lane. Immunoblot was probed with the Cambridge Research Biochemicals anti GluRl 
antibody at a 1 in 500 dilution. The immunoreactive species of interest, corresponding to 
GluRl is indicated by the black arrow and emphasised in the F3 eluted fractions from 
dayl. 
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Figure 4.11: Immunoblo t of T r i t o n X - 1 0 0 ™ soluble f ron ta l cortex fractions pur i f ied 
using the immunof f in i t y column generated using the T A R P 78 C-terminal antibody 
probed f o r the GluR2 A M P A R subunit. 
For eluted fractions 150pl of sample was chloroform-methanol precipitated and 
resuspended in 25\i\ 2X SDS-PAGE sample buffer, of which 10^1 of sample was loaded 
per lane. Immunoblot was probed with the Santa Cruz anti GluR2 antibody at a 1 in 250 
dilution. The immunoreactive species of interest, corresponding to GluR2 is indicated by 
the black arrow. 
The immunoaf f in i ty column generated using the T A R P 78 i soform specific 
antibodies are capable o f p u r i f y i n g intact T A R P 78 interacting complexes. 
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Figures 4.1 and 4.7 demonstrate that both o f the immunoaffmity columns generated with 
either the N-terminal directed or C-terminal directed TARP yS specific antibodies are 
capable o f purifying TARP yS from a Triton-XlOO^'^ solubilised cerebral cortex 
preparation, with the presence o f known TARP interacting proteins, namely the A M P A 
receptor subunits GluRl and GluR2 being co-purified, demonstrating the ability o f the 
column to purify TARP y8 interacting partners successftilly (Figures 4.5, 4.6, 4.10 and 
4.11). 
The immunoaffinity column generated using the TARP y8C antibody demonstrated the 
greatest efficiency o f the two columns at purifying TARP y8 and the interacting A M P A 
receptors from the tissue preparation. A l l the TARP y8 that was detectable in the input 
was purified by the TARP y8 C-terminal directed column, whereas the N-terminal 
directed TARP y8 immunoaffinity column demonstrates approximately 50% efficiency at 
purifying TARP y8. This potentially suggests that the N-terminal domain, particularly the 
site o f the antigenic epitope, is partially masked or occluded by interacting proteins or 
structural properties o f TARP y8 that are not present in the C-terminal epitope. 
Differences in the amounts o f A M P A receptor subunits purified using each o f the 
columns is most likely attributable to the lower purification levels obtained using the anti 
TARP y8N column as such it w i l l purify significantly less TARP y8 that is potentially 
interacting with A M P A receptor subunits. 
A 5HT2C receptor-like species is purified as a protein interacting with T A R P y8. 
Both immunoaffinity columns purified a protein o f approximately 60 kDa in the peak 
fraction o f the TARP y8 purified material, which was detectable using three different 
antibodies raised to the 5HT2c receptor (Figures 4.2, 4.3, 4.8 and 4.9). This protein was 
not discemable in the input or flow-through material, indicating that the protein was 
concentrated by the immunopurification to a detectable level as a consequence of 
purifying TARP y8 and its interacting parmers. The use o f multiple antibodies, whilst not 
137 
confirming the proteins identity fiilly, gives strong indication that the protein is the 5HT2c 
receptor. 
PSD-95 is co-purified with T A R P 78 in Triton X-lOO"^^ soluble material. 
Despite the majority of PSD-95 being present in the Triton X-100™ insoluble material, 
as was expected with a synaptic protein, a modest amount of PSD-95 was also detectable 
in the Triton X-100 ™ soluble input, of which a small, but detectable amount was co-
purified using the TARP 78 antibodies (Figure 4.4), indicating that some PSD-95 is 
located non-synaptically and is interacting with TARP 78. 
50 kDa 
37kDa 
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TX Sol 
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Figure 4.12: Immunoblot of Triton X-100^'^ soluble and immunopurified frontal 
cortex fractions using control I g G , or the anti T A R P 78 N-terminal antibody, or the 
anti T A R P 78 C-terminal antibody column, probed for T A R P 72. 
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For eluted fractions 150|i,l of sample was chloroform-methanol precipitated and 
resuspended in 25jj,l 2X SDS-PAGE sample buffer, of which 10\x\ of sample was loaded 
per lane. Immunoblot was probed with the anti TARP y2 antibody at a working 
concentration of 1 pg/ml. Fractions containing the highest concentrations of purified 
protein were selected. The immunoreactive species of interest, corresponding to TARP 
y2, are indicated by the black arrow. 
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Figure 4.13: Immunoblo t of T r i t o n X-100^'^ soluble and immunopur i f i ed f ron ta l 
cortex fractions using the immunof f in i t y column generated using control IgG, or the 
anti T A R P y8 N-terminal antibody, or the anti T A R P y8 C-terminal antibody 
column, probed f o r T A R P y4. 
For eluted fractions 150|il of sample was chloroform-methanol precipitated and 
resuspended in 25pl 2X SDS-PAGE sample buffer, of which lOul of sample was loaded 
per lane. Immunoblot was probed with the anti TARP y4 antibody at a working 
concentration of 2^ig/ml. Again the immunopurified fractions containing the peak 
amounts of protein were used. The immunoreactive species of interest, corresponding to 
TARP y4 are indicated by the brackets and detectable in the Input, ySN and y8C columns. 
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T A R P y8 associates with other T A R P isoforms within an interacting complex. 
Figures 4.12 and 4.13 demonstrate the presence o f TARPs y2 and y4 within the TARP y8 
purified material. Due to the specificity o f the antibody, it is not due to cross-reactivity o f 
the TARP y8 antibodies with the other TARP isoforms, but rather, that TARP y2 and y4 
interact with TARP y8, either directly, or via an intermediate protein such as PSD-95, or 
more likely A M P A receptor subunit(s). 
Proteomic analysis of T A R P y8 interacting proteins. 
Using the immunoaffinity columns generated with the TARP y8 specific N and C 
terminal directed antibodies, a series o f immunopurifications was conducted on Triton X -
lOO^'^ soluble frontal cortex, with the peak eluted fractions being pooled and prepared for 
proteomic analysis using M A L D I - T O F and MALDI-TOF/TOF. 
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78C 
NS 78N 78C Mol .wt 
Figure 4.14: Representative examples of the 1-Dimensional gels used for proteomics. 
Mol. wt 
On the left is the Nu-PAGE 10% SDS gel loaded with the peak eluted fractions fi-om the 
immunoaffinity columns generated using non-specific IgG (NS), TARP 78 N-terminal 
(78N), and TARP 78 C-terminal (78C) antibodies prior to extraction of the bands of 
interest. The image on the right, shows the same gel subsequent to band extraction. 
To identify banding pattern, the gels were silver stained, with this being the most suitable 
method of labelling the protein when compared with RubyPro staining with regard to 
being able to detect the proteins and extract them manually. Unfortunately, the scaimer 
used to record the image on the left, means that its resolution carmot be enhanced to show 
the bands selected on the gel itself Not all bands extracted from the gels were identified 
successftilly. 
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Proteins purified by the N-terminal 
T A R P 78 immunoaffinity column 
Proteins purified by the C-terminal T A R P 78 
immunoafnnity column 
Vesicle-fiising ATPase (Vesicular-fiision 
protein NSF) (N-ethylmaleimide sensitive 
fusion protein) 
[Mus musculus] - Identified by M A L D I -
TOF/TOF 
2'.3'-cyclic-nucieolide 3'-phosphodiesterase 1 
[Mus nuisculus] - Identified by both M A L D I -
rOF and MALDI-TOF/TOF on separate 
samples. 
Na+/K-r -ATPase beta 1 subunit [Mus 
musculus] - identified using M A L D I -
TOF/TOF 
Myelin basic protein - Identified by both 
M A L D I - T O F and MALDI-TOF/TOF on 
sepeirate samples. 
2'.3'-cyclic-nucleotide 3'-phosphodiestenise 
1 |Mus musculusj - Identified by M A L D i -
TOF/TOF 
Gamma-actin [Mus musculus] - Identified by 
M A L D I - T O F 
Purine rich element binding protein B [Mus 
musculus] - Identified by M A L D I - T O F 
Na+/K+ -ATPase beta 1 subunit [Mus 
musculus] - Identified by MALDI-TOF/TOF 
Figure 4.15: Summary table showing the different proteins purified using the T A R P 
78 immunoaffinity columns that were subsequently identified by proteomic analysis 
of the extracted bands. 
For the immunoaffinity columns generated using the anti TARP y8 antibodies, only 
protein bands detectable using silver staining that were completely distinct f rom any 
existing bands in the material purified using the non-specific IgG immunoaflfinity column 
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were analysed. Some bands unique to the non-specific material were also analysed, but 
no positive identification was possible. Six interacting proteins were identified using 
proteomics, with two o f those proteins being identified in material purified by both the N 
and C terminal directed TARP 78 immunoaffinity columns (blue). The raw data 
generated from the M A L D I - T O F analysis can be located in Appendix B (Pages 187-196). 
The proteomic analysis o f the bands was conducted, as mentioned in the materials and 
methods, page 50, by Joanne Robson (University o f Durham). 
The T A R P 78 immunoaffinity columns both demonstrate the ability to purify 
previously unknown T A R P 78 interacting proteins 
The diverse range o f proteins selectively purified by the TARP 78 specific 
immunoaffinity colurains, including myelinafion-related proteins and those related to the 
cytoarchitecture highlight the suitability of these columns and the proteomic 
methodology for identifying unknown TARP 78 interacting proteins. The presence of N -
ethylmaleimide sensitive fiision protein (NSF) provides reassurance regarding the 
specificity o f the proteomic analysis by virtue o f its already described interactions with 
A M P A receptors. 
Discussion 
The immunoaffinity columns generated, whilst both successfiil at purifying TARP y8 and 
its interacting proteins, display different levels o f immunopurification o f the TARP 78 
isoform. The 78C immunoaffinity column purified TARP 78 to the extent that none was 
detectable in the flow-through after a single immunopurification, indicating that the 
immunoaffmity column has a high affini ty and binding capacity for TARP 78 that was 
not saturated by the amount o f material added to the column. Consequentially, the 78C 
immunoaffinity column also successfully purified the highest concentration o f interacfing 
proteins, particularly the A M P A receptor subunits, when compared with the 78N 
immunoaffinity column. Whilst explicable by the relative aff ini ty o f the antibodies for 
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TARP y8, the possibility o f epitope masking in the N-terminus, which is an issue due to 
the purification method retaining intact protein complexes, cannot be dismissed. 
Regardless o f the explanation and whether or not a sub-population o f TARP y8 defined 
by its interacting partners is being undetected by the y8N immunoaffinity column, the 
y8C immunoaffinity column is purifying all the detectable TARP y8 from the sample, so 
the eluted fractions obtained from that column are not lacking any detectable functional 
sub-population o f TARP y8. 
Both immunoaffinity columns also successfiilly purified a protein o f approximately 60 
kDa that was recognised with multiple commercial anti-5HT2c receptor antibodies. The 
molecular weight o f this protein corresponds with the molecular weight o f a glycosylated 
5HT2C receptor (Abramowski et al. 1995, Backstrom et al. 1999, Parker et al. 2003), 
providing some reassurance that this is 5HT2c receptor. Due to the antibodies lack o f 
congruent specificity in native tissue where 5HT2c receptor appears to be expressed at 
sufTiciently low levels to avoid detection, the commonality o f this band is reassuring, 
providing yet more support that this protein is 5HT2c receptor. At the current time the 
identity cannot be fu l ly confirmed because of the absence o f demonstrable 5HT2c 
receptor protein expression in the native tissue due to physiologically low concentrations 
o f the protein in most CNS regions and the absence o f choroid plexi material as a positive 
control. 
The presence o f PSD-95 in the TARP y8 purified material, offers further support to the 
original hypothesis in that it may be the intermediate protein interacting with 5HT2c 
receptors and TARPs/AMPA receptors. However, it may not be the only intermediate 
protein or even in the same complex as both TARPs/AMPA receptors and 5HT2c 
receptors. 
As such, whilst the columns and methodology does demonstrate the capacity to purify 
proteins interacting with TARP y8, it does not provide evidence that they are all 
interacting with TARP y8 in the same complex or at the same time, with the likely 
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possibility existing that mulfiple protein complexes exist within the TARP y8 purified 
material. 
To fiirther complicate the number o f potenfial protein complexes being purified by the 
columns, is the presence o f both TARP y2 and TARP y4 in the TARP y8 immunopurified 
material. Due to the specificity o f the TARP y8 antibodies, that showed no cross-
reactivity with the other TARP isoforms, this interaction has to be believed to be genuine, 
and somewhat unprecedented with nothing in the literature indicating multiple TARP 
isoforms being present within the same complex. Indeed, at the current time, there is sfill 
speculation as to the precise number o f TARPs present within an A M P A receptor 
complex at any one Ume, so the functional significance o f multiple TARP isoforms 
within the same complex is purely speculafive. It is most likely that the assortment o f 
TARPs within an A M P A receptor complex, combined with the combinations o f A M P A 
receptor subunits, would be responsible for targeting specific populations o f A M P A 
receptors to different cellular locations, via interactions with different key proteins. 
One final observation from the data is that TARP y8 appears to be predominantly non-
synaptic, with the vast majority being present in the Triton X-100^^ soluble material. 
This does not imply however, that TARP y8 is mostly extra-synaptic, because the 
solubilised material contains both extra-synaptic membrane proteins and intracellular 
proteins. As such, it is possible that the interactions o f TARP y8 with not only the other 
TARP isoforms, but also the 5HT2c receptor-like species occur intracellularly, and no 
information is given as to what cellular processes these interactions occur in. 
The data obtained from the material purified using the TARP y8 immunoaffmity columns 
and subsequently analysed via proteomic techniques offers a novel and in some cases, 
previously unconsidered set o f interacting proteins to those detected by immunoblotting. 
O f the two proteomic techniques used for analysis; M A L D I - T O F and MALDI-TOF/TOF, 
one o f the only common proteins identified was myelin basic protein, a protein that is, as 
its name would suggest, extensively associated with myelin (Komguth et al. 1965, Boggs 
2006). This is an unusual and novel finding, for whilst myelin is an integral component in 
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the nervous system architecture, it wouldn't obviously be associated with a protein such 
as TARP 78; a protein whose role in the myelin sheath has not even been considered, but 
may have implications in conditions such as multiple sclerosis (Sarchielli et al. 2007). 
The other protein common to both proteomic techniques and both TARP 78 
immunoaffinity columns was 2' ,3 ' cyclic-nucleotide 3' phosphodiesterase 1 (CNPase), 
again another protein exclusive to myelinated regions o f the CNS, predominantly 
expressed in oligodendrocytes as opposed to neurones (Nishizawa et al. 1981, Brunner et 
al. 1989). Significantly, CNPase has been implicated in schizophrenia and other 
neurological conditions where incorrect myelination has been identified as a potentially 
important component, although the specific role o f CNPase in these conditions is unclear 
(Yin et al. 2006, McCullumsmith et al. 2007). CNPase is known to have a role in 
mictrotubule assembly and subsequent linkage to cellular membranes (Lee et al. 2005), 
suggesting that its most likely interaction with TARP 78 is in the trafficking/targeting 
stages o f the TARP 78 fimctional role, possibly in a complex with M A P - I A , a 
mictrotubule associafing protein demonstrated to interact with both TARPs and A M P A 
receptors (Ives et al. 2004 Seog 2004). 
These results essentially facilitate the possibility that TARP 78 is present in other cells in 
the central nervous system, most likely with a basic functional role similar to that in 
neuronal cells, but in different processes, a possibility that, due to the presence o f 
ionotropic glutamate receptors on non-neuronal cells in the CNS, is a logical 
consideration, but a poorly investigated one (Patneau 1994, Chew et al. 1997, Karadottir 
et al. 2005). 
The implications for this have the potential to be considerable, with the role o f A M P A 
receptors in oligodendrocytes believed to potentially promote development from 
progenitors into mature oligodendrocytes and myelinafion (Pende et al. 1994); but also 
includes the mediation o f excitotoxic cell death fol lowing injury, particularly in the spinal 
cord (Sanchez-Gomez and Matute 1999, L i and Stys 2000, Park et al. 2003). 
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Perhaps the most significant o f the proteins purified with regard to confirming the 
practical fiinctionality o f the immunoaffinity columns, and an established A M P A 
receptor interacting protein, was N-ethylmaleimide sensitive fusion protein (NSF). NSF 
has been shown to interact with GluR2 containing A M P A receptors in a range of brain 
regions; promoting their cycling at the synapse, most likely to and f rom intracellular 
pools, via NMDA-activated disruption o f PICKl binding (Lee et al. 2002, Sossa et al. 
2006, 2007, Steinberg et al. 2004). 
The presence o f this protein provides strong positive evidence o f intact interacting 
complexes being purified by the immunoaffinity columns as well as increasing 
confidence in the identification techniques. The inability o f the proteomic methodology 
to identify either TARPs or A M P A receptor subunits is not a cause for concern due to the 
number o f interacting proteins purified coupled with the large quantity o f proteins at 
similar molecular weights being present in the sample. As such ftirther separation o f the 
protein bands, possibly by 2-D gel electorphoresis may be required in future studies. 
Other notable proteins identified by either M A L D I - T O F or MALDI-TOF/TOF as 
interacting with TARP 78 include subunits o f both beta and gamma actin, suggesting that 
the TARP 78 purified material contains at least some TARP 78 interacting in a complex 
with elements o f the cytoarchitecture, possibly in trafficking, or in anchoring at the cell 
surface. This interaction between TARP 78 and elements o f the cytoarchitecture again 
raises the possibility o f M A P - I A and components o f the microtubule network being 
present in this interaction, contributing to its functional significance. 
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Chapter 5: An investigation of the functional significance of 
the interactions between TARPs and 5HT2c receptors using 
mice with altered forebrain expression of 5HT2c receptors. 
Introduction 
One of the most potentially significant results of the immunoaffinity purifications in the 
previous chapter was the presence of a band detectable with multiple commercial 5HT2c 
receptor antibodies that was co-purified with TARP y8. This provides evidence 
supporting the hypothesis of 5HT2c receptors physically interacting with TARPs and 
potentially AMPA receptors within a protein complex. 
The 5HT2C receptor is a G-protein coupled receptor involved in the stimulation of 
phospholipase C and subsequent increase in inositol 1, 2, 3 triphosphate (IP3), leading to 
an increase in intracellular Ca'" .^ 
The 5HT2C receptor also possesses five adenosine sites, labelled as A, B, C, D and E, 
located in the amino acids at positions 156-160 (5'-3') that undergo mRNA editing. This 
property means that there are potentially 32 5HT2c receptor mRNA variants, fi-om which 
24 different protein splice variants are possible (Bums et al. 1997, Nakae et al. 2008). 
From these potential 24 variants, 22 have been seen to be expressed in the CNS. The 
unedited variant of the receptor displays the highest levels of constitutive activity and G 
protein coupling, and the fully edited variaint displays neither, with the partially edited 
variants displaying differing degrees of both; Editing at either the C and E sites appears 
to have the greatest effect on these properties (Herrick-Davis et al. 1999, Niswender et al. 
1999, Wang et al. 2000, Berg et al. 2001, Flomen et al. 2004). 
The splice variants also display specific regional distributions, with further evidence 
indicating that they frequently form fionctional conformational heteromeric dimers at the 
cell surface (Mancia et al. 2008). 
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There is also evidence that changes in the editing of 5HT2c receptor mRNA can occur as 
a consequence of chronic treatment with some pharmacological agents, or as a 
consequence of chronic changes brought about by a neurological condition, within certain 
brain regions, indicating that the specific splice variants may play individual roles in 
5HT2C receptor pharmacology in the CNS as a whole. A good example of this are the 
enhanced levels of editing at site A in the post-mortem samples of frontal cortex obtained 
from clinically depressed individuals who had successfully committed suicide (Niswinder 
et al. 2001). 
Functionally, the 5HT2c receptor displays multiple roles in the central nervous system, 
with evidence of 5HT2c receptors having a role in appetite, locomotion, anxiety, 
schizophrenia and depression (Pandey et al. 1995, Moreau et al. 1996, Jenck et al. 1998, 
Clenet et al. 2001, Frank et al. 2002, Nunes-de-Souza et al. 2008). It is the latter of these 
roles that is of interest in this study, due to the increasing prevalence of evidence for an 
AMPA receptor component in depression, and more specifically, the pharmacological 
treatment of depression, then the possibility of a functional interaction between 5HT2c 
receptors and AMPA receptors could be a key component in understanding depression 
and developing future treatments. 
The 5HT2C receptor is also unusual in the fact that it undergoes intemalisation in both the 
presence of agonists and antagonists (Van Oekelen et al 2003). 
Unfortunately, due to the inherent limitations of both the proteomic technique and the 
versatility of the 5HT2c receptor antibodies, the band identified following 
immunopurification was lacking positive confirmation, so an alternative approach to 
investigate a potential interaction between 5HT2c receptors and AMPA receptors via 
TARP y8 was required. Dr Megan Holmes, based at Edinburgh University, had 
developed mice both over-expressing 5HT2c receptors and mice exhibiting 5HT2c 
receptor knockdown within the frontal cortex, and kindly provided access to these 
resources so that any physiological consequences of these two experimental phenotypes 
upon the levels of TARPs and AMPA receptors could be investigated. 
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Results 
Hemispheres from the mice possessing altered 5HT2c receptor expression were 
contrasted with their relevant controls, with the differences in TARP and AMPA receptor 
subunit expression levels measured by quantitative immunoblotting. Further differences 
in protein expression were recorded by immunohistochemical and autoradiographical 
methodologies, with the observations providing data regarding the presence of a 
functional interaction between SHTic receptors and TARPs/AMPA receptors. 
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Figure 5.1.1: Representative immunoblot of 5HT2c receptor overexpressing 
forebrain Vs control probed with the TARP 78C antibody. 
One cerebral hemisphere, minus the cerebellum, from either control (COE) or SHTic 
receptor over-expressing (OE) mice was loaded onto a 10% SDS-PAGE gel. Three 
separate control mice and their over-expressing equivalents were used for a total « of 3. 
Protein amounts calculated by Lowry protein assay allowed 10 |.ig of protein to be loaded 
per lane. Immunoblot was probed with the TARP y8C antibody and band intensity 
calculated using ImageJ. 
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The immunoreactive species indicated by the black arrow is TARP yS. The 
immunoreactive species indicated by the blue arrow, and not shown at actual molecular 
weight, is a representative example of the p-actin loading control. The immunoblot was 
repeated in triplicate with the mean TARP y8/p-actin intensities for the knockdown 
condition and the controls were calculated, with these values being used as described in 
Section 2.11 on page 50. 
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Figure 5,1.2: Graph showing the mean percentage expression of TARP yS in the 
forebrain of the 5HT2c receptor over-expressing mice compared with controls. 
Shows the mean percentage difference in forebrain expression of TARP y8 between the 
5HT2C receptor over-expressing mice and their controls calculated using triplicate 
samples from an « of 3. For the Control the mean percentage was set as 100%. The 
asterisk signifies that this percentage difference corresponds to a statistically significant 
(at the <0.05 probability level) difference between the expression of TARP y8 in the 
5HT2C receptor over-expressing mice compared with controls. 
151 
Total levels of TARP yS are significantly increased in the forebrain 5HT2c receptor 
over-expressing mice. 
The total levels of TARP 78 in 5HT2c receptor over-expressing mice demonstrated a 
statistically significant increase in total TARP 78 expression of 17% compared to the 
control. Results were significant at the probability of <0.05, P = 0.0328 based upon an n 
of 3. 
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Figure 5.2.1: Representative immunoblot of 5HT2c receptor overexpressing 
forebrain Vs control probed with the TARP y2 antibody. 
One cerebral hemisphere, minus the cerebellum, fi-om either control (COE) or 5HT2c 
receptor over-expressing (OE) mice was loaded onto a 10% SDS-PAGE gel. Three 
separate control mice and their over-expressing equivalents were used for a total « of 3. 
Protein amounts calculated by Lowry protein assay allowed 10 ^g of protein to be loaded 
per lane. Immunoblot was probed with the TARP y2 antibody and band intensity 
calculated using ImageJ. The immunoblot was repeated in triplicate with the mean TARP 
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Y2/p-actin intensities for the knockdown condition and the controls were calculated, with 
these values being used as described in Section 2.11 on page 50. The immunoreactive 
species corresponding to TARP 72 is indicated by the black arrow. 
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Figure 5.2.2: Graph showing the mean percentage expression of TARP y2 in the 
forebrain of the 5HT2c receptor over-expressing mice compared with controls. 
Shows the mean percentage difference in forebrain expression of TARP y2 in 5HT2c 
receptor over-expressing mice compared with their controls calculated using triplicate 
samples from an « of 3. For the Control the average was set as 100% 
Total levels of TARP yl appear to be lower in the forebrain of 5HT2c receptor over-
expressing mice. 
All repeats of the TARP y2 analysis displayed a trend towards a decrease in the levels of 
TARP y2 expression, however, this decrease was not seen to be significantly significant, 
P = 0.5345, based on an « of 3. 
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Figure 5.3.1: Representative immunoblot of 5HT2c receptor overexpressing 
forebrain Vs control probed with the GluRl antibody. 
One cerebral hemisphere, minus the cerebellum, from either control (COE) or SHTic 
receptor over-expressing (OE) mice was loaded onto a 10% SDS-PAGE gel. Three 
separate control mice and their over-expressing equivalents were used for a total n of 3. 
Protein amounts calculated by Lowry protein assay allowed 10 |ag of protein to be loaded 
per lane. Immunoblot was probed with the GluRl antibody and band intensity calculated 
using ImageJ. The immunoblot was repeated in triplicate with the mean GluRl/p-actin 
intensities for the knockdown condition and the controls were calculated, with these 
values being used as described in Section 2.11 on page 50. The immunoreactive species 
corresponding to GluRl is indicated by the black arrow. 
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Figure 5.3.2: Graph showing the mean total levels of GluRl in the forebrain of the 
5HT2C receptor over-expressing mice. 
Shows the mean percentage difference in forbrain expression of GluR 1 in the 5HT2c 
receptor over-expressing mice compared with their controls calculated using triplicate 
samples from an « of 3. For the Control the average was set as 100%. 
Total levels of GluRl appear to be unaffected in the forebrain or 5HT2c receptor 
over-expressing mice. 
A trend towards a slight (less than 10%) decrease in total GluRl expression was noticed 
in the 5HT2c receptor over-expressing mice forebrains, however, this was not statistically 
significant, P = 0.2657, based upon an « of 3. 
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Figure 5.4.1: Representative immunoblot of 5HT2c receptor overexpressing 
forebrain Vs control probed with the GluR2 antibody. 
One cerebral hemisphere, minus the cerebellum, fi-om either control (COE) or 5HT2c 
receptor over-expressing (OE) mice was loaded onto a 10% SDS-PAGE gel. Three 
separate control mice and their over-expressing equivalents were used for a total « of 3. 
Protein amounts calculated by Lowry protein assay allowed 10 \ig of protein to be loaded 
per lane. Immunoblot was probed with the GluR2 antibody and band intensity calculated 
using ImageJ. The immxmoblot was repeated in triplicate with the mean GluR2/p-actin 
intensities for the knockdown condition and the controls were calculated, with these 
values being used as described in Section 2.11 on page 50. The immunoreactive species 
corresponding to GIuR2 is indicated by the black arrow 
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Figure 5.4.2: Graph showing the mean percentage expression of GluR2 in the 
forebrain of the 5HT2c receptor over-expressing mice. 
Shows the mean percentage difference in GluR2 expression in the forbrains of 5HT2c 
receptor over-expressing mice calculated using triplicate samples from an n of 3. For the 
Control the average was taken as 100%. 
Total levels of GluR2 appear to be elevated in the forebrain of 5HT2c receptor over-
expressing mice. 
Al l repeats of the GluR2 analysis showed a trend towards an increase in the levels of 
GluR2 expression. However, this increase was not seen to be significantly significant, P 
= 0.1215, based on an n of 3.. 
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Figure 5.5: Immunohistochemical sections of 5HT2c over-expressing (A) and control 
(B) mice frontal cortex probed with the TARP ySC. Magnification X200. Scale bars 
= 100 ^m. 
The 5HT2C receptor over-expressing mouse shows a greater level of TARP y8 
immunoreactivity compared to the control, with subtle differences in the labelling 
distribution detectable. 
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Figure 5.6: Immunohistochemical sections of 5HT2c over-expressing (A) and control 
(B) mice hippocampal formation probed with the TARP y8C. Magnification X200. 
Scale bars = 100 ^ m. 
As can be seen, there is no detectable differences in hippocampal TARP y8 expression 
between the 5HT2c receptor over-expressing mouse and the control. 
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Figure 5.7.1: Autoradiography showing ' ^ ' H AMPA binding in the 5HT2c receptor 
Over-expressing mouse (A) and control ( B ) . Scale bars = 5mm. 
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Figure 5.7.2: Graph showing the percentage of ' ^ ' H labelled AMPA binding in the 
cerebral cortex of 5HT2c receptor over-expressing mice compared with control. 
Results are measured as a comparable percentage, taking the control percentage as 100%. 
The asterisk signifies that the percentage of ^^ 'H AMPA binding in the cerebral cortex of 
the 5HT2C receptor over-expressing mice corresponds to a statistically significant (at the 
<0.05 probability level) difference (a mean increase of 67%) compared with the controls. 
5HT2C receptor over-expressing mice display elevated levels of AMPA binding in 
the frontal cortex. 
The results show an increase in AMPA binding in the 5HT2c receptor over-expressing 
mice of 67%, a result taken as statistically significant at the <0.05 level, P = 0.0085, 
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based on an « of 3. Results were calculated from the mean of 5 measured sections taken 
from 5 separate brain slices fi-om 3 individual mice. 
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Figure 5.8.1: Representative immunoblot of 5HT2c receptor knockdown forebrain 
Vs control probed with the TARP ySC antibody. 
One cerebral hemisphere, minus the cerebellum, from either control (CKD) or 5HT2c 
receptor knockdown (KD) mice was loaded onto a 10% SDS-PAGE gel. Three separate 
control mice and their knockdown equivalents were used for a total « of 3. Protein 
amounts calculated by Lowry protein assay allowed 10 ^ig of protein to be loaded per 
lane. Immunoblot was probed with the TARP y8C antibody and band intensity calculated 
using ImageJ. The immunoblot was repeated in triplicate and the mean TARP y8/p-actin 
intensities for the knockdown condition and the controls were calculated, with these 
values being used as described in Section 2.11 on page 50. 
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The immunoreactive species indicated by the black arrow is TARP y8. The 
immunoreactive species indicated by the blue arrow, and not shown at actual molecular 
weight, is a representative example of the P-actin loading control. 
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Figure 5.8.2: Graph showing the mean percentage expression of T A R P yS in the 
forebrain of the SHTac receptor knockdown mice compared with controls. 
Shows the mean difference in percentage expression o f TARP y8 between the 5HT2c 
receptor knockdown mice and their respective controls using triplicate samples from an n 
o f 3. For the Control the mean percentage expression was set as 100%. The asterisk 
signifies that the difference in percentage o f mean TARP y8 expression between the 
5HT2C receptor knockdown mice compared with their controls, as shown in this graph, 
represents a difference that is statistically significant at the <0.05 probability level. 
Total levels of T A R P y8 are significantly increased in the forebrain 5HT2c receptor 
knock-down mice. 
The total levels o f TARP y8 in 5HT2c receptor knockdown mice demonstrated a 
significant increase o f approximately 66% on average compared wi th the controls. 
Results were significant at the probability o f <0.05 (P = 0.0030) based upon an « of 3. 
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Figure 5.9.1: Representative immunoblot of 5HT2c receptor knockdown forebrain 
Vs control probed with the T A R P Y2 antibody. 
One cerebral hemisphere, minus the cerebellum, from either control (CKD) or SHTic 
receptor knockdown ( K D ) mice was loaded onto a 10% SDS-PAGE gel. Three separate 
control mice and their knockdown equivalents were used for a total n o f 3. Protein 
amounts calculated by Lowry protein assay allowed 10 fj.g o f protein to be loaded per 
lane. Immunoblot was probed wi th the TARP y2 antibody and band intensity calculated 
using ImageJ. The immunoblot was repeated in triplicate and the mean TARP y2/p-actin 
intensities for the knockdown condition and the controls were calculated, wi th these 
values being used as described in Section 2.11 on page 50. The immunoreactive species 
corresponding to TARP y2 is indicated by the black arrow. 
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Figure 5.9.2: Graph showing the mean percentage of T A R P y2 expression in the 
forebrain of the 5HT2c receptor knockdown mice relative to controls. 
Shows the mean percentage difference o f TARP y2 expression in the SHTic receptor 
knockdown mice compared with the controls calculated using triplicate samples wi th an n 
of 3. For the Control the average was taken as 100%. 
Total levels of T A R P yZ appear to be unchanged in the forebrain of S H T j c receptor 
knockdown mice. 
A l l repeats o f the TARP y2 analysis displayed a trend towards a minimal increase in the 
levels o f TARP y2 expression. However, this increase was not seen to be significantly 
significant, P = 0.7374, based upon an « o f 3. The immunoblot shown is misleading in 
appearance, the higher intensity in TARP y2 expression being due predominantly to a 
higher total level o f protein loaded in the sample. 
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Figure 5.10.1: Representative immunoblot of 5HT2c receptor knockdown forebrain 
Vs control probed with the G l u R l antibody. 
One cerebral hemisphere, minus the cerebellum, from either control (CKD) or SHTic 
receptor knockdown ( K D ) mice was loaded onto a 10% SDS-PAGE gel. Three separate 
control mice and their knockdown equivalents were used for a total « o f 3. Protein 
amounts calculated by Lowry protein assay allowed 10 p.g o f protein to be loaded per 
lane. Immunoblot was probed with the GluRl antibody and band intensity calculated 
using ImageJ. The irrmiunoblot was repeated in triplicate wi th the mean GluRl/p-actin 
intensities for the knockdown condition and the controls calculated and used as described 
in Section 2.11 on page 50. Differences in the immunoreactive species detected with this 
antibody (primarily the losses o f multiple bands at 50-70 kDa), compared wi th Figure 
5.3.1 are due to a change in the anti GluRl antibody used in this project, wi th the original 
batch no longer being an option for use in this project. The immunoreactive species 
corresponding to GluRl is indicated by the black arrow. 
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Figure 5.10.2: Graph showing the mean percentage of G l u R l expression in the 
forebrain of the 5HT2c receptor knockdown mice relative to the controls. 
Shows the mean percentage difference in GluRl expression between the 5HT2c receptor 
knockdown mice and the controls taken f rom triplicate samples wi th an « o f 3. For the 
Control the mean percentage expression was set as 100%. 
Total levels of G l u R l appear to be increased in the forebrain or 5HT2c receptor 
knockdown mice. 
A n trend towards an increase in total GluRl expression was noticed in the 5HT2c 
receptor knockdown mice forebrains, however, this was not calculated as statistically 
significant, only reachmg a P = 0.113, based upon an n o f 3, most likely as a consequence 
o f high variability, and consequently large error bars, in the increased expression 
resulting f rom the change in antibody probe and their different affinities for G l u R l . 
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Figure 5.11.1: Representative immunoblot of 5HT2c receptor knockdown forebrain 
Vs control probed with the GluR2 antibody. 
One cerebral hemisphere, minus the cerebellum, f rom either control (CKD) or 5HT2c 
receptor knockdown (KD) mice was loaded onto a 10% SDS-PAGE gel. Three separate 
control mice and their knockdown equivalents were used for a total « o f 3. Protein 
amounts calculated by Lowry protein assay allowed 10 (xg o f protein to be loaded per 
lane. Immunoblot was probed wi th the GluR2 antibody and band intensity calculated 
using ImageJ. The immunoblot was repeated in triplicate, the mean GluR2/p-actin 
intensities for the knockdown condition and the controls were calculated, with these 
values being used as described in Section 2.11 on page 50. The immunoreactive species 
corresponding to GluR2 is indicated by the black arrow 
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Figure 5.11.2: Graph showing the mean percentage of GluR2 expression in the 
forebrain of the 5HT2c receptor knockdown mice. 
Shows the mean percentage difference in the expression o f GluR2 in the 5HT2c receptor 
knockdown mice compared with controls, calculated using triplicate samples from an n 
of 3. For the Control the mean percentage expression was set as 100% 
Total levels of GluR2 in the forebrain of 5HT2c receptor knockdown mice show a 
slight, but not significant increase in expression. 
The total levels o f GluRZ measured in the 5HT2c receptor knockdown mice showed no 
statistically significant difference once the ratio o f GluR2/p-actin was calculated, P = 
0.7873, based upon an n o f 3, although a trend towards a slightly increased expression 
was observed. 
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Figure 5.12: Immunohistochemical sections of 5HT2c knockdown (A) and control 
(B) mice frontal cortex probed with the T A R P ySC. Magnification X200. Scale bars 
= 100 fim. 
The 5HT2C receptor knockdown mouse shows a much greater level o f TARP y8 
immunoreactivity compared to the control, wi th noticeable differences in the labelling. 
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Figure 5.13: Immunohistochemical sections of 5HT2c knockdown (A) and control 
(B) mice hippocampal formation probed with the T A R P y8C. Magnification X200. 
Scale bars = 100 ^m. 
As can be seen, there is no detectable differences in hippocampal TARP y8 expression 
between the 5HT2c receptor knockdown mouse and the control. 
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Figure 5.14.1: Autoradiography showing '^ 'H A M P A binding in the SHTic receptor 
knockdown mouse (A) and control ( B ) . Scale bars = 5mm. 
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Figure 5.15.2: Graph showing percentage of ' ^ ' H labelled A M P A binding in the 
cerebral cortex of 5HT2c receptor knockdown mice compared with control. 
Results are measured as a comparable percentage, taking the control percentage as 100%. 
The asterisk signifies that this percentage increase reflects a statistically significant (at the 
<0.05 probability level) difference between the ' ^ ' H A M P A binding in the SHTac receptor 
knockdown mice compared with their respective controls. 
5HT2C receptor knockdown mice display elevated levels of A M P A binding in the 
frontal cortex. 
The results show an increase in the mean percentage o f total '^^H A M P A binding in the 
5HT2C receptor knockdown mice o f 100% compared with the controls, a result 
statistically significant at the <0.05 level, P = 0.0499, based on an n o f 3. Results were 
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calculated from the mean of 5 measured sections taken from 5 seperate brain slices from 
3 individual mice. 
Discussion 
The alteration of 5HT2c receptor expression appeared to have somewhat similar effects 
upon T A R P isoform expression, irrespective of the specific experimental condition. 
It is certainly not without precedent for a G Protein-coupled receptor to regulate AMPA 
receptor trafficking and expression via interactions with GABAergic intemeurones, with 
the influence of Dopamine receptors, such as D4 on AMPA receptors being known (Gao 
and Wolf 2007, Kwon et al. 2008, Yuen and Van 2009). 
This would appear to be the case here, with both the 5HT2c receptor over-expressing 
mice and the 5HT2c receptor knockdown mice both demonstrating significant increases 
in TARP y8 expression within the forebrain. 
In the 5HT2C receptor over-expressing mice this statistically significant increase in the 
levels of T A R P y8 is associated with an observed, trend towards increased expression of 
GluRZ, but no change in the expression GluRl and T A R P y2. 
These data suggests that the over-expression of 5HT2c receptors induces a consequential 
increase in the level of T A R P y8 and GluRZ containing AMPA receptors in the forebrain. 
This is somewhat contradictory as, whilst the AMPA receptors present in the synapse are 
not exclusively, GluRZ containing AMPA receptors, the majority of GluRZ containing 
AMPA receptors are present within the synapse. T A R P y8 on the other hand, is primarily 
Triton X-100™ soluble, implying that the majority of T A R P y8 is non-synaptic. 
The autoradiography data, suggests an increase in total AMPA receptor number in the 
frontal cortex, indicating that an enhancement of some excitatory component of the CNS 
is effected, if this was associated with an increase in GluRZ subunit containing AMPA 
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receptor expression, then this might indicate a chronic enhancement of synaptic AMPA 
receptor mediated currents as opposed to acute L T P (Kauer and Malenka 2006, 
McCormick et al. 2006). However, unlike circumstances with other types of 
neurotransmitter receptor, for example, the G A B A A receptors, determining the specific 
composition of these up-regulated AMPA receptors is not possible based upon 
autoradiography data alone. 
The 5HT2C receptor knockdown mice also demonstrated a statistically significant 
increase in the levels of T A R P yS expressed in the forebrain. These mice also displayed 
an observed trend in the increase in the expression of TARP y2. With regard to the 
AMPA receptor subunits screened, there was a trend towards increased expression of the 
GluRl subunit, and slight trend of increased expression level of GluR2. 
This observation appears to be the reverse of the AMPA receptor effects induced by the 
over-expression of 5HT2c receptors, despite having the same effect of increasing total 
T A R P yS expression levels. The increase in expression of the GluRl subunit in 
preference to the GluR2 subunit, which by comparison only displays a very slight and 
non-significant observable increase, implies that the predominant AMPA receptors being 
expressed in the forebrain as a consequence of 5HT2c receptor knockdown are those that 
contain G l u R l , quite possibly as the predominant subunit. A logical speculation on this 
would be that the upregulated AMPA receptors are lacking the GluR2 subunit, similar to 
the AMPA receptors that are upregulated following L T P . 
Indeed, this may well be the case, as it has been observed repeatedly with other neural 
circuits in other CNS regions that the activation of one type of neurotransmitter receptor 
has knock-on effects upon AMPA receptor subunit expression, particularly the GluRl 
subunit. This can most readily be observed by the activity of dopaminergic neurones 
within the Nucleus Accumbans (NAc), as a consequence of reward seeking behaviour, 
where the activation of D | dopaminergic receptors, results in an increase in synaptic 
GluRl expression (Bespalov et al. 2007). Similar interactions, whereby dopaminergic 
activity at the Di receptor regulates both synaptic and surface GluRl expression, often 
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within dopaminergic neurones, can be observed in the ventral tegmental area (VTA) and 
dorsal striatum, and are of particular importance with regard to addictive substances of 
abuse such as cocaine (Bachtell and Self 2008, Bachtell et al. 2008, Kim et al. 2008), 
morphine (Lane et al. 2008), and heroin (LaLuimiere and Kalivas 2008). However, the 
fundamental difference here would be the implication that as it is the loss of 5HT2c 
receptor activation, that the increase in GluRl expression is occurring as a result of the 
activation of other, currently unknown, receptors as a consequence of decreased 5HT2c 
receptor mediated inhibition. 
This potential decrease in an inhibitory component of the frontal cortex in the 5HT2c 
receptor knockdown mice would be as a consequence of the loss of 5HT2c receptor 
mediated excitation of GABAergic intemeurones (Liu et al. 2007). In the 5HT2c receptor 
over-expressing mice forebrains, these GABAergic neurones are most likely going to 
display elevated excitation levels compared to wildtype mice. When this increased 
excitation is taken into account with the agonist-induced down-regulation of 5HT2c 
receptors, then the resulting system is most likely highly sensitive to 5HT but the 
consequential effects are limited by the responses of 5HT2c receptors to activation, 
leading to a more pronounced display of effects upon inhibitory circuits in the frontal 
cortex of the 5HT2c receptor knockdown mice. 
The autoradiography data shows there is a large increase in the number of AMPA 
receptors in the frontal cortex, an observation that is logical considering the most likely 
decreased inhibitory component in that region following 5HT2c receptor knockdown. 
Unfortunately, there is the same problem conceming the exact subunit identity of these 
AMPA receptors. 
When data from both of the experimental mice is combined it implies that 5HT2c receptor 
over-expression and knockdowns both have effects on enhancing AMPA receptor 
signalling, but most likely via different mechanisms leading to different AMPA receptor 
compositions and most likely different AMPA receptor functions. However, both appear 
to cause an increase in T A R P y8 expression. The reasons for this could be; 
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• Different neuronal populations are being affected by each condition. 
• TARP y8 is primarily involved in cell surface trafficking o f A M P A receptors in 
preference to synaptic targeting and that its increased expression is a common 
pathway for the mobilisation o f all A M P A receptors to the cell surface in TARP 
y8 expressing neurones irrespective o f the mechanisms determining A M P A 
receptor expression and composition. 
The fol lowing series o f schemas attempt to explain these two points within a simplified 
framework. 
A 
A 
Glutamatergic 
neurone 
GABAergic 
neurone 
Direction o f 
neurotransmission 
• Excitatory 
signal 
^ _ Inhibitory 
signal 
Figure 5.15.1 Simplified schema showing net neurotransmission in control mice. 
Excitatory input is received by the glutamatergic neurone (1). The neurone itself is also 
influenced by inhibitory signals received from GABAergic intemeurones (2), which 
dampen the netexcitatory output o f the neurone, reducing the excitatory signal received 
by neurones at its axonal terminals (3). This reduced net excitatory signal is subsequently 
transmitted along to interconnected neurones (4). 
178 
With the excitation o f the GABAergic intemeurones being regulated, at least in part, by 
5HT2C receptor activity, then alteration o f 5HT2c receptor expression can affect this 
neuronal network by altering the inhibitory regulation o f the glutamatergic neurones. The 
constitutive activity o f 5HT2c receptors ensures that there is always some form o f 
inhibitory regulation present in neuronal pathways. 
< 
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Direction o f 
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Figure 5.15.2 Simplified schema showing speculative net neurotransmission in 
5HT2C receptor over-expressing mice. 
Excitatory input is received by the glutamatergic neurone (1). Enhanced constitutive 
activity o f the GABAergic intemeurone (2), in this instance as a consequence o f 
increased expression o f 5HT2c receptors, results in an increase in the regulatory 
inhibition o f the glutamatergic neuronal pathways (3). This increased inhibition results in 
a significantly reduced excitatory signal being transmitted along the neuronal pathway 
(4). This has the net effect o f significantly reducing spontaneous excitatory activity, but 
also dampens mduced excitatory neurotransmission which w i l l logically alter the synaptic 
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composition of those neurones as this is dependent upon levels of activity. This could 
result in the subsequent increase in the ratio of non-synaptic: synaptic AMPA receptors, 
which as previously discussed, are largely dependent upon TARP isoforms for 
trafficking, with TARP y8 being largely present in the non-synaptic material as observed 
from the Triton X-100^'^ solubilisations discussed in Chapter 4, then it would be a logical 
consequence, that there would be increased TARP y8 expression. There is also the highly 
like probability that the increased inhibition of some excitatory pathways in the CNS will 
result in an enhancement of the activity of others. As such, the increased TARP y8 
expression in the 5HT2c receptor mice may be occurring in neuronal networks not 
directly affected by the 5HT2c receptor expression. 
+ + 
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Figure 5.15.3 Simplified schema showing speculative net neurotransmission in 
5HT2C receptor knockdown mice. 
Excitatory input is received by the glutamatergic neurone (1). The absence/significant 
decrease of SHTic receptors on the GABAergic intemeurones results in their decreased 
excitation, and a net loss of inhibitory signals on the neuronal pathway (2). This loss of 
inhibitory signalling results in a much larger excitatory signal being transmitted from the 
180 
primary glutamatergic neurone to subsequent neurones in the network (3) than would be 
transmitted i f the inhibitory signals were present. 
This increase in net excitatory signalling, due in this instance to a loss of inhibition, will 
result in profound changes in the synaptic composition of the excitatory neurones directly 
involved in the network affected, potentially increasing synaptic AMPA receptor number 
as well as total AMPA receptor expression. The increased glutamate likely being released 
in this model would in greater activation of peripheral synapses as a consequence of 
extra-synaptic AMPA receptor activation following the spill-out of glutamate from 
synaptic boutons. This increase in glutamatergic activity would necessitate an increase in 
TARP expression and whilst TARP y2 shows no increase, other TARP isoforms, 
including TARP y8, may have an increased ftinctional role. 
Looking at the results, it is extremely likely that any functional interaction between 
5HT2C receptors and AMPA receptors, and by extension TARPs, will involve other 
neuronal receptors. Again, returning to the increasingly well investigated area of 
dopamine receptors interacting with AMPA receptors, this concept of multiple 
mechanisms facilitating the effects of the interactions between G-protein coupled 
receptors and AMPA receptors has been demonstrated, with the presence of a NMDA 
receptor dependent component in the enhanced GluRl containing AMPA receptor 
expression following cocaine administration that facilitates the dopaminergic response 
(Engblom et al. 2008). 
Of course, the aberrant activity of the neurones in these mice, such as enhanced 
glutamatergic signalling, would have knock-on effects on other neuronal pathways that 
are influenced both directly and indirectly by the neurones described in this schema. A 
good example involving other 5HT receptors, would be the activity dependent 
modulation by AMPA receptor to 5HT afferents from the dorsal raphe nucleus and 
median raphe nucleus to frontal cortex. This interaction is a complex interplay known to 
incorporate both 5HTIA receptors and neurokinin receptors (Gartside et al. 2007, Guiard 
et al. 2007). Another particularly relevant example is the regulation of dopaminergic 
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neurones in the NAc, which are actually inhibited by 5HT2c receptor activation 
(Dremencov et al 2005). This is particularly relevant to the 5HT2c receptor knockdown 
mice, with the loss of 5HT2c receptor-mediated inhibition likely to result in enhanced 
reward seeking behaviour, and subsequent increases in AMPA receptor activity within 
the NAc, most likely explaining some of the increased TARP yS expression within the 
forebrain of these mice. 
One thing regarding 5HT2c receptor interactions that these results do suggest is that the 
functional effects of this potential interaction is not limited to purely physical 
interactions, the 5HT2c receptor knockdown mouse suggesting a signalling component of 
5HT2C receptors that determines AMPA receptor composition, a purely physical 
interaction would be most likely to see opposite effects between the two conditions 
regarding TARP/AMPA receptor expression, but the reality is that whilst there are 
seemingly opposite effects, they are in AMPA receptor composition and not number. 
A complication, based upon the limited amount of material available, is that the 
quantitative immunoblotting had to be conducted on whole forebrain hemispheres. As a 
consequence, there is the, quite likely possibility, that any modest altered TARP/AMPA 
receptor expression i f confined to a specific region of the forebrain would not be 
detectable in a whole forebrain preparation, only dramatic changes in expression would 
be easily detectable. Indeed, it is not even certain whether the altered TARP y8 
expression even occurs in the same neurones between the two conditions. 
Another potential factor to be taken into consideration for fiiture work is the presence of 
chronobiology. The 5HT2c receptor is intrinsically involved in the maintenance of 
biorhythmical processes, with specific phases of each circadian cycle correlating with 
specific properties of the endogenous 5HT2c receptors (Pan and Gala 1988, Weiner et al. 
1992, Holmes etal. 1997). 
Of course the information obtained in this chapter is limited by the fact that with the 
exception of the TARP y8 data the other data is not stafistically significant and whilst 
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there are observed patterns, it is possible that the results are due to chance. This appears 
to be due to limitations in the methodology; 
• The accessibility of the mice allowed only a n number of 3 to be used, with the 
quantifications repeated in triplicate. 
• Experiments were only capable, due to limitations in tissue amounts, to be 
conducted on entire hemispheres of forebrain material, which, as seen by the 
immunhistochemistry and in situ hybridisation, did not display effects 5HT2c 
receptor throughout across these regions in a uniform manner. 
Further studies using only the frontal cortex from more source animals would most likely 
show statistically significant and much more readily measurable differences in the level 
of TARP isoform and AMPA receptor subunit expression as a consequence of altered 
5HT2C receptor expression within these tissues. 
In conclusion, further investigation is necessary, possibly with more precise dissections 
of specific sub-regions of the forebrain, to positively identify exact changes in 
TARP/AMPA receptor expression in specific regions, possibly using better 
immunohistochemical probes, a severely limiting factor in this instance, to more 
successfully identify regions of interest. This could be coupled with more exact 
investigation using immunological probes specific to AMPA receptor phosphorylation 
states and confocal studies to determine exactly which neurones were being affected by 
these changes in 5HT2c receptor expression. 
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Final Discussion and Future Work 
With the original intentions of this project being to investigate the potential interactions 
between 5HT2c receptors and TARPs/AMPA receptors in the mammalian fi-ontal cortex, 
by designing, generating and characterising novel immunological probes specific for each 
individual TARP isoform - probes that are capable of immunologically isolating specific 
TARPs and their respective interacting proteins - some progress was made, with each of 
the antibodies being used to generate information regarding TARP protein distribution. 
The TARP y8 C-terminal directed antibody quickly became the focus of study, following 
the confirmation of the prevalence of TARP y8 within the hippocampus, a region of 
importance in cognition, but also in neurological disorders, such as depression. Evidence 
of antidepressant enhancement of the hippocampal-medial-prefi-ontal cortical pathway 
(Ohashi et al. 2002), coupled with the effects of the SSRI and 5HT2c receptor antagonist 
fluoxetine upon calcineurin and GluRl (Crozatier et al. 2007) within the hippocampus, 
and the distribution of TARP y8 within not only the hippocampus, but also throughout 
the frontal cortex, within a very distinct distribution, made it highly likely that any 
AMPA receptor involvement in depression that would inevitably affect AMPA receptor 
trafficking or targeting, would involve TARP y8. 
This reasoning was fiirther supported by the evidence that the distribution of the GluR2 
AMPA receptor subunit within the frontal cortex, was very similar to that of the TARP y8 
isoform. The distribution of GluR2 within the prefrontal cortex being shown to undergo 
decreased expression in chronic social defeat models of depression in tree shrews, with 
this decreased expression being reversible by the application of D2 dopamine receptor 
partial agonist which possessed SSRI activity (Michael-Titus et al. 2008). 
The hippocampus was also the region of the forebrain that displayed the highest levels of 
GluRl expression, making it likely that TARP y8 and GluRl would interact within that 
region which is interesting in light of evidence that has recently been presented of a 
GluRl knock-out mouse that demonstrates depressive behaviour, with profound 
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neurotransmitter deficits within the hippocampus (Chourbaji et al. 2008). With this 
disruption within the hippocampus of AMPA receptors as a consequence of the GluRl 
knockout, a disruption of the TARP isoform expression within the hippocampus would 
be likely to occur, most likely affecting TARP 78 and its interactions significantly. 
With TARP 78 being the predominant TARP isoform within the hippocampus, there is 
also a logical consideration that TARP yS has an important role in LTP. 
Hippocampal LTP is believed to play a ftindamental role in memory and cognition and 
ironically, there is another member of the 5HT receptor family that may have a role in 
LTP within the hippocampus, that receptor being the 5HTIA receptor. Activation of the 
5HTiA receptor in the hippocampus prevents the activity of calmodulin-dependent protein 
kinase I I , a protein important in delivery of AMPA receptors to silent synapses (Shi et al. 
2001), in addition to reducing PPl and protein kinase A activity (Schiaparelli et al. 2005), 
whereas antagonism of the 5HTIA receptor results in enhanced surface expression of 
phosphorylated AMPA receptor subunits (Schiaparelli et al. 2006). Considering the 
aforementioned importance of CAMKII in phosphorylating TARP 72 (Tomita et al. 
2005) and, due to the sequence homology, potentially TARP y8, and both of these 
proteins high expression within the hippocampus as well, it is highly likely that both 
proteins are affected by 5 H T I A receptor activity. However, further investigation would be 
required to elucidate which TARP isoforms were affected by GluRl knockout and 5HTIA 
receptors. 
The relationship between 5HTIA receptors and AMPA receptors is not limited to the 
hippocampus, there is also evidence of 5HTIA in regions of the prefrontal cortex, 
localised with glutamatergic synapses (Kia et al. 1996). With the frontal cortex being 
another region of CNS with high expression of TARP 78, it is likely that there would be 
at the very least some form of functional interaction between 5HT|A receptors and AMPA 
receptors that would be affected by TARP 78 expression. 
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The immunopurifications also enabled the purification of a protein that was identified 
using multiple 5HT2c receptor antibodies and possessed a molecular weight 
corresponding to 5HT2c receptors. This result provides credible evidence of a physical 
interaction between 5HT2c receptors and TARPs/AMPA receptors and although it offers 
no further data regarding the fimctional purpose of this interaction, it does generate a 
suitable starting point for further investigation into the nature of this interaction. 
This direct physical interaction may have some significance even though it is uncertain 
exactly how mature either the TARP 78 or the 5HT2c receptor is and where in the cell the 
interaction occurs. It has been observed that within the hypothalamic tuberlomamillary 
nucleus, there is evidence of expression of both AMPA receptors and 5HT2c receptors 
within the same histaminergic neurone, where activation of either is capable of inducing 
neuronal excitation (Sergeeva et al. 2007). 
The experimental work on mice with altered 5HT2c receptor expression generated some 
complex data, suggesting that the functional interactions between 5HT2c receptors and 
TARPs/AMPA receptors is anything but simple. Both the 5HT2c receptor over-
expressing mice and the forebrain knockdown mice display elevated levels of TARP y8 
expression, but appear to have altered AMPA receptor subunit expression, suggesting 
that whilst 5HT2C receptors have a physical interaction with TARP y8 at some point in 
their existence, they also possess an independent functional interaction influencing 
AMPA receptor composition. 
This would not be the first such example of modulation of AMPA receptors by SHT? 
receptors, with 5HT2 receptor activation altering AMPA receptor conductance and 
activity in a signalling pathway incorporating protein kinases and phosphatases but 
requiring activation of Type 1 Metabotropic glutamate receptors (Bocchiaro and Feldman 
2004, Neverova et al. 2007). Indeed, in the prefrontal cortex, there is even evidence of 
5HT2Aand SHTic receptors modulating LTD (Zhong et al. 2008), but also possessing 
opposing ftinctional effects (Marek 2008) which, when considering the importance of 
GluR2 containing AMPA receptors in LTD and the aforementioned similarity in TARP 
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78 and GluR2 distributions, would represent a tantalising starting point for investigating 
the mechanisms explaining how 5HT2c receptors when over-expressed or knocked-down 
both result in increased expression of TARP 78 within the frontal cortex. 
At the current time, none of the current studies of AMPA receptors in neurological 
dysfunction have examined the potential impact of TARP interactions, making the probes 
generated in this project a valuable basis for future work within this field. It has also, 
unfortunately, made the knowledge provided by these probes, more speculative than 
definitive, with the information provided by them being making intriguing starting points 
for fiirther investigation, but not offering complete answers to any questions currently 
asked. 
Using the TARP y4 and TARP 78 probes, this project has enabled a more accurate 
expansion of the existing data regarding these two TARP isoforms distributions in the 
CNS than what is in the literature, with TARP 78 in particular being demonstrated to be 
expressed at the protein level in several tissues previously ignored by the literature, such 
as the spinal cord. 
The antibodies have also led to the observation of differences in TARP 78 distribution 
with regard to Triton X-100™ solubility, implying that TARP 78 has a preference for 
non-synaptic domains. Of course, this is only an observation at this current stage, but 
offers up an area of potential future investigation. 
The generation of immunoaffinity columns using the TARP isoform-specific antibodies 
has enabled proteomic analysis of material purified using a TARP antibody to identify 
previously unknown and unsuspected interacting partners. 
Proteomic analysis of TARP 78 interacting partners within the frontal cortex has 
generated a several previously unknown interacting partners, including proteins involved 
in neuronal myelination, as well as proteins involved in the cytoarchitecture, implying 
TARP 78 is expressed in non-neuronal cells in the CNS and interacts with a host of 
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structural proteins whilst fulfilling its functional role. This is one of the areas that offers 
the most potential avenues for branched investigation, with each of the interacting 
partners providing links to other aspects of the CNS. 
Since the completion of the practical work outlined in this thesis, all of the proteins co-
purified with TARP y8 using the anti TARP y8 immunoaffinity columns and identified 
with MALDI-TOF or MALDI-TOF/TOF have since been identified by immunoblotting 
using antibodies specific to these proteins and providing some positive confirmation 
regarding these proteins respective identities. 
The combination of proteins identified by proteomic analysis as a result of the TARP y8 
immunoaffinity purification, all have a stronger relationship with oligodendrocytes in the 
CNS and not neurones, which is an unexpected occurance. It is known that developing 
oligodendrocytes express fiinctional AMPA receptors (Patneau et al. 1994, Follett et al. 
2000) that, whilst poorly defined in terms of their specific functional role, they are 
believed to be involved in Ca^ * mediated signalling and regulating development (Gallo et 
al. 1996, Gallo and Ghiani 2000, Butt 2006). The presence of AMPA receptors within 
oligodendrocytes is known to be a major contributing factor in excitotoxic death 
following ischaemia or injury (Deng et al. 2006, McCarran and Goldberg 2007). The 
presence of TARP y8 in oligodendrocytes, the first TARP knowingly identified as such, 
would not only set a precedent of TARP y8 being another protein likely involved in 
AMPA receptor mediated excititoxic shock in oligodendrocytes, but also other TARP 
isoforms as well. Indeed, the selective inhibition of Na'^/K* ATPase, one of the proteins 
identified as a TARP y8 interacfing partner, is associated directly with excitotoxic 
damage in oligodendrocytes (Chen et al. 2007). 
Furthermore, this AMPA receptor mediated excitotoxic shock may have implications in 
other neurological disorders such as Multiple Sclerosis, where glutamatergic activity 
semmingly contributes both directly to the autoimmune component of this disorder by 
intensifying demyelination of axons (Bannerman et al. 2007) or indirectly, by promoting 
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microglial secretions of other neurotoxic compounds such as tumor necrosis factor a 
(Matute 2007). 
In addition to roles in multiple sclerosis (Musse and Harauz 2007, Stem and Keskin 
2008), Myelin basic protein and CNPase both also have an implied link with 
schizophrenia (Dracheva et al. 2006, Martins-de-Souzaet al. 2008), a neurological 
condition which already has a strongly implied glutamatergic component (Hsu et al. 
2008, Wiedholz et al. 2008). 
All of this evidence, would indicate a strong relationship between those proteins 
identified by proteomic analysis and AMPA receptors, so it is not a fantastic stretch of 
logic to appreciate the presence of an interaction with TARP y8, a question to be 
answered now would be why, what is the specific significance of this interaction? 
Another interesting observation, not directly related to unknown interacting proteins and 
one that would most certainly be worth pursuing, is the possibility of strain variation of 
specific neuronal proteins within a species. An observation was made that TARP y8 
appeared to have a slightly different pattern of expression when the 
immunohistochemical data taken from the €57 background strain of mice was contrasted 
with the C3B6Fe+ strain. 
Although, this is only an observation at this point, there are documented differences 
between these strains (Ennaceur et al. 2006), including, but not limited to, anxiety and 
other behavioural traits that could be related to this altered protein expression. At an 
extreme range of relevance, taking into account that this entire thesis has been 
investigating potential interactions of TARPs/AMPA receptors with 5HT2c receptors, 
then differences between mice strains and their significance with regard to behavioural 
effects may have properties analogous to humans individual susceptibility to neurological 
disorders. Individual regions of the brain may have significantly different expression 
levels of TARP isoforms, which, depending on the region, may have effects on 
personality traits. 
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Figure 6: Images A and B show TARP yS distribution in C57/B6 mice. Images C 
and D show TARP y8 distribution in C3/B6 mice. Whilst there are similarities, 
certainly within the forebrain, there appear to be noticeable differences in the 
olfactory bulb, cerebellum and midbrain. These differences are especially apparent 
when the relative intensity of the hippocampahforebrain labelling in the C57/B6 
mice is compared to that in the C3/B6. Scale bars = 5mm. 
Regions such as the basal ganglia, which display differences between these two strains of 
mice (Figure 6), can have dramatic effects on personality i f impaired (Saint-Cyr et al. 
1995), so it is possible that subtle changes, but not impairment, would produce subtle 
differences in personality traits or the processing of emotional stimuli (Engels et al. 
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2007), which may have implications for treatment of disorders using compounds that 
effect TARPs/AMPA receptors. It would certainly support the usage of AMPAkines in 
treating disorders i f there was a link between differential TARP expression and the 
development of negative personality traits/mood disorders. Indeed, cognitive enhancers, 
although not specifically AMPAkines, have been shown to have anti-anxiety effects even 
though, at the current time, the precise reasons for their effectiveness is not known 
(Dusseldorp et al. 2007), it would, speculatively be possible, that in the areas affected 
abnormal TARP expression was detectable. 
As with all initial forays into avenues of science where the previous data is limited, the 
project has generated more potential areas of interest and more questions than answers, 
exposing a rich vein of complexities concerning the TARPs and their interactions in the 
CNS, including those with the 5HT2c receptor. It has, however, established a basic 
identification of a physical interaction between 5HT2c receptors and TARPs/AMPA 
receptors, in addition to identifying the basis of a fimctional interaction - the underlying 
aims behind the reasoning of this thesis. However, the fi i l l contribution can only be 
measured when the tools developed in this project are taken into account and used to 
expand upon the the initial data generated by this project. In short, the understanding 
provided by this project into this particular field is dwarfed by the potential this project 
provides for further, directed, investigation. 
Work that could continue from the flndings of this project: 
• Investigations into Triton X-lOO^*^ insoluble (Synaptic) Material - Al l 
experiments so far have examined Triton X-lOO^"^ soluble, predominantly non-
synaptic material. As such differences in tissue solubilisation and methods of 
purifying synaptic proteins could be used to investigate TARP 78 interacting 
proteins within the synapse. 
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Investigations into the nature of the interaction between 5HT2c receptors and 
TARPs/AMPA receptors: 
• Surface biotinylation assays - Using material prior to solubilisation and 
subsequent immunopurification to determine the location of some of the TARP y8 
interactions, potentially providing information regarding the nature and function 
of some of these interactions. With specific reference to 5HT2c receptor 
interactions it would help enable the determination as to where the interaction 
occurs, i.e. at the cell surface or in within some intracellular domain. 
• Hippocampal/cortical co-cultures or pure cultures - Could determine the 
effects on AMPA receptor and TARP expression, both protein levels and 
phosphorylation states, following application of compounds acting upon the 
5HT2C receptor. Of course compounds, such as AMPA receptor modulators, 
tianeptine, etc could be investigated. By creating a system to test numerous 
compounds in vitro, cultures would provide a wealth of data on protein 
interactions and the effects of various compounds. 
• Investigations into spUce variants of 5HT2c receptors and their effects on 
TARP/AMPA receptor expression and 5HT2c receptor interaction - Using 
the abnormal 5HT2c receptor expression mice supplied by Megan Holmes has 
provided evidence of a functional interaction between TARPs/AMPA receptors 
and 5HT2C receptors, but no actual information regarding whether individual 
splice variants have specific effects. Several possible experiments would require 
generation of the antibodies specific to the splice variants of the 5HT2c receptor 
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which, whilst problematic because of the pre-existing difficulties with generating 
highly specific antibodies to the 5HT2c receptor, has been achieved with some 
success by at least one research group. The most simple of which would be using 
splice variant specific antibodies on the protein purified using the TARP y8 
immunoaffinity column. There would also be the possibility of conducting 
immunopurifications using these splice variant antibodies and determining which 
purify TARPs/AMPA receptor subunits. 
Work that could expand upon this project: 
• TARP distribution differences between different strains of mice - As an 
observation, this finding deserves at least some investigation and i f demonstrable 
could be combined with behavioural studies to identify correlations between 
TARP isoform distribution and behavioural characteristics, with relation 
specifically to TARP y8, but also potentially TARP y4. 
• Investigation into the Triton X-lOO^*^ interacting proteins of TARPs in 
different regions of the CNS using proteomics - Initially TARP y8, but also 
potentially TARP y4 s. Lab has already conducted studies into TARP y8 
interacting proteins in the cerebral cortex and cerebellum, with some data being 
generated. 
• Immunopurification of T A R F Y4 - Identification of interacting proteins similar 
to that conducted for TARP y8 with specific attention to whether the 5HT2c 
receptor-like protein is present in material purified using the TARP y4 
immunoaffinity column. 
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• Hippocampal/cortical co-cultures or pure cultures - The experiments using 
culture systems to investigate the signalling pathways and the nature of the 
functional interaction between 5HT2c receptors and TARPs/AMPA receptors 
could also be applied to other proteins, such as G A B A A receptor modulators and 
their interactions with 5HT2c/TARPs/AMPA receptors. 
• Co-localisation of 5HT2c receptors, TARPs, AMPA receptor subunits and 
PSD-95 - The transfection of the key players in the original hypothesis into 
recombinant cells. Complications even i f TARP y8 is the only TARP transfected, 
include the choice of vector, the diversity of AMPA receptor subunits and their 
flip or flop configurations, and the possibility that the interacting protein is not 
Oust) PSD-95. 
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Appendix A: Laboratory Solutions 
2.4.1 
PBS: 0.14M NaCl, 0.0027M KCl, O.OIM Na2HP04, 0.0018M KH2PO4 - made up in 
dH20 
2.4.2 
Glycine elution buffer (for antibody purification): lOOmM Glycine, pH 2.5 (achieved 
using H2SO4) - made up in dH20 
IM Tris: Literally I M Tris in dH20 
2.6.1 
2X SDS-PAGE sample buffer: Made by diluting 3X SDS-PAGE sample buffer (30mM 
NaH2P04, 30% (v/v) glycerol, 0.05% (w/v) Bromophenol blue, 7.5% (w/v) sodium 
dodecyl sulphate, made up in dH20) with 200mM Dithiothreitol (DTT) and dH20 in a 
10:3:2 ratio. 
2.6.2 
SDS-PAGE resolving gels: 49.4% (v/v) dH20, 25.3% (v/v) Acrylogel-3 solution (from 
VWR -30% acrylamide), 25.25% (v/v) running gel buffer (1.5M Tris, 8mM EDTA, 0.4% 
(w/v) SDS, pH 8.8 using H2SO4, made up in dH20), to which 0.06% (w/v) ammonium 
persulphate was added prior to degassing in a vacuum dessicater for 30 minutes. 
Following degassing, 24jj,l of TEMED was added before the mixture was allowed to set, 
with each gel being kept hydrated by an upper layer of H20-saturated iso-butanol added 
once the mixture was in the gel stacker. 
SDS-PAGE stacking gels: 76.1% (v/v) dHzO, 9% (v/v) Acrylogel-3 (final concentration 
is 3.5%), 12.5% I M Tris-HCl (pH 6.8), 1% (w/v) SDS (fi-om 10% (w/v) SDS stock), 1% 
ammonium persulphate. Mixture was degassed for 10 minutes, then lOul of TEMED was 
added before the mixture was poured and allowed to set. 
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Electrode buffer: O.OIM Tris, 0.8M Glycine, 0.0046M EDTA, 0.2% (w/v) SDS, pH 8.8 
using NaOH, made up in dH20. Buffer was diluted 1:1 with dH20 prior to use. 
Transfer buffer: 0.025M Tris, 0.4M Glycine, 20% (v/v) Methanol, final volume made 
up with dH20. Buffer was diluted 1:1 with dH20 prior to use. 
2.6.3 
Blocking buffer for immunblotting: 5% (w/v) skimmed, dried milk, 0.2% Tween-20, 
made up in PBS. 
Incubation buffer: 2.5% (w/v) skimmed, dried milk in PBS. 
Wash buffer for immunoblotting: 2.5% (w/v) skimmed, dried milk, 0.2% Tween-20, 
made up in PBS. 
Luminol: 1.25mM Luminol, O.IM Tris-HCl pH 8.5, made up in dH20. 
2.7.1 
Paraformaldhyde Fixative: Made by combining Dibasic sodium phosphate buffer 
(0.2M Na2HP04 in dH20) with monobasic sodium phosphate buffer (0.2M NaH2P04 in 
dH20) in a 1:4 ratio. Heated up to, but not exceeding 60°C before 4% paraformaldehyde 
was added along with 4-10 drops o f I M NaOH until the paraformaldehyde had dissolved 
into solution. Fixative was stored at 4°C. 
2.7.2 
Sucrose infiltration of fixed tissue: Essentially PBS with either 10%, 20%, or 30% 
(w/v) sucrose. Increments increased on subsequent days, all conducted at 4°C. 
2.7.3 
T B S : 50mM Tris, 0.9% (w/v) NaCl, pH 7.2. Made up in dH20. 
2.8.1 
Sigels buffer: lOOmM NaCl, 2mM MgCb, I m M EGTA, lOmM HEPES, pH 7.5. Made 
up in dH20. 
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Glycine elution buffer for immunopurification of T A R P interacting compounds: 
50mM glycine, 10% (w/v) sucrose, 500mM K C l , 0.2% (v/v) Triton X-100™. Made up in 
dH20. 
2.9.1 
Loading Buffer for Proteomics ( P R O M E G A recipe): lOmM Tris, 50mM EDTA, 
0.25% (w/v) bromophenol blue, 30% (v/v) glycerol, pH 7.5. Made up in ultra-pure dH20. 
NuPAGE buffer: This was bought commercially, but subjected to a 1 in 20 dilution with ultra-pure 
dHzO. 
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Appendix B: Proteomic Data from MALDI-TOF Analysis 
12 plus-one silver stained ID bands, from mouse brain 
Spot 
ID 
Sample 
ID 
Best Match M O W S E 
Score 
E06 1 ATP synthase, H+ transporting, mitochondrial F l 
complex, alpha subunit, isoform 1, isoform CRA e 
[Mus musculus] 
240 
E07 2 
E08 3 tubulin, beta 5 [Mus musculus] 89* 
E09 4 
ElO 5 2',3'-cyclic-nucleotide 3'-phosphodiesterase I [Mus 
musculus] 
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E l l 6 gamma-actin [Mus musculus] 89 
E12 7 put. beta-actin (aa 27-375) [Mus musculus] 98 
FOl 8 purine rich element binding protein B [Mus musculus] 151 
F02 9 
F03 10 myelin basic protein isoform 4 [Mus musculus] 147 
F04 11 
F05 12 Chain A, Crystal Structure O f Apoenzyme Camp-
Dependent Protein Kinase Catalytic Subunit [Mus 
musculus] 
85* 
N B . Scores less than 80 are not significant 
Spots not in the above table gave no good database hits 
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CNPase proteomic analysis data. 
g i I 2160434 Mass: 45025 Score: 194 Expect: 2.3e-13 Queries matched: 23 
2 ' , 3 ' - c y c l i c - n u c l e o t i d e 3 ' - p h o s p h o d i e s t e r a s e I [Mus musculus] 
g i I 14 193678 Mass: 45025 Score: 194 Expect: 2.3e-13 Queries matched: 23 
c y c l i c n u c l e o t i d e p h o p h o d i e s t e r a s e 1 [Mus musculus] 
g i I 14 8670605 Mass: 48562 Score: 190 Expect: 5.9e-13 Queries matched: 23 
c y c l i c n u c l e o t i d e p h o s p h o d i e s t e r a s e 1, i s o f o r m CRA_a [Mus musculus] 
g i 12634 1378 Mass: 47267 Score: 185 Expect: 1.9e-12 Queries matched: 23 
unnamed p r o t e i n p r o d u c t [Mus musculus] 
g i I 51338761 Mass: 47 493 Score: 185 Expect: 1.9e-12 Queries matched: 23 
2 ' , 3 ' - c y c l i c - n u c l e o t i d e 3 ' - p h o s p h o d i e s t e r a s e (CNP) (CNPase) 
g i I 6753476 Mass: 47493 Score: 185 Expect: 1.9e-12 Queries matched: 23 
2 ' , 3 ' - c y c l i c n u c l e o t i d e 3' p h o s p h o d i e s t e r a s e [Mus musculus] 
g i I 14 9054231 Mass: 45227 Score: 121 Expect: 4.7e-06 Q u e r i e s matched: 17 
c y c l i c n u c l e o t i d e p h o s p h o d i e s t e r a s e 1, i s o f o r m CRA_b [ R a t t u s n o r v e g i c u s ] 
g i I 57 977323 Mass: 47638 Score: 115 Expect: 1.9e-05 Queries matched: 17 
c y c l i c n u c l e o t i d e p h o s p h o d i e s t e r a s e 1 [ R a t t u s n o r v e g i c u s ] 
g i I 159164 662 Mass: 24 374 Score: 62 Expect: 3.5 Queries matched: 9 
Chain A, S o l u t i o n S t r u c t u r e Of C a t a l y t i c Domain Of Rat 2 ' , 3 ' - C y c l i c -
N u c l e o t i d e 3'-Phosphodiesterase (Cnp) P r o t e i n 
g i I 33303781 Mass: 4 8061 Score: 61 Expect: 4.6 Queries matched: 12 
2 ' , 3 ' - c y c l i c n u c l e o t i d e 3' p h o s p h o d i e s t e r a s e [ s y n t h e t i c c o n s t r u c t ] 
g i I 180687 Mass: 4 54 69 Score: 5 6 Expect: 14 Queries matched: 11 
2 ' , 3 ' - c y c l i c - n u c l e o t i d e 3 ' - p h o s p h o d i e s t e r a s e (EC 3.1.4.37) 
gj- [94721261 Mass: 4 7 948 Score: 52 Expect: 38 Q u e r i e s matched: 11 
2', 3 ' - c y c l i c n u c l e o t i d e 3' p h o s p h o d i e s t e r a s e [.Homo s a p i e n s ] 
g i I 114 667114 Mass: 59510 Score: 47 Expect: 1.3e+02 Queries matched: 11 
PREDICTED: 2 ' , 3 ' - c y c l i c n u c l e o t i d e 3' p h o s p h o d i e s t e r a s e [Pan t r o g l o d y t e s ] 
g i I 85014 175 Mass: 9607 5 Score: 61 Expect: 4.6 Queries matched: 16 
t e l o m e r a s e r e v e r s e t r a n s c r i p t a s e [ E n c e p h a l i t o z o o n c u n i c u l i GB-Ml] 
g i I 164658011 Mass: 10056 Score: 60 Expect: 6.4 Queries matched: 7 
h y p o t h e t i c a l p r o t e i n MGL_2513 [ M a l a s s e z i a globosa CBS 7966] 
g i I 399268 Mass: 4 5360 Score: 58 Expect: 9.3 Queries matched: 11 
2 ' , 3 ' - c y c l i c - n u c l e o t i d e 3 ' - p h o s p h o d i e s t e r a s e (CNP) (CNPase) 
g i I 30794282 Mass: 4 5332 Score: 58 Expect: 9.3 Queries matched: 11 
2 ' , 3 ' - c y c l i c n u c l e o t i d e 3' p h o s p h o d i e s t e r a s e [Bos t a u r u s ] 
g i I 75042630 Mass: 4 7 949 Score: 53 Expect: 32 Queries matched: 11 
2 ' , 3 ' - c y c l i c - n u c l e o t i d e 3 ' - p h o s p h o d i e s t e r a s e (CNP) (CNPase) 
g i I 1802684 1 Mass: 11961 Score: 52 Expect: 39 Q u e r i e s matched: 
P12 [ R i c e t u n g r o b a c i l l i f o r m v i r u s ] 
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g i I 34 687463 Mass: 15348 Score: 51 Expect: 4 8 Queries matched: 6 
h y p o t h e t i c a l p r o t e i n RB2654_17936 [ R h o d o b a c t e r a l e s b a c t e r i u m HTCC2654] 
gi [ 3 8 0 8 5 1 8 9 Mass: 103631 Score: 50 Expect: 
PREDICTED: h y p o t h e t i c a l p r o t e i n [Mus musculus] 
g i I 14 8710101 Mass: 55561 Score: 47 Expect 
mCG148476 [Mus musculus] 
54 Queries matched: 17 
1.2e+02 Queries matched: 12 
Search Parameters 
Type of s e a r c h 
Enzyme 
F i x e d m o d i f i c a t i o n s 
V a r i a b l e m o d i f i c a t i o n s 
Mass v a l u e s 
P r o t e i n Mass 
Peptide Mass T o l e r a n c e 
Peptide Charge S t a t e 
Max Missed Cleavages 
Nvuaber of q[ueries 
Peptide Mass F i n g e r p r i n t 
T r y p s i n 
Carbami dome thy1 (C) 
Oxi d a t i o n (M) 
Monoisotopic 
Unres t r i c t e d 
± 50 ppm 
1+ 
1 
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Gamma actin proteomic analysis data 
31. 151176139 Mass: 42053 Score: 100 
b e t a - a c t i n [Anas p l a t y r h y n c h o s ] 
g i I 15277503 Mass: 40536 
ACTB p r o t e i n [Homo s a p i e n s ] 
g i I 1703127 Mass: 42163 
A c t i n , c y t o p l a s m i c t y p e 8 
g i ! 73964 667 Mass: 42053 
Score: 92 
Score: 92 
Score: 91 
PREDICTED: h y p o t h e t i c a l p r o t e i n XP_533132 [Canis f a m i l i a r i s ] 
g i I 1703123 Mass: 42165 Score: 90 
A c t i n , c y t o p l a s m i c t y p e 5 
g i I 56119084 Mass: 42151 Score: 90 
a c t i n , gamma 1 p r o p e p t i d e [ C a l l u s g a l l u s 
g i I 113271 Mass: 42163 Score: 90 
A c t i n , c y t o p l a s m i c 1 (Beta a c t i n ) 
g i I 148222128 Mass: 42119 Score: 90 
h y p o t h e t i c a l p r o t e i n LOC734918 [Xenopus l a e v i s ] 
g i i126272476 Mass: 42169 Score: 90 Expect: 0.0057 
PREDICTED: h y p o t h e t i c a l p r o t e i n [Monodelphis d o m e s t i c a ] 
Expect: 0.00063 Queries matched: 16 
Expect: 0.0036 Queries matched: 15 
Expect: 0.0038 Queries matched: 15 
Expect: 0.0051 Queries matched: 15 
Expect: 0.0057 Queries matched: 15 
Expect: 0.0057 Queries matched: 15 
Expect: 0.0057 Queries matched: 15 
Expect: 0.0057 Queries matched: 15 
Queries matched: 
g i I 126338084 Mass: 42311 Score: 90 
PREDICTED: s i m i l a r t o b e t a a c t i n i s o f o r m 
g i I 1184 19977 Mass: 4 08 94 Score: 90 
b e t a - a c t i n [Eubalaena g l a c i a l i s ] 
g i I 809561 Mass: 4 1335 Score: 89 
gamma-actin [Mus musculus] 
g i I 157881403 Mass: 41921 Score: 89 
Expect: 0.0057 Queries matched: 
2 [Monodelphis d o m e s t i c a ] 
Expect: 0.0066 Queries matched: 
Expect: 0.0067 
Expect: 
Queries matched: 15 
0.0069 Queries matched: 
15 
15 
15 
15 
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Chain A, The S t r u c t u r e Of C r y s t a l l i n e P r o f i l i n - B e t a - A c t i n 
q i I 157878210 Mass: 4 1895 Score: 89 Expect: 0.0069 Queries matched: 15 
Chain A, S t r u c t u r e Of Bovine B e t a - A c t i n - P r o f i l i n Complex W i t h A c t i n Bound 
Atp Phosphates S o l v e n t A c c e s s i b l e 
gi!37698410 Mass: 41745 Score: 89 
b e t a - a c t i n [Passer d o m e s t i c u s ] 
a i l 18034011 Mass: 42069 Score: 89 
Expect: 0.007 4 Queries matched: 15 
Expect: 
Expect: 
b e t a - a c t i n [ M o r u l i u s c a l b a s u ] 
g i I 16924319 Mass: 40819 Score: 89 
Unknown ( p r o t e i n f o r I^4AGE: 3538275) [Homo s a p i e n s ] 
g i I 47550655 Mass: 417 92 Score: 88 Expect: 
b e t a - a c t i n [ S e r i o l a q u i n q u e r a d i a t a ] 
g i I 1703118 Mass: 42041 Score: 88 Expect: 
A c t i n , c y t o p l a s m i c 3 ( B e t a - a c t i n C) 
g i I 148231177 Mass: 42082 Score: 88 Expect 
h y p o t h e t i c a l p r o t e i n LOC398459 [Xenopus l a e v i s ] 
0.007 4 Queries matched: 15 
0.0081 Queries matched: 15 
0.008 3 Queries matched: 15 
0.00 93 Queries matched: 15 
0.0093 Queries matched: 15 
g i I ^ 2560193 Mass: 42068 Score: 88 
A c t i n , c y t o p l a s m i c 1 ( B e t a - a c t i n ) 
g i I 4501885 Mass: 42052 Score: 88 
b e t a a c t i n [Homo s a p i e n s ] 
g i I 1351867 Mass: 42053 Score: 88 
A c t i n , c y t o p l a s m i c 1 ( B e t a - a c t i n ) 
g i I 82213656 Mass: 42066 Score: 88 
A c t i n , c y t o p l a s m i c 2 (Gamma-actin) 
g i I 4 501887 Mass: 42108 Score: 88 
a c t i n , gamma 1 p r o p e p t i d e [Homo s a p i e n s ] 
g i I 474 98068 Mass: 42068 Score: 88 
a c t i n , b e t a [Xenopus t r o p i c a l i s ] 
Expect: 0.0093 Queries matched: 15 
Expect: 0.0093 Queries matched: 15 
Expect: 0.0093 
Expect: 0.0093 
Expect: 0.00 93 Queries matched: 15 
Expect: 0.0093 Queries matched: 15 
Queries matched: 15 
Queries matched: 15 
g i I 3182899 Mass: 4 20 98 Score: 100 Expect: 0 
A c t i n , c y t o p l a s m i c 1 ( B e t a - a c t i n ) 
g i i 674 62093 Mass: 42082 Score: 100 Expect: 
A c t i n , c y t o p l a s m i c 1 ( B e t a - a c t i n A) 
g i I 904 9272 Mass: 42094 Score: 100 Expect: 0 
bet a a c t i n [ C a r a s s i u s a u r a t u s ] 
g i I 62298523 Mass: 42082 Score: 100 Expect: 
A c t i n , c y t o p l a s m i c 1 ( B e t a - a c t i n - 1 ) 
g i I 45361511 Mass: 42080 Score: 100 Expect: 
a c t i n , gamma 1 [Xenopus t r o p i c a l i s ] 
g i I 334 1584 6 Mass: 42096 Score: 100 Expect: 
c y t o p l a s m i c a c t i n t y p e 4 [Rana l e s s o n a e ] 
g i I 47218950 Mass: 4 28 90 Score: 94 Expect: 
unnamed p r o t e i n p r o d u c t [ T e t r a o d o n n i g r o v i r i d i s ] 
g i I 27805142 Mass: 4 2050 Score: 92 Expect: 
b e t a a c t i n [ D i c e n t r a r c h u s l a b r a x ] 
g i I 10971624 1 Mass: 4 2111 Score: 91 Expect: 
b e t a - a c t i n [ S p i n i b a r b u s d e n t i c u l a t u s ] 
g i I 28279111 Mass: 42068 Score: 90 Expect: 
B a c t i n l p r o t e i n [Danio r e r i o ] 
g i i 33318285 Mass: 4 20 98 Score: 90 Expect: 
.00063 Queries matched: 16 
0.00063 Queries matched: 16 
.00063 Queries matched: 16 
0.00063 Queries matched: 16 
0.00063 Queries matched: 16 
0.00063 Queries matched: 16 
0.002 4 Queries matched: 15 
0.0034 Queries matched: 15 
0.004 7 Queries matched: 15 
0.0052 Queries matched: 15 
0.0054 Queries matched: 15 
20! 
b e r a - a c t i n [ T i g r i o p u s j a p o n i c u s ] 
g i I 13858335 Mass: 4 2068 Score: 90 
b a c t i n l [Danio r e r i o ] 
g i I 1184 19973 Mass: 40948 Score: 99 
Expect: 0.00 64 Queries matched: 15 
Expect: 0.00074 Queries matched: 16 
b e t a - a c t i n [Lagenorhynchus a c u t u s ] 
g i I 14250401 Mass: 41321 Score: 99 
a c t i n , b e t a [Homo s a p i e n s ] 
g i I 66731680 Mass: 4 04 95 Score: 91 
b e t a - a c t i n [ P u n g i t i u s p u n g i t i u s ] 
Expect: 0.00077 Queries matched: 16 
Expect: 0.004 5 Queries matched: 15 
g i i 33318289 Mass: 42041 Score: 99 
b e t a - a c t i n [ T i g r i o p u s j a p o n i c u s ] 
g i I 164 472819 Mass: 42139 Score: 89 
a c t i n [ I x o d e s p e r s u l c a t u s ] 
Expect: 0.00081 Queries matched: 16 
Expect: 0.007 4 Q u e r i e s matched: 15 
g i I 4 9868 Mass: 39446 Score: 92 Expect: 0.004 Queries matched: 15 
p u t . b e t a - a c t i n (aa 27-375) [Mus musculus] 
g i I 74204 169 Mass: 42039 Score: 91 
unnamed p r o t e i n p r o d u c t [Mus musculus] 
g i I 156759 
a c t i n 
Mass: 42181 Score: 90 
g i I 4 7116231 Mass: 42034 Score: 90 
A c t i n , c y t o p l a s m i c 1 ( B e t a - a c t i n ) 
Expect: 0.004 4 Queries matched: 15 
Expect: 0.0056 Queries matched: 15 
Expect: 0.0066 Queries matched: 15 
gi128336 Mass: 42128 Score: 89 Expect: 0.0077 Queries matched: 16 
mutant b e t a - a c t i n ( b e t a ' - a c t i n ) [Homo s a p i e n s ] 
Search Parameters 
Type of s e a r c h 
Enzyme 
F i x e d m o d i f i c a t i o n s 
V a r i a b l e m o d i f i c a t i o n s 
Mass v a l u e s 
P r o t e i n Mass 
Peptide Mass Toleraince 
Peptide Charge S t a t e 
Max Missed Cleavages 
Number of q u e r i e s 
Peptide Mass F i n g e r p r i n t 
T r y p s i n 
Carbamidomethyl (C) 
Oxida t i o n (M) 
Monoisotopic 
U n r e s t r i c t e d 
± 50 ppm 
1+ 
1 
118 
Purine rich element binding protein proteomic data 
g i I 6755252 Mass: 33995 Score: 151 Expect: 4.7e-09 Queries matched: 11 
202 
p u r i n e r i c h element b i n d i n g p r o t e i n B [Mus musculus] 
g i I 62945366 Mass: 33512 Score: 124 Expect: 2.3e-06 Queries matched: 16 
h y p o t h e t i c a l p r o t e i n LOC498407 [ R a t t u s n o r v e g i c u s ] 
gi1149047690 Mass: 33636 Score: 124 Expect: 2.3e-06 Queries matched: 16 
t r a n s c r i p t i o n f a c t o r Pur-beta [ R a t t u s n o r v e g i c u s ] 
g i i15147219 Mass: 33392 Score: 105 Expect: 0.00019 Queries matched: 15 
p u r i n e - r i c h element b i n d i n g p r o t e i n B [Homo s a p i e n s ] 
g i i126302985 Mass: 34121 Score: 103 Expect: 0.00029 Queries matched: 15 
PREDICTED: h y p o t h e t i c a l p r o t e i n [Monodelphis d o m e s t i c a ] 
g i I 74009720 Mass: 36909 Score: 102 Expect: 0.00037 Queries matched: 15 
PREDICTED: s i m i l a r t o p u r i n e r i c h element b i n d i n g p r o t e i n B [Canis f a m i l i a r i s ] 
g i I 147899952 Mass: 35022 Score: 67 Expect: 1.1 Queries matched: 12 
p u r i n e - r i c h element b i n d i n g p r o t e i n B [Xenopus l a e v i s ] 
g i I 82186781 Mass: 34 7 02 Score: 58 Expect: 8.5 Queries matched: 11 
T r a n s c r i p t i o n a l a c t i v a t o r p r o t e i n Pur-beta-A ( P u r i n e - r i c h e l e m e n t - b i n d i n g 
p r o t e i n B-A) 
g i I 108744015 Mass: 32779 Score: 50 Expect: 57 Queries matched: 10 
p u r i n e - r i c h element b i n d i n g p r o t e i n - b e t a [ A s t a t o t i l a p i a b u r t o n i ] 
g i I 74228215 Mass: 11281 Score: 46 Expect: 1.4e + 02 Queries matched: 6 
unnamed p r o t e i n p r o d u c t [Mus musculus] 
g i I 26340180 Mass: 11224 Score: 46 
unnamed p r o t e i n p r o d u c t [Mus musculus] 
Expect: 1.4e+02 Queries matched: 
a i I 45768686 Mass: 32455 Score: 63 Expect: 3 Queries matched: 12 
Purb p r o t e i n [Danio r e r i o ] 
g i I 4 1054521 Mass: 32586 Score: 62 
p u r i n e - r i c h element b i n d i n g p r o t e i n B [Danio r e r i o ] 
g i I 47221521 Mass: 31312 Score: 54 Expect: 23 
unnamed p r o t e i n p r o d u c t [ T e t r a o d o n n i g r o v i r i d i s ] 
Expect: 4 Queries matched: 12 
Queries matched: 11 
gi[108760572 Mass: 20846 Score: 61 
h y p o t h e t i c a l p r o t e i n MXAN_3968 [Myxococcus xanthus DK 1622] 
Expect: 4.6 Queries matched: 9 
g i I 148692166 Mass: 29682 Score: 61 Expect: 4.6 Queries matched: 9 
s i r t u i n 2 ( s i l e n t m a t i n g t y p e i n f o r m a t i o n r e g u l a t i o n 2, homolog) 2 (S. 
c e r e v i s i a e ) , i s o f o r m CRA_b [Mus musculus] 
g i I 68359605 Mass: 33852 Score: 5 9 Expect: 7.9 Queries matched: 12 
PREDICTED: s i m i l a r t o P u r i n e - r i c h element b i n d i n g p r o t e i n B i s o f o r m 1 [Danio r e r i o ] 
a i I 47228540 Mass: 28639 Score: 5 6 Expect: 13 Queries matched: 10 
unnamed p r o t e i n p r o d u c t [ T e t r a o d o n n i g r o v i r i d i s ] 
g i i 74 138663 Mass: 40008 Score: 55 
unnamed p r o t e i n p r o d u c t [Mus musculus] 
g i I 12851673 Mass: 40155 Score: 55 
unnamed p r o t e i n p r o d u c t [Mus musculus] 
g i 138258618 Mass: 43856 Score: 54 
Expect: 19 Queries matched: 10 
Expect: 2 0 Queries matched: 10 
Expect: 2 3 Q u e r i e s matched: 10 
NAD-dependent d e a c e t y l a s e s i r t u i n - 2 ( S I R 2 - l i k e p r o t e i n 2) (mSIR2L2) 
g i I 31982681 Mass: 43866 Score: 54 Expect: 2 3 Queries matched: 10 
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s i r t u i n 2 ( s i l e n t m a t i n g t y p e i n f o r m a t i o n r e g u l a t i o n 2, homolog) 2 [Mus musculus] 
g i I 1114 1704 Mass: 4 3872 Score: 53 Expect: 31 Queries matched: 10 
SIR2L2 [Mus musculus] 
g i I 148692167 Mass: 4 6857 Score: 52 Expect: 34 Queries matched: 10 
s i r t u i n 2 ( s i l e n t m a t i n g t y p e i n f o r m a t i o n r e g u l a t i o n 2, homolog) 2 (S. c e r e v i s i a e ) , 
i s o f o r m CRA_c [Mus musculus] 
g i i 56605812 Mass: 39921 Score: 46 Expect: 1.6e + 02 Queries matched: 9 
s i r t u i n ( s i l e n t m a t i n g t y p e i n f o r m a t i o n r e g u l a t i o n 2 homolog) 2 [ R a t t u s n o r v e g i c u s ] 
g i [ 1 4 9056443 Mass: 43763 Score: 45 Expect: 2e + 02 Queries matched: 9 
s i r t u i n ( s i l e n t m a t i n g t y p e i n f o r m a t i o n r e g u l a t i o n 2 homolog) 2 (S. c e r e v i s i a e ) , 
i s o f o r m CRA_a [ R a t t u s n o r v e g i c u s ] 
g i I 780454 61 Mass: 8 0777 Score: 54 Expect: 25 Queries matched: 15 
DNA t o p o i s o m e r a s e TraE [Xanthomonas c a m p e s t r i s pv. v e s i c a t o r i a s t r . 85-10] 
g i i 90086129 Mass: 32300 Score: 53 Expect: 29 Queries matched: 10 
unnamed p r o t e i n p r o d u c t [Macaca f a s c i c u l a r i s ] 
g i I 76818322 Mass: 17 4 04 Score: 53 Expect: 30 Queries matched: 7 
h y d r o l a s e , NUDIX f a m i l y [Bur)«holderia p s e u d o m a l l e i 1710b] 
Search Parameters 
Type o f s e a r c h 
Enzyme 
F i x e d m o d i f i c a t i o n s 
V a r i a b l e m o d i f i c a t i o n s 
Mass v a l u e s 
P r o t e i n Mass 
Peptide Mass Tol e r a n c e 
Peptide Charge S t a t e 
Max Missed Cleavages 
Number of q^ueries 
Peptide Mass F i n g e r p r i n t 
T r y p s i n 
Carbamidomethyl (C) 
Ox i d a t i o n (M) 
Monoisotopic 
U n r e s t r i c t e d 
± 50 ppm 
1 + 
1 
85 
Myelin basic protein proteomic data 
q i 1 6 9 8 8 5 0 5 6 Mass: 17272 Score: 147 Expect: 1.2e-08 
m y e l i n b a s i c p r o t e i n i s o f o r m 4 [Mus musculus] 
g i I 14 3 6774 35 Mass: 314 68 Score: 113 Expect: 2.9e-05 
Queries matched: 15 
Queries matched: 15 
m y e l i n b a s i c p r o t e i n , i s o f o r m CRA_a [Mus musculus] 
g i I 69835073 Mass: 14202 Score: 139 Expect: 7.4e-08 Queries matched: 1^. 
m y e l i n b a s i c p r o t e i n i s o f o r m 6 [Mus musculus] 
g i \ 4454313 Mass: 17254 Score: 132 Expect: 3.7e-07 Queries matched: 13 
m y e l i n b a s i c p r o t e i n [ R a t t u s n o r v e g i c u s ] 
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g i I 114 1 9 9 0 8 3 Mass: 1 3 8 6 3 Score: 130 
m y e l i n b a s i c p r o t e i n [Mus musculus] 
g i I 7 0 1 6 6 2 6 2 Mass: 1 7 2 7 2 Score: 130 Expect 
m y e l i n b a s i c p r o t e i n i s o f o r m 3 [ R a t t u s n o r v e g i c u s ] 
g i I 4 4 5 4 3 1 1 Mass: 14184 Score: 124 Expect: 
m y e l i n b a s i c p r o t e i n [ R a t t u s n o r v e g i c u s ] 
q i I 8 3 9 3 7 5 9 Mass: 1 4 2 0 2 
m y e l i n b a s i c p r o t e i n i s o f o r m 
g i I 6 9 8 8 5 0 4 0 Mass: 2 0 2 9 9 
m y e l i n b a s i c p r o t e i n i s o f o r m 
q i I 6 9 8 8 5 0 3 2 Mass: 2 1 5 4 6 
m y e l i n b a s i c p r o t e i n i s o f o r m 
g i I 6 9 8 8 5 0 6 5 Mass: 1 7 2 3 0 
m y e l i n b a s i c p r o t e i n i s o f o r m 
q i I 6 9 8 8 5 0 4 9 Mass: 184 7 6 
m y e l i n b a s i c p r o t e i n i s o f o r m 
q i I 1 9 9 0 5 1 Mass: 16216 
m y e l i n b a s i c p r o t e i n 
q i I 1 4 9 0 1 5 9 0 0 Mass: 3 1 6 1 2 
Expect: 5 . 9 e - 0 7 Queries matched: 13 
5 . 9 e - 0 7 Queries matched: 13 
2 . 3 e - 0 6 Queries matched: 12 
Score: 121 Expect: 4.7e-06 Queries matched: 12 
5 [ R a t t u s n o r v e g i c u s ] 
Score: 113 Expect: 2.9e-05 Q u e r i e s matched: 13 
2 [Mus musculus] 
Score: 111 Expect: 4.7e-05 Queries matched: 13 
1 [Mus musculus] 
Score: 108 Expect: 9.3e-05 Queries matched: 12 
5 [Mus musculus] 
Score: 106 Expect: 0.00015 Q u e r i e s matched: 12 
3 [Mus musculus] 
Score: 100 Expect: 0.00059 Queries matched: 11 
Queries matched: 13 Score: 98 Expect: 0.00095 
m y e l i n b a s i c p r o t e i n , i s o f o r m CRA_b [ R a t t u s n o r v e g i c u s ] 
g i I 4454317 Mass: 21528 Score: 97 Expect: 0.0013 Queries matched: 11 
m y e l i n b a s i c p r o t e i n [ R a t t u s n o r v e g i c u s ] 
g i I 70166245 Mass: 21546 Score: 95 Expect: 0.0019 Queries matched: 11 
m y e l i n b a s i c p r o t e i n i s o f o r m 1 [ R a t t u s n o r v e g i c u s ] 
q i I 6754658 Mass: 27151 Score: 94 Expect: 0.0021 Queries matched: 12 
G o l l i - m b p i s o f o r m 1 [Mus musculus] 
g i I 70166270 Mass: 17230 Score: 92 Expect: 0.0039 Queries matched: 10 
m y e l i n b a s i c p r o t e i n i s o f o r m 4 [ R a t t u s n o r v e g i c u s ] 
g i I 4454315 Mass: 184 58 Score: 91 Expect: 0.004 3 Queries matched: 10 
m y e l i n b a s i c p r o t e i n [ R a t t u s n o r v e g i c u s ] 
g i i 70166255 Mass: 184 7 6 Score: 90 Expect: 0.0066 Queries matched: 10 
m y e l i n b a s i c p r o t e i n i s o f o r m 2 [ R a t t u s n o r v e g i c u s ] 
g i I 148677439 Mass: 34 4 95 Score: 88 Expect: 0.01 Queries matched: 13 
m y e l i n b a s i c p r o t e i n , i s o f o r m CRA_e [Mus musculus] 
q i I 158260809 Mass: 20320 Score: 86 Expect: 0.014 Queries matched: 10 
unnamed p r o t e i n p r o d u c t [Homo s a p i e n s ] 
g i I 14 9015901 Mass: 27 2 95 Score: 8 0 Expect: 0.0 63 Queries matched: 10 
m y e l i n b a s i c p r o t e i n , i s o f o r m CRA_c [ R a t t u s n o r v e g i c u s ] 
g i I 14 9015899 Mass: 34 639 Score: 7 4 Expect: 0.2 4 Queries matched: 11 
m y e l i n b a s i c p r o t e i n , i s o f o r m CRA_a [ R a t t u s n o r v e g i c u s ] 
g i I 90075526 Mass: 1537 0 Score: 72 Expect: 0.39 Queries matched: 8 
unnamed p r o t e i n p r o d u c t [Macaca f a s c i c u l a r i s ] 
g i I 74268137 Mass: 19166 Score: 71 Expect: 0.4 5 Queries matched: 8 
MBP p r o t e i n [Bos t a u r u s ] 
g i I 69885018 Mass: 20991 Score: 69 
G o l l i - m b p i s o f o r m 2 [Mus musculus] 
g i I 126796 Mass: 18312 Score: 69 Expect: 0.77 
M y e l i n b a s i c p r o t e i n (MBP) ( M y e l i n A l p r o t e i n ) (20 kDa 
m i c r o t u b u l e - s t a b i l i z i n g p r o t e i n ) 
g i I 126797 Mass: 18202 Score: 68 Expect: 1 
Expect: 0.7 2 Queries matched: 9 
Queries matched: 
Queries matched: 
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Expect: 2.5 Queries matched: 6 
M y e l i n b a s i c p r o t e i n (MBP) 
g i I 12655896 Mass: 5865 Score: 64 
m y e l i n b a s i c p r o t e i n [Bos t a u r u s ] 
g i I 4505123 Mass: 2 0290 Score: 63 Expect: 3 Queries matched: 8 
m y e l i n b a s i c p r o t e i n i s o f o r m 2 [Homo s a p i e n s ] 
g i I 68509930 Mass: 21537 Score: 62 Expect: 4.2 Queries matched: 
m y e l i n b a s i c p r o t e i n i s o f o r m 1 [Homo s a p i e n s ] 
Q i I 1162922 Mass: 22359 Score: 61 Expect: 5 Queries matched: 8 
m y e l i n b a s i c p r o t e i n 
g i i 3309629 Mass: 16334 Score: 59 Expect: 7.2 Queries matched: 7 
m y e l i n b a s i c p r o t e i n ; MBP [Cavia p o r c e l l u s ] 
g i I 114 673653 Mass: 28900 Score: 57 Expect 11 Queries matched: 9 
PREDICTED: s i m i l a r t o [Human G o l l i - m b p gene, complete c d s . ] , gene p r o d u c t 
i s o f o r m 23 [Pan t r o g l o d y t e s ] 
g i i 68509932 Mass: 17 333 Score: 57 Expect: 12 Queries matched: 7 
m y e l i n b a s i c p r o t e i n i s o f o r m 4 [Homo s a p i e n s ] 
g i I 55731101 Mass: 17 307 Score: 57 Expect: 12 Queries matched: 7 
h y p o t h e t i c a l p r o t e i n [Pongo pygmaeus] 
g i I 90074 964 Mass: 17335 Score: 57 Expect: 
unnamed p r o t e i n p r o d u c t [Macaca f a s c i c u l a r i s ] 
g i I 60834 666 Mass: 174 4 8 Score: 57 Expect: 
m y e l i n b a s i c p r o t e i n [ s y n t h e t i c c o n s t r u c t ] 
12 Queries matched: 7 
12 Queries matched: 7 
g i I 126802 Mass: 18548 Score: 57 
M y e l i n b a s i c p r o t e i n (MBP) 
g i I 17378880 Mass: 18206 
M y e l i n b a s i c p r o t e i n (MBP) 
g i I 55732188 Mass: 18553 Score: 56 
Expect: 12 Queries matched: 7 
Score: 5 6 Expect: 13 Queries matched: 
( M y e l i n A l p r o t e i n ) ( M y e l i n PI p r o t e i n ) 
Expect: 17 Queries matched: 7 
h y p o t h e t i c a l p r o t e i n [Pongo pygmaeus] 
g i I 68509928 Mass: 18579 Score: 56 Expect: 
m y e l i n b a s i c p r o t e i n i s o f o r m 3 [Homo s a p i e n s ] 
g i I 60652959 Mass: 18693 Score: 55 Expect: 
m y e l i n b a s i c p r o t e i n [ s y n t h e t i c c o n s t r u c t ] 
g i I 70166179 Mass: 21303 Score: 55 
G o l l i - m b p i s o f o r m 1 [ R a t t u s n o r v e g i c u s ] 
17 Q u e r i e s matched: 7 
17 Queries matched: 7 
Expect: 17 Queries matched: 7 
g i I 49168552 Mass: 
MBP [Homo s a p i e n s ] 
17337 Score: 81 Expect: 0.04 9 Queries matched: 10 
g i I 223882 Mass: 21634 Score: 7 4 
p r o t e i n 21.5K,myelin b a s i c 
Expect: 0.22 Queries matched: 9 
g i I 1165134 10 Mass: 28552 Score: 52 Expect: 35 Queries matched: 7 
h y p o t h e t i c a l p r o t e i n LB[JL_0202 [ L a c t o b a c i l l u s d e l b r u e c ] < i i subsp. b u l g a r i c u s 
ATCC BAA-365] 
g i I 1491 85269 Mass: 66748 Score: 52 Expect: 38 Queries matched: 9 
g l u c o s e - i n h i b i t e d d i v i s i o n p r o t e i n A [ E r y t h r o b a c t e r sp. SD-21] 
g i I 11674 9197 Mass: 3 6950 Score: 50 Expect: 55 Queries matched: 7 
a l d o / k e t o r e d u c t a s e [ S y n t r o p h o b a c t e r f u m a r o x i d a n s MPOB] 
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Search Parameters 
Type of s e a r c h 
Enzyme 
F i x e d m o d i f i c a t i o n s 
V a r i a b l e m o d i f i c a t i o n s 
Mass v a l u e s 
P r o t e i n Mass 
Peptide Mass Tol e r a n c e 
Peptide Charge S t a t e 
Max Missed Cleavages 
Number of q u e r i e s 
Peptide Mass F i n g e r p r i n t 
T r y p s i n 
Carbamidomethyl (C) 
Oxida t i o n (M) 
Monoisotopic 
U n r e s t r i c t e d 
± 50 ppm 
1 + 
1 
48 
207 
Appendix C - Representative Graphs Showing TARP yS/Actin 
for Mice with Altered 5HT2c Receptor Expression. 
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Figure C . l : T A R P y8/p-Actin Intensities f o r SHTzc Receptor Over-expressing Mice 
and their Respective Controls, n=3. 
-> s 
0 5 
KD Contiol 
Figure C.l: T A R P yS/p-Actin Intensities f o r 5HT2c Receptor Knockdown Mice and 
their Respective Controls, n=3. 
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